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Introduction to “Cystic Fibrosis Foundation Consensus Guidelines for
Diagnosis of Cystic Fibrosis”
Philip M. Farrell, MD, PhD1, and Terry B. White, PhD2
This Supplement focuses on quality improvement in the diagnosis of cystic fibrosis (CF) and provides a comprehensivedescription of the long-standing diagnostic challenges with an informative historical perspective and in the context ofthe most recent advances. The featured component is a group of 27 new consensus statement recommendations from
the US CF Foundation. Readers are encouraged to begin with the first article,1 which gives a succinct overview of the state-
ments, and then proceed sequentially to appreciate the historical aspects, genetics, and then the issues and evidence related to
diagnosis in screened and nonscreened populations (ie, the elements that led to the consensus statements). A summary of the
challenges faced when diagnosing CF and consensus-seeking processes employed follows.
CF, the most common life-threatening autosomal recessive disease among Caucasians in the US, is a multisystem
disorder caused by mutations in the gene for the CF transmembrane conductance regulator (CFTR) ion channel with more
than 2000 mutations identified to date.2 A diagnosis of CF has traditionally relied on recognition of characteristic clinical signs
and symptoms, as described previously3,4 and reviewed herein5 for nonscreened populations; however, with universal CF newborn
screening (NBS) and more prenatal testing, an increasing proportion of diagnoses are being made before symptoms occur. Al-
though the majority of infants who screen positive for CF can be readily diagnosed after a confirmatory sweat test showing
high sweat chloride concentration, the diagnosis is not clear in some individuals.4,6 In addition, universal CF NBS was imple-
mented only recently in the US, and many individuals born there before 2010 have not been screened. Lastly, all clinicians agree
that diagnoses of CF in unscreened populations can be difficult because the age of onset and severity of signs/symptoms as a
result of CFTR dysfunction can be highly variable.
The value in providing an accurate, early CF diagnosis is clear; both for the newborn, who can then receive early therapy
and potentially retain optimal health for decades,7 and for the older individual presenting with symptoms, who can benefit from
the application of appropriate therapies, as well as from simply understanding the cause of symptoms that may have required
a lengthy “diagnostic odyssey” before diagnosis.1 The need to re-examine the rules for a CF diagnosis for newborns became
increasingly apparent as NBS programs collected more and more data showing a significant number of screen-positive infants
with unclear diagnostic results.4,6 A new look at diagnostic guidelines for the individual presenting symptomatically also is timely,
as all clinicians agree that diagnoses of CF in unscreened populations can be difficult because of variability in age of onset and
severity of signs/symptoms, and new genetic information and CFTR functionality testing can now be usefully applied to the
problem. Since the most recent diagnostic consensus conference,4 there has been significant growth of phenotypic and geno-
typic information on CF that can help with interpretation of the disease status in many of these patients. International collec-
tion of clinical data from individuals with CF and recent laboratory advances8-11 have provided new insights into the physiological
impact of the most common mutations.12,13 Because of this new information, and to seek harmony with the diagnostic criteria
and terminology14 of the European CF Society (ECFS), it was decided that the diagnostic guidelines of the CF Foundation4
published in 2008 should be revised.
Consequently, the CF Foundation under the leadership of Drs Preston Campbell and Bruce Marshall planned an extraor-
dinary, in fact unique, consensus conference with worldwide participation, appointed a steering committee of 3 cochairs (Drs
Philip Farrell, Clement Ren, and Patrick Sosnay). Six months later, they convened and supported a committee of 32 experts in
the diagnosis of CF representing 9 countries. During the planning phase, a decision was made to engage the ECFS in an effort
to harmonize diagnostic criteria and terminology14 applied to the 2 largest populations of patients with CF.
The goals of the consensus-seeking processes included probable revising/updating of diagnostic guidelines and, if possible,
achieving global standardization of definitions and terminology. Thus, the mission of this committee was to develop clear and
actionable consensus guidelines on diagnosis of CF and other conditions associated with mutations in the CFTR gene such as
CFTR-related metabolic syndrome (CRMS)6 or CF screen positive, inconclusive diagnosis (CFSPID),15 and CFTR-related disorder.16
The recommendations in this report address individuals with both clear and unclear
CF Cystic fibrosis
CFSPID CF screen positive, inconclusive diagnosis
CFTR CF transmembrane conductance regulator
CRMS CFTR-related metabolic syndrome
ECFS European CF Society
NBS Newborn screening
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diagnoses, including infants with positive NBS and/or prena-
tal presumptive diagnosis,13 and individuals with CF-like symp-
toms who were either never screened or who had false negative
newborn or prenatal screening results.5
After studying the most relevant literature, the committee
convened to review evidence, illustrative cases, and potential
consensus statements in Phoenix, Arizona, on October 6, 2015,
before the North American CF Conference. A carefully se-
lected, international subgroup of the participants served as an
executive subcommittee (“working/writing group”) before and
after the conference to consider a variety of issues as consul-
tants. Following the conference, the consensus statements were
developed by the executive subcommittee and voted on by the
entire consensus committee. An a priori threshold of ≥80%
affirmative votes was required for acceptance of each state-
ment. The consensus committee approved 27 of 28 state-
ments, 7 of which needed revisions and another round of
voting. The executive subcommittee also reviewed an initial,
lengthy proceedings manuscript that served as the precursor
to the 6 articles published herein and subsequently gave special
attention to the consensus summary article1 as did all the con-
ference participants.
After the 27 consensus statements were approved by at least
80% of the consensus committee participants, the list was pre-
sented for review and discussion at the annual meeting of the
ECFS Diagnostic Network Working Group in February 2016
and later presented to the ECFS Board. Next, the consensus
summary manuscript was sent for review and comments to
the Canadian CF Foundation, the national CF organizations
in Australia and New Zealand, a group of parents of children
identified with CRMS, all CF center directors in the US, and
the CF Foundation centers committee. Although the recom-
mendations herein are those of the US CF Foundation, all of
the feedback and suggested revisions were taken into account
in completing theoverviewarticle1 andothers in the Supplement.
The differences between the 2008 diagnostic criteria and the
recommendations herein are summarized in the fourth article13
focused on screened populations. First and foremost, it is rec-
ommended as essential that diagnoses of disorders associ-
ated withCFTRmutations be established in all individuals from
newborn to adult by evaluation of CFTR function with a sweat
chloride test or, if this is not possible, another established test
of chloride channel functioning as described herein by Farrell
et al13 and Ren et al.17 Newborn infants with a high level of
immunoreactive trypsinogen and inconclusive CFTR func-
tional and genetic testing may be designated either CRMS or
CFSPID; these 2 terms are nowmerged and equivalent, so that
CRMS/CFSPIDmay be used as was done recently by Castellani
et al.18 The committee also recommends that the latest mu-
tation classifications annotated in the CFTR2 project19 should
be used to aid in CF diagnosis. Finally, as described in the
Supplement article on genetic aspects by Sosnay et al,12 all pa-
tients with CF should be genotyped, even if the diagnosis was
confirmed with sweat test results and/or they had DNA analy-
ses as part of NBS.
Currently, in association with this Supplement, efforts will
be put in place to facilitate implementation. Most impor-
tantly, all CF clinic/center leaders are urged to read carefully
every article in the Supplement because, as emphasized under
historical aspects herein20 and elsewhere,21 “Every physician’s
first duty is to diagnose–accurately and promptly. Diagnosis
is the first step of treatment.” ■
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Diagnosis of Cystic Fibrosis: Consensus Guidelines from the
Cystic Fibrosis Foundation
Philip M. Farrell, MD, PhD1, Terry B. White, PhD2, Clement L. Ren, MD3, Sarah E. Hempstead, MS2, Frank Accurso, MD4,
Nico Derichs, MD5, Michelle Howenstine, MD3, Susanna A. McColley, MD6, Michael Rock, MD1,
Margaret Rosenfeld, MD, MPH7, Isabelle Sermet-Gaudelus, MD, PhD8, Kevin W. Southern, MBChB, PhD9,
Bruce C. Marshall, MD2, and Patrick R. Sosnay, MD10
Objective Cystic fibrosis (CF), caused by mutations in the CF transmembrane conductance regulator (CFTR)
gene, continues to present diagnostic challenges. Newborn screening and an evolving understanding of CF ge-
netics have prompted a reconsideration of the diagnosis criteria.
Study design To improve diagnosis and achieve standardized definitions worldwide, the CF Foundation con-
vened a committee of 32 experts in CF diagnosis from 9 countries to develop clear and actionable consensus guide-
lines on the diagnosis of CF and to clarify diagnostic criteria and terminology for other disorders associated with
CFTR mutations. An a priori threshold of ≥80% affirmative votes was required for acceptance of each recommen-
dation statement.
Results After reviewing relevant literature, the committee convened to review evidence and cases. Following the
conference, consensus statements were developed by an executive subcommittee. The entire consensus com-
mittee voted and approved 27 of 28 statements, 7 of which needed revisions and a second round of voting.
Conclusions It is recommended that diagnoses associated with CFTR mutations in all individuals, from newborn
to adult, be established by evaluation of CFTR function with a sweat chloride test. The latest mutation classifica-
tions annotated in the Clinical and Functional Translation of CFTR project (http://www.cftr2.org/index.php) should
be used to aid in diagnosis. Newborns with a high immunoreactive trypsinogen level and inconclusive CFTR func-
tional and genetic testing may be designated CFTR-related metabolic syndrome or CF screen positive, inconclu-
sive diagnosis; these terms are now merged and equivalent, and CFTR-related metabolic syndrome/CF screen
positive, inconclusive diagnosis may be used. International Statistical Classification of Diseases and Related
Health Problems, 10th Revision codes for use in diagnoses associated with CFTR mutations are included. (J Pediatr
2017;181S:S4-15).
Cystic fibrosis (CF) is the most common life-threatening autosomal reces-sive disease in the US, affecting approximately 1 in 4000 newborns in theUS,1-3 and occurring at higher frequencies in some European countries.4,5
CF is a multisystem disorder caused by mutations in the gene for the CF trans-
membrane conductance regulator (CFTR), which encodes an ion channel protein,6
with more than 2000 mutations identified to date (http://www.genet.sickkids.on.ca/
cftr/app7).
A diagnosis of CF initially relied on phenotype, with clinical recognition of char-
acteristic signs and symptoms.8,9 However, because of widespread CF newborn
screening (NBS), at least 64% of new CF diagnoses in the US now occur in
CF Cystic fibrosis
CFSPID CF screen positive, inconclusive diagnosis
CFTR CF transmembrane conductance regulator
CFTR2 Clinical and Functional Translation of CFTR
CRMS CFTR-related metabolic syndrome
ECFS European CF Society
ICD-10 International Statistical Classification of Diseases and Related Health Problems,
10th Revision
ICM Intestinal current measurement
IRT Immunoreactive trypsinogen
NBS Newborn screening
NPD Nasal potential difference
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asymptomatic or minimally symptomatic infants following a
positive NBS result.10 Although the majority of infants who
screen positive can be readily diagnosed with CF after a con-
firmatory test showing high sweat chloride concentration, the
diagnosis is not clear in some individuals,11,12 leading to per-
sistent challenges13 and stresses, including a potentially dis-
turbed parent/child relationship.14-16 Furthermore, universal NBS
was implemented only recently in the US, and many individu-
als born prior to 2010 have not been screened. Diagnosis of
CF in the nonscreened population can be challenging because
the age of onset and severity of symptoms can differ greatly
as a result of highly variable levels of CFTR dysfunction. Pre-
senting manifestations can include pancreatitis, respiratory
symptoms, chronic sinusitis, and male infertility.9,17-19
The last few years have seen significant growth of pheno-
typic and genotypic information on CF that can help with in-
terpretation of the disease status in many patients. International
collection of clinical data from individuals with CF20 and labo-
ratory advances21 provide insight into the functional and physi-
ological impact of the most common mutations.22 Because of
this new information, and to seek harmony with the diagnos-
tic criteria and terminology23 of the European CF Society
(ECFS), it was decided that the 2008 diagnostic guidelines24
of the CF Foundation should be revised.
The CF Foundation convened an international committee
of experts in the diagnosis of CF to update diagnostic guid-
ance and achieve standardization in definitions worldwide. The
mission of this committee was to develop clear and action-
able consensus guidelines on diagnosis of CF and other con-
ditions associated with mutations in the CFTR gene such as
CFTR-relatedmetabolic syndrome (CRMS)25 or CF screen posi-
tive, inconclusive diagnosis (CFSPID),26 and CFTR-related
disorders.27 The recommendations in this article address in-
dividuals with both clear and unclear diagnoses, including
infants with positive NBS (defined as any result other than
normal) and/or prenatal diagnosis,28 and individuals with CF-
like symptoms who were either never screened or who had false
negative newborn or prenatal screening results.9 Case studies,
designed to show how the recommendations should be applied
in challenging clinical scenarios, can be found in additional
articles published throughout this Supplement.9,28,29
Methods
An international consensus committee was selected and tasked
with the development of guidelines on the diagnosis of CF;
32 experts made up this committee. Committee selection was
designed to include participants representative of worldwide
CF care communities, particularly pediatric CF providers with
NBS experience, and other relevant specialists, including adult
CF providers. Before the consensus conference, the commit-
tee reviewed the existing CF Foundation diagnosis guidelines24
and a list of publications on CF diagnosis published since the
2008 CF Foundation Diagnosis Guidelines, including 10 key
articles selected by conference cochairs. The conference was
held immediately prior to the North American CF Confer-
ence in October 2015.
At the consensus conference, committee members pre-
sented and discussed new studies and data on CF diagnosis.
An executive subcommittee, consisting of 10 representatives
from 4 countries, developed the consensus statements at sub-
sequent meetings. These statements were reviewed by the entire
consensus committee and voted on by the members using an
electronic survey tool (SurveyMonkey, Palo Alto, California).30
An a priori threshold of ≥80% affirmative votes was re-
quired for acceptance. Individuals voting against a statement
were asked to provide a revised statement and/or explana-
tion for their vote. Feedback on the statements that did not
reach 80% agreement was reviewed by the committee co-
chairs, and those statements were revised with input from the
rest of the executive subcommittee. The revised statements were
then resubmitted for voting.
After the recommendation statements were agreed upon, they
were presented to the ECFS at the Diagnostic NetworkWorking
Group annual meeting in February 2016 to help engage all
parties in the discussion. The draft manuscript was distrib-
uted for feedback from the executive subcommittee, confer-
ence committee, the CF Foundation’s CF Center Committee,
all CF centers in the US, parents of screened infants, and a
variety of international organizations and their members during
a public comment period.
Results
In the survey, participants were able to vote in agreement, dis-
agreement, or to abstain. However, in each of the 2 surveys dis-
tributed for reviewing the consensus statements and voting,
1 committee member (a different person each time) did not
respond. Thus, the 1 committee member who did not par-
ticipate in the first voting exercise did not constitute an ab-
stention. A vote was taken on 28 statements initially; 8 did not
reach at least 80% agreement. The 8 statements that did not
pass were reviewed and revised, and reduced to 7 statements
by the chairs and the executive committee and sent out for a
second round of voting. All but 1 member of the 32 commit-
tee members participated in this vote (ie, 1 was nonrespon-
sive). All 7 of the revised statements passed the 80% threshold
in the second round of voting.
The committee approved 27 consensus statements (Table I)
in 4 overlapping categories that apply to: (1) both screened and
nonscreened populations; (2) newborn screened popula-
tions and fetuses undergoing prenatal testing; (3) infants with
uncertain diagnosis and designated either CRMS or CFSPID
(now considered to be the same); and (4) patients presenting
clinically who represent nonscreened populations, including
children born at home or in regions before NBS implemen-
tation, those with false negative screening tests, and older
nonscreened individuals.
The Figure provides a simplified algorithm for how these
consensus statements should be applied to individuals sus-
pected of having CF because of a positive NBS result, the ap-
pearance of signs or symptoms, or recognition of immediate
family history of CF (most often sibling, but may also include
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Table I. Consensus recommendations for diagnosis of CF*
Statement
numbers Consensus statements Vote
Abstain
(n)
1 Sweat chloride testing should be performed according to approved procedural guidelines published in established, international
protocols such as the CLSI 2009 Guidelines.
100% 0
2 Newborns with a positive CF newborn screen, to increase the likelihood of collecting an adequate sweat specimen, should have
the test performed bilaterally and when the infant weighs >2 kg, and is at least 36 wk of corrected gestational age.
87% 0
3 Newborns greater than 36 wk gestation and >2 kg body weight with a positive CF newborn screen, or positive prenatal genetic
test, should have sweat chloride testing performed as soon as possible after 10 d of age, ideally by the end of the neonatal
period (4 wk of age).
93% 1
4 In infants with presumptive CF identified through NBS, CF treatment should not be delayed while efforts to establish a diagnosis
of CF are initiated.
83% 1
5 Sweat chloride analysis should be performed within a few hours of sweat collection and the results and interpretations should
be reported to clinicians and parents or patients, as soon as possible and certainly on the same day.
90% 0
6 In individuals presenting with a positive newborn screen, clinical features consistent with CF, or a positive family history, a
diagnosis of CF can be made if the sweat chloride value is ≥60 mmol/L.
93% 0
7 Individuals who are screen-positive and meet sweat chloride criteria for CF diagnosis should undergo CFTR genetic testing if
the CFTR genotype was not available through the screening process or is incomplete.
100% 0
8 In individuals with a positive newborn screen, a sweat chloride <30 mmol/L indicates that CF is unlikely. 82% 2
9 Individuals with clinical features that may be consistent with CF who have a sweat chloride <30 mmol/L indicates that CF is
less likely. It may, however, be considered if evolving clinical criteria and/or CFTR genotyping support CF and not an
alternative diagnosis.
80% 0
10 Individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, and sweat chloride values in
the intermediate range (30-59 mmol/L) on two separate occasions may have CF. They should be considered for extended
CFTR gene analysis and/or CFTR functional analysis.
90% 0
11 The latest classifications identified in the CFTR2 project (http://www.cftr2.org/index.php) should be used to aid with CF
diagnosis:
• CF-causing mutation: individuals with 2 copies on separate alleles will likely have CF (clinical sweat confirmation needed)
• Mutation of varying clinical consequence (MVCC): a mutation that in combination with a CF-causing mutation or another
MVCC mutation may result in CF
• Uncharacterized mutation/mutation of UNK: mutation that has not been evaluated by CFTR2 and may be disease causing or
of variable clinical consequence or benign
• Non-CF-causing mutation: individuals with 1 or more are unlikely to have CF (as a result of that allele)
100% 0
12 In individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, the identification of 2
CF-causing mutations (defined by CFTR2) is consistent with a diagnosis of CF. Sweat chloride testing is necessary, though, to
confirm the diagnosis.
87% 0
13 The absence of detection of 2 CF-causing CFTR mutations does not exclude a diagnosis of CF. 93% 1
14 If further CF functional testing is needed (NPD and ICM), it should be performed in a validated reference center with trained staff
certified by the CF Foundation TDN or ECFS Clinical Trial Network.
100% 0
15 In individuals with a positive newborn screen but variable or uncharacterized CFTR mutations (<2 CF-causing mutations), the
diagnosis of CF can be made by demonstrating CFTR dysfunction (a sweat chloride ≥ 60 mmol/L or CF-typical NPD or ICM).
93% 0
16 The term CRMS is used in the US for healthcare delivery purposes and CFSPID is used in other countries, but these both
describe an inconclusive diagnosis following NBS.
96% 2
17 The term CRMS/CFSPID is reserved for individuals who screen positive without clinical features consistent with a diagnosis of
CF.
83% 1
18 The definition of CRMS/CFSPID is an infant with a positive NBS test for CF and either:
• A sweat chloride value <30 mmol/L and 2 CFTR mutations, at least 1 of which has unclear phenotypic consequences
OR
• An intermediate sweat chloride value (30-59 mmol/L) and 1 or 0 CF-causing mutations
86% 1
19 Children designated as CRMS/CFSPID should undergo at least one repeat sweat chloride test at CF centers with suitable
expertise, such as an accredited CF center.
86% 1
20 Children designated as CRMS/CFSPID should have clinical evaluation performed by CF providers to identify the minority that
may develop clinical symptoms.
83% 1
21 Children designated as CRMS/CFSPID can be considered for extended CFTR gene analysis (sequencing and or deletion
duplication testing), as well as CFTR functional analysis (NPD/ICM) testing to further define their likelihood of developing CF.
80% 0
22 The decision to reclassify children designated as CRMS/CFSPID as CF is an integrated decision that should take into account
functional assessment of CFTR (sweat chloride, and possibly NPD/ICM), CFTR genetic analysis, and clinical assessment by
the CF clinicians caring for the patient.
90% 0
23 Genetic counseling should be offered to families of individuals followed for CRMS/CFSPID, including a discussion of the risk in
future pregnancies.
100% 1
24 Research Recommendation: Infants with a designation of CRMS/CFSPID (by definition) do not have clinical features consistent
with a diagnosis of CF and further research is needed to determine the prognosis and best practices for frequency and
duration of follow-up.
96% 0
25 For individuals presenting with CF symptoms, the same diagnostic criteria recommended for the screened population for sweat
chloride testing, CFTR genetic analysis, and CFTR functional testing should be used to confirm a CF diagnosis.
93% 0
26 The diagnosis of CFTR-related disorder has been defined as a monosymptomatic clinical entity (CBAVD/pancreatitis/
bronchiectasis) associated with CFTR dysfunction that does not fulfill the diagnostic criteria for CF.
86% 2
27 Clinicians should avoid the use of terms like classic/nonclassic CF, typical/atypical CF, delayed CF, because these terms have no
harmonized definition and could be confusing for families or caregivers.
83% 1
CBAVD, congenital bilateral absence of the vas deferens; CLSI, Clinical and Laboratory Standards Institute; CTN, Clinical Trial Network; ICM, intestinal current measurement; MVCC, mutation of
varying clinical consequence; NPD, nasal potential difference; TDN, Therapeutics Development Network; UNK, unknown clinical consequence.
*In each of the 2 surveys distributed for reviewing the consensus statements drafted and voting, 1 committee member, a different person each time, did not respond.
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parent or child). It should be noted that a positive NBS result
does not mean the infant has CF; the probability of a CF di-
agnosis following a positive result varies greatly depending on
the NBS method used.
Even though many individuals enter this algorithm through
a positive newborn screen in which CFTR genetic testing was
done, the diagnosis of CF is primarily based on the direct dem-
onstration of abnormal CFTR function by measurement of
chloride concentration in the sweat.24 Although obtaining an
adequate sweat specimen for chloride measurements can be
challenging, particularly in very young infants, experience and
studies have shown that this is feasible in full-term infants
during the first postnatal month (ie, during the neonatal
period).31-34 Following the committee’s recommendations will
improve reliability of the sweat test result.
Sweat Chloride Testing and Presumptive Diagnosis
(1) All populations: Sweat chloride testing should be per-
formed according to approved procedural guidelines
published in established, international protocols such as the
Clinical and Laboratory Standards Institute 2009 Guide-
lines. Following appropriate protocols for performing the
sweat test32 is important for achieving accurate results and
minimizing collection of inadequate amounts of sweat
(quantity not sufficient).28,33-37
(2) For newborns: Newborns with a positive CF newborn screen,
to increase the likelihood of collecting an adequate sweat speci-
men, should have the test performed bilaterally and when
the infant weighs >2 kg and is at least 36 weeks’ corrected
gestational age. Sweat samples collected bilaterally must not
be combined; instead, they should be analyzed sepa-
rately, providing a useful quality control measure.33
(3) For newborns: Newborns greater than 36 weeks’ gestation
and >2 kg body weight with a positive CF newborn screen,
or positive prenatal genetic test, should have sweat chloride
testing performed as soon as possible after 10 days of age,
ideally by the end of the neonatal period (4 weeks of age).
For a variety of reasons related to efficient, effective follow-
up and optimizing care, sweat chloride testing should occur
as soon as possible when positive screening results are
reported and can be as early as 48 hours after birth.33
The committee recognizes that many NBS programs do
not report results by this time and, therefore, recom-
mends that sweat chloride testing proceed as soon as pos-
sible after results are available; generally, this is no later
than 10 days of age. Although gestational age and weight
must be considered,38 testing should occur if at all pos-
sible before the end of the neonatal period because mal-
nutrition and other risks such as potentially fatal
hyponatremic dehydration may occur even in the first
few weeks of life.39-42
Figure. CF is diagnosed when an individual has both a clinical presentation of the disease and evidence of CFTR dysfunc-
tion. The tests of CFTR function are not always done in this order, but hierarchically to establish the diagnosis of CF, sweat
chloride should be considered first, then CFTR genetic analysis, and then CFTR physiologic tests. All individuals diagnosed
with CF should have a sweat test and a CFTR genetic analysis performed. Rare individuals with a sweat chloride <30 mmol/L
may be considered to have CF if alternatives are excluded and the other confirmatory tests (genetic, physiologic testing) support
CF. If only 1 CFTR variant is identified on limited analysis, further (“extended”) CFTR testing should be performed.22 CF is
possible if both alleles possess CF-causing, undefined, or mutation of varying clinical consequence (MVCC) mutations; CF is
unlikely if only non-CF-causing mutations are found. If a CF diagnosis is not resolved, CRMS/CFSPID (following NBS) or CFTR-
related disorder should be considered.9,29 Rarely, no distinct label may be appropriate but further follow-up may be warranted.
In these cases, the use of “CF carrier” or the specific clinical problem should be used for characterization/labeling purposes.
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(4) For newborns: In infants with presumptive CF identified
through NBS, CF treatment should not be delayed while
efforts to establish a diagnosis of CF are initiated. Optimal
outcomes depend on early intervention. Efforts to obtain
adequate quantities of sweat and accurate sweat chloride
values should not delay start of salt supplementation or
other appropriate therapies.43 The CF Foundation rec-
ommends that infants with CF have an initial visit at an
accredited CF care center within 24-72 hours of diagnosis,43
and timing of the initial visit for infants with a presump-
tive diagnosis should aim to meet this timeframe. A pre-
sumptive diagnosis of CF for purposes of treatment
initiation can include the following clinical circum-
stances: (1) positive CF newborn screen showing 2 CF-
causing CFTR mutations (see below); (2) positive CF
newborn screen and clinical signs and symptoms of CF;
and (3) meconium ileus, with or without a positive
newborn screen.
However, definitive diagnosis requires demonstration of
CFTR dysfunction.A date of presumptive diagnosis should
be recorded to permit evaluation of timeliness of diag-
nosis and treatment within NBS programs. However, for
purposes of providing standardized data to the CF Foun-
dation Patient Registry, the date of the first positive sweat
chloride test should be reported as the date of diagnosis.
(5) All populations: Sweat chloride analysis should be per-
formed within a few hours of sweat collection, and the results
and interpretations should be reported to clinicians and
parents or patients, as soon as possible and certainly on the
same day. Prompt reporting should be made regardless of
sweat test results to reduce family or patient stress.44-47 A
second, confirmatory, sweat test following an initial posi-
tive result is not necessary; this is a change from previ-
ous CF Foundation diagnostic guidelines.24,48
Sweat Chloride Test Results ≥60 mmol/L
(6) All populations: In individuals presenting with a positive
newborn screen, clinical features consistent with CF, or a posi-
tive family history, a diagnosis of CF can be made if the sweat
chloride value is ≥60 mmol/L. Even though the sweat test
is commonly used for diagnosis of individuals present-
ing with symptoms of CF, many newborns are reported
as having CF based solely on a positive NBS result.
However, NBS tests must always be considered as screen-
ing procedures and not diagnostic studies. The genetic
analysis included as part of many NBS programs must not
be relied upon for conclusive diagnosing and/or
genotyping, as errors can arise from problems with Guthrie
card labelling,49,50 changes in the mutation panel used by
the NBS program (eg, as described byWatson et al51), NBS
laboratory errors including DNAmisinterpretations, or de-
tection of 2 CFTR mutations in cis (ie, on the same
chromosome).22,52,53 All of these problems have occurred
and will occur again.
(7) For newborns: Individuals who screen positive and meet
sweat chloride criteria for CF diagnosis should undergo CFTR
genetic testing if the CFTR genotype was not available through
the screening process or is incomplete. Genetic testing is an
important part of the diagnostic work-up, and it is not
uncommon for a positive NBS result to include the rec-
ognition of 2 CF-causing mutations. Even in the pres-
ence of a positive sweat test, the identification of 2 CF-
causing mutations should be confirmed in a clinical
genetics laboratory capable of performing in-depth genetic
analysis when required to further define CF risk (eg, the
length of polyT tracts with the c.350G>A [legacy: R117H]
CFTR mutation).54,55 Confirmation of genetic testing results
with an FDA-approved companion diagnostic test also has
additional value in therapy selection56 and access.57,58
Sweat Chloride Test Results <30 mmol/L
(8) For newborns: In individuals with a positive newborn screen,
a sweat chloride <30 mmol/L indicates that CF is unlikely.
Sweat chloride testing may be repeated if indicated by
family history, or if symptoms suggestive of CF occur.
(9) All populations: Individuals with clinical features that may
be consistent with CF who have a sweat chloride <30 mmol/L
indicates that CF is less likely. It may, however, be consid-
ered if evolving clinical criteria and/or CFTR genotyping
support CF and not an alternative diagnosis. The level of
sweat chloride below which CF is considered unlikely is
30 mmol/L for all age groups. This is a change from pre-
vious guidelines for individuals >6 months of age (the pre-
vious limit was 40 mmol/L) because patients have been
definitively diagnosed with CF with chloride values in the
30-39 mmol/L range.
Details regarding the diagnosis of CF in the very rare
individual with sweat chloride <30 mmol/L are pub-
lished elsewhere.22 Some CFTR mutations, such as
c.3717 + 12191C>T (legacy: 3849 + 10 kb C- > T), are as-
sociated with low sweat chloride values; in these cases, an
alternative diagnosis does not need to be ruled out.9,59,60
Sweat Chloride Test Results of 30-59 mmol/L
(10) All populations: Individuals presenting with a positive
newborn screen, symptoms of CF, or a positive family history,
and sweat chloride values in the intermediate range (30-
59 mmol/L) on 2 separate occasions may have CF. They
should be considered for extended CFTR gene analysis and/
or CFTR functional analysis. Individuals with sweat chlo-
ride concentrations in the intermediate range will need
further study to establish or rule out a CF diagnosis.12,61-63
Evidence may be provided by CFTR genotype20 (an article
in this Supplement provides a discussion of CFTR genetic
testing and interpretation in detail22) or by further CFTR
physiologic testing.64-67 Other articles in this Supple-
ment present a discussion of the demonstration of CFTR
dysfunction including the use of nasal potential differ-
ence (NPD) or intestinal current measurement (ICM) on
the screen-positive newborn28 and information on the
symptomatic patient.9
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Next Steps for Intermediate Sweat Test Results
(11) All populations: The latest classifications identified in the
Clinical and Functional Translation of CFTR (CFTR2)
project20 should be used to aid with CF diagnosis: (1) CF-
causing mutation: individuals with 2 copies on separate
alleles will likely have CF (clinical sweat confirmation
needed). (A sweat chloride test result ≥30 mmol/L is con-
firmatory for patients with this genotype); (2) muta-
tion of varying clinical consequence: A mutation that in
combination with a CF-causing mutation or another mu-
tation of varying clinical consequence mutation may result
in CF; (3) uncharacterized mutation/mutation of unknown
clinical consequence: mutation that has not been evalu-
ated by CFTR2 and may be disease causing or of variable
clinical consequence or benign; and (4) non-CF-causing mu-
tation: individuals with 1 or more are unlikely to have CF
(as a result of that allele).
The CFTR2 project provides a detailed characteriza-
tion of CFTR mutations by collecting clinical and
laboratory evidence of phenotypic consequence.20 For
each mutation, the CFTR2 website provides informa-
tion and classification as listed above. The CFTR2 project
is updated as mutation-specific functional analyses are
completed. Also, because mutation categorization may
change over time, it is important to confirm genotype
interpretation on the most current version of the website.
Mutations that are not analyzed as part of CFTR2 may
still be interpretable if adequate research exists. For
example, if a mutation is detected that is not annotated
in CFTR2 and has been shown to be seen previously in
patients with CF, has functional evidence that the
nucleotide/protein change is deleterious; and does not
occur commonly in databases of general (healthy)
population, that mutation can be characterized as
CF-causing.22
(12) All populations: In individuals presenting with a positive
newborn screen, symptoms of CF, or a positive family history,
the identification of 2 CF-causing mutations (defined by
CFTR2) is consistent with a diagnosis of CF. Sweat chlo-
ride testing is necessary, though, to confirm the diagnosis.
A sweat chloride test result ≥30 mmol/L is confirma-
tory in individuals with 2 CF-causing mutations on sepa-
rate chromosomes. As stated above, there are situations
in which repeated sweat chloride testing does not provide
further clarity, such as in individuals with CFTR muta-
tions known to be associated with normal or interme-
diate sweat chloride.59,60 Another article in this Supplement
provides further exploration of this topic.9
(13) All populations: The absence of detection of 2 CF-causing
CFTR mutations does not exclude a diagnosis of CF.
Because classification and identification of CF-causing
CFTR mutations is ongoing, there are individuals with
a CF diagnosis in whom 2 CFTR mutations have not been
detected. Thus, even though the CFTR2 initiative has been
a valuable step forward in improving the diagnostic char-
acterization of patients with CFTR mutations, it does not
take the place of clinical observation and expertise. Other
articles in this Supplement present more in-depth dis-
cussions on this topic. 9,22,29
To explore further a CF diagnosis in individuals with a
positive newborn screen, symptoms of CF, or a positive
family history, intermediate sweat chloride values (30-
59 mmol/L), and fewer than 2 CF-causing mutations, the
committee recommends additional CFTR physiologi-
cal testing that directly measures CFTR function, such
as NPD and ICM.68
(14) All populations: If further CF functional testing is needed
(NPD and ICM), it should be performed in a validated ref-
erence center with trained staff certified by the CF Foun-
dation Therapeutics Development Network or ECFS Clinical
Trial Network. When performed correctly, NPD can dis-
criminate a wide range of CFTR function.69,70 ICM also
can be used to confirm a diagnosis of CF in the context
of intermediate sweat chloride levels,66-68,70-73 and may be
useful when NPD testing is unsuccessful (eg, when at-
tempting to conduct NPD testing in the uncooperative
child) (I Sermet-Gaudelus, personal communication,
October 2015). Few CF centers in the US are prepared
to conduct these tests. However, the added value that the
results have provided to situations of diagnostic uncer-
tainty (especially in Europe where they are more widely
used) suggests that there will be widespread uptake of
the tests in the future. There are patients with interme-
diate sweat chloride test results and an undefined CFTR
genotype for whom NPD or ICM testing could provide
diagnostic clarity; these patients should be seen in centers
certified for the test in their country. Another article in
this Supplement presents further discussion of NPD and
ICM testing.28
(15) For newborns: In individuals with a positive newborn screen
but variable or uncharacterized CFTR mutations (<2 CF-
causing mutations), the diagnosis of CF can be made by
demonstrating CFTR dysfunction (a sweat chlo-
ride ≥60 mmol/L or CF-typical NPD or ICM). Identifi-
cation of diagnostic levels for NPD and ICM
measurements must be performed at the level of the ref-
erence center conducting the tests. Another article in this
Supplement presents further discussion on this topic.28
For the Newborn with an Inconclusive Diagnosis
(16) For newborns: The term CRMS is used in the US for
healthcare delivery purposes and CFSPID is used in other
countries, but these both describe an inconclusive diagno-
sis following NBS. Newborn infants with a high level of
immunoreactive trypsinogen (IRT) and inconclusive
CFTR functional and genetic testing may be labeled either
CRMS or CFSPID.25,26,29 CFSPID describes the incon-
clusive nature of the condition in a manner that is
easy for patients and families to understand and can be
designated by International Statistical Classification of Dis-
eases and Related Health Problems, 10th Revision (ICD-
10) code P09. However, because of the US healthcare
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system requirements,74 CRMS (ICD-10 code E88.89) must
be used in clinical settings in the US for continuing,
follow-up care. These 2 terms are nearly identical, and
the consensus committee recommends that the 2 terms
be harmonized, for improved international communi-
cations and analysis of clinical outcomes. The term
CRMS/CFSPID will be used throughout this Supple-
ment and is recommended.75
(17) For newborns: The term CRMS/CFSPID is reserved for in-
dividuals who screen positive without clinical features con-
sistent with a diagnosis of CF. The CRMS/CFSPID
diagnosis should not be used in other clinical sce-
narios, including those involving individuals who have
not received a positive NBS result, or individuals who have
clinical symptoms attributable to CFTR dysfunction.9
(18) For newborns: The definition of CRMS/CFSPID is an
infant with a positive NBS test for CF and either: (1) sweat
chloride value <30 mmol/L and 2 CFTR mutations, at least
1 of which has unclear phenotypic consequences; or (2) in-
termediate sweat chloride value (30-59 mmol/L) and 1 or
0 CF-causing mutations. Individuals designated as CRMS/
CFSPID initially appear asymptomatic and may never
develop CF symptoms; however, they should be re-
ferred to a CF specialist at an accredited CF care center
to ensure there are no hidden signs or symptoms of CF
and to establish a plan for follow-up.25,76
Next Steps in the Newborn with CRMS/CFSPID
Designation
(19) For newborns: Children designated as CRMS/CFSPID
should undergo at least 1 repeat sweat chloride test at CF
centers with suitable expertise, such as an accredited CF
center. This test should be used to confirm the CRMS/
CFSPID designation. Appropriate timing for the repeat
sweat chloride test is discussed elsewhere in this
Supplement.29
(20) For newborns: Children designated as CRMS/CFSPID
should have clinical evaluation performed by CF provid-
ers to identify the minority that may develop clinical symp-
toms. This group of children must be monitored for
development of symptoms, and surveillance evalua-
tions conducted (respiratory tract cultures, imaging,
and spirometry or lung-clearance index when age-
appropriate). Measuring fecal elastase levels or follow-
ing IRT or pancreatitis associated protein trends may be
considered if clinically indicated to identify CF clinical
manifestations (phenotypes) objectively.11,25,76-78 CF cannot
be diagnosed through the identification of elevated levels
of IRT alone; elevated IRT can occur in the context of
other tissue stress.79,80 Another article in this Supple-
ment presents information about appropriate timing for
monitoring.29
(21) For newborns: Children designated as CRMS/CFSPID can
be considered for extended CFTR gene analysis (sequenc-
ing and or deletion duplication testing), as well as CFTR
functional analysis (NPD/ICM) testing to further define
their likelihood of developing CF. Other articles in this
Supplement present information on the genetic tests that
are useful in this scenario and useful functional analy-
sis testing.22,29
(22) For newborns: The decision to reclassify children desig-
nated as CRMS/CFSPID as CF is an integrated decision
that should take into account functional assessment of CFTR
(sweat chloride, and possibly NPD/ICM), CFTR genetic
analysis, and clinical assessment by the CF clinicians caring
for the patient. The decision to change a designation from
CRMS/CFSPID to CF is a difficult one and should be
made by an experienced CF physician.25,26,29
(23) For newborns: Genetic counseling should be offered to fami-
lies of individuals followed for CRMS/CFSPID, including
a discussion of the risk in future pregnancies. The CF Foun-
dation recommends that genetic counseling be offered
to all families of newborns diagnosed with CF.24 This is
also important for families of newborns designated
CRMS/CFSPID. Our understanding of the impact of
various CFTR mutations is evolving and will continue
to be clarified for many years. Genetic counseling is im-
portant for parents to understand the risk of a child
having CF or being designated as CRMS/CFSPID in future
pregnancies.25,26
(24) For newborns (research recommendations): Infants with
a designation of CRMS/CFSPID (by definition) do not have
clinical features consistent with a diagnosis of CF and further
research is needed to determine the prognosis and best prac-
tices for frequency and duration of follow-up. There is in-
adequate evidence to recommend a standard period and
frequency for follow-up of these individuals. Further re-
search on this will require common definitions, and the
merging of CRMS and CFSPID designations is, there-
fore, especially timely.
General Note for the Nonscreened Individual
(25) For individuals presenting with CF symptoms, the same di-
agnostic criteria recommended for the screened popula-
tion for sweat chloride testing, CFTR genetic analysis, and
CFTR functional testing should be used to confirm a CF
diagnosis.AlthoughNBS encompasses themajority of new
diagnoses, diagnosis of CF in the nonscreened popula-
tion, particularly those born before the initiation of NBS
at all accredited CF centers, still occurs. (There will also
be individuals that present with symptoms following a
false negative CF NBS result28,50 who should then be con-
sidered as in the nonscreened population.) In these in-
dividuals, the diagnostic algorithm (Figure) remains
applicable. However, the assignment of a diagnosis of
CF will be weighed against alternative diagnostic expla-
nations of the presenting symptom or feature. There-
fore, the pretest probability of CF will influence the
interpretation of sweat chloride testing, CFTR genetic
analysis, or CFTR physiologic testing. Definitive diag-
nostic criteria for nonscreened populations include the
presence of CF symptoms or a family history and sweat
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chloride ≥60 mmol/L OR presence of 2 CF-causing CFTR
mutations and sweat chloride ≥30 mmol/L or physi-
ologic testing demonstrating CFTR dysfunction.
The diagnosis of CF also can be appropriate if the above
testing is not definitive, but CFTR dysfunction is the best
explanation of the patient’s symptoms. In keeping with
the reasons for recommending genetic analysis of new-
borns diagnosed with CF (statement 7) or CRMS/
CFSPID (statement 23), we suggest that all nonscreened
individuals diagnosed with CF or a CFTR-related dis-
order also undergo genetic analysis, and they or their
families be provided with genetic counseling to clarify
the risk of disease in future pregnancies. Of course, as
with all other diseases, it should be said that phenotype
can vary in individuals with the same genotype.
For the Nonscreened Individual with an
Inconclusive Diagnosis
There are scenarios in which a given patient may not meet the
above diagnostic criteria to be diagnosed with CF but also
cannot be “ruled-out” as not having CF. Although this situa-
tion is similar to infants with CRMS/CFSPID, those classifi-
cations are not appropriate for the nonscreened populations.
(26) The diagnosis of CFTR-related disorder has been defined
as a monosymptomatic clinical entity (congenital bilat-
eral absence of the vas deferens/pancreatitis/bronchiectasis)
associated with CFTR dysfunction that does not fulfill the
diagnostic criteria for CF. Individuals with a CFTR-
related disorder27 (generally mono-organ) should be as-
sessed and followed by a CF physician to ensure that if
any additional symptoms develop that are typical of CF,
they are detected.9
(27) Clinicians should avoid the use of terms such as classic/
nonclassic CF, typical/atypical CF, and delayed CF, because
these terms have no harmonized definition and could be
confusing for families or caregivers. In these and other situ-
ations, education on clinical entities and organ patholo-
gies associated with CF and their relationship with CFTR-
related disorder should be provided to patients, families,
and primary care providers to aid in the early recogni-
tion of symptoms of CF. The CF Foundation reaffirms
the view that it is essential to avoid confusion of parents
and patients, and also caregivers, with imprecise terms
like atypical or nonclassic because early diagnosis and
more effective treatments can lead to relatively mild
disease for many years even in c.1521_1523delCTT
(legacy: F508del) homozygotes. However, it is under-
stood that some European countries will continue to
use such terminology as they pursue research on mild
cases.
ICD-10 Codes for Individuals with CFTR
Dysfunction
The ICD81 system is a medical classification list created
collaboratively by the World Health Organization to be “the
international standard for defining and reporting diseases and
health conditions. It allows the world to compare and share
health information using a common language.”82 It is an al-
phanumeric system containing codes for diseases, signs and
symptoms, abnormal findings, complaints, social circum-
stances, and external causes of injury or diseases. The ICD
system is valuable, indeed essential, for many purposes in-
cluding: (1) entry and continuation into the healthcare deliv-
ery mechanisms of some countries such as the US where the
ICD codes are an integral and required component of billing;
(2) coding death certificates internationally, thus, allowing as-
sessment of mortality data; (3) epidemiologic research; and (4)
medical economics research.
Table II. ICD-10 codes for use in individuals with CF and other CFTR dysfunctional diseases or disorders
Diseases/disorders Primary ICD-10 code Secondary ICD-10 code
CF, unspecified E84.9
CF, with meconium ileus E84.11
CF, with other intestinal manifestations (eg, DIOS) E84.19
CF, with pulmonary manifestations E84.0 Use secondary code for details such
as infectious organisms present
(eg, B96.5 for Pseudomonas aeruginosa)
CF, with acute pneumothorax E84.09 J93.83
CF, with pneumothorax not otherwise specified E84.09 J93.9
CF, with hemoptysis E84.09 R04.2
CRMS, metabolic disorder unspecified E88.89
CFSPID P09 (abnormal findings on neonatal screening)*
Or:
E88.89 (if CRMS/CFSPID is adopted
as the preferred terminology)
CFTR-related disorder
(Code the signs/symptoms as described but do not use E84.9)
Pancreatitis, recurrent
CBAVD
Bronchiectasis, chronic acquired
K85.9
Q55.4†
J47.9
Z14.1
(CF carrier status)
DIOS, distal intestinal obstruction syndrome.
*Describes positive newborn screen result with an inclusive diagnosis but only applies to the newborn period and thus cannot be used in follow-up care.
†Preferred over N46.025 (azoospermia because of a systemic disease).
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The most recent revision of the system, ICD-10, imple-
mented in October 2015, provides more than 14 400 differ-
ent codes and can be expanded to over 16 000 codes by using
optional subclassifications. It is not possible to convert ICD
Ninth Revision datasets to ICD-10. In the ICD-10 coding system,
characters 1-3 indicate the category of disease; 4-6 indicate eti-
ology, anatomic site, severity or other clinical detail of disease;
and character 7 is a placeholder for extending the code to in-
crease specificity. The designation “E” indicates endocrine, nu-
tritional, and metabolic diseases, and “J” applies to diseases of
the respiratory system.
Some CF specialists were engaged in the ICD-10 develop-
ment process, but the degree of influence was limited, and
coding for diseases or disorders caused by CFTR dysfunction
is not ideal, including the absence of a code for CFTR-
related disorder. The current ICD-10 code is undergoing re-
vision to ICD 11th Revision which is due to be completed in
2018. Participation is invited (http://www.who.int/classifications/
icd/revision/en/), and we encourage involvement by CF
caregivers.
A list of ICD-10 codes that should be used in the delivery
of care for those disorders associated with CFTR mutations
(that is, CF, CRMS/CFSPID, and CFTR-related disorder) is
shown in Table II.
Summary of Revisions to the 2008 CF
Foundation Guidelines
The basic strategy necessary for diagnosis of CF in the large
majority of individuals remains unchanged from the process
recommended in 2008.24 However, some of the diagnostic
tools presented in this document and the recommended
application of those tools in more complex clinical scenarios
do represent significant changes. A summary of the main
changes to the 2008 diagnostic algorithm is presented in
Table III.
Discussion
Although NBS is now widely implemented, the diagnosis of
CF is not always clear. A sweat test is required for confirma-
tion of CF; a sweat chloride level ≥60 mmol/L indicates a di-
agnosis of CF and a sweat chloride level <30 mmol/L indicates
Table III. Summary of revisions to the 2008 CF Foundation guidelines for diagnosis of CF
Revisions to guidelines for screened populations
2015 Consensus 200824 Comparison
• Sweat testing: same recommendation in 2008, but is not being followed and
is, therefore, re-emphasized here
• Sweat testing: should be done in everyone
• Sweat Cl−: < 30 mmol/L is normal threshold for all ages (exceptions occur) • Sweat Cl−: < 40 mmol/L was normal threshold for ages ≥6 mo (exceptions
occur)
• NPD/ICM: useful; testing should be conducted in a validated lab • NPD: limited to contributory evidence; ICM: used only in research
• CFTR mutations: use CFTR2 mutation list, with guidelines given for mutations
not included in CFTR2
• CFTR mutations: Used ACMG/ACOG panel of 23 mutations51
• Presumptive diagnosis of CF: can be made (NBS+ and 2 CF mutations or signs
and symptoms of CF; or meconium ileus) and treatment started; diagnosis
must be confirmed with a sweat test
• Not discussed
• Genetic analysis: recommended in addition to that done during NBS • Genetic analysis: recommended if not part of NBS
Revisions to guidelines for CRMS/CFSPID
2015 Consensus 200824 Comparison
• CRMS = CFSPID: now a harmonized definition • (Neither term in use)
• Repeat sweat testing recommended; NPD/ICM testing may be considered • Repeat sweat testing: every 6-12 mo, but recommendation considered to
be “evolving”
• Clinical assessment: by age 2 mo; duration and frequency of follow-up
remains to be determined
• Clinical assessment: by age 2 mo; repeat every 6-12 mo
Revisions to guidelines for nonscreened population
with inconclusive sweat chloride values
2015 Consensus 200824 Comparison
• Sweat Cl−: < 30 mmol/L is normal threshold for all ages (exceptions
occur)
• Sweat Cl−: < 40 mmol/L was normal threshold for ages ≥ 6 mo
(exceptions occur)
• Ancillary testing: NPD/ICM • Ancillary testing: NPD only
Revisions to general definitions
2015 Consensus 200824 Comparison
• CFTR-related disorder: a symptomatic entity that does not meet diagnostic
criteria for CF
• CFTR-related disorder: Individuals with 0-1 CF-causing mutations and
clinical signs (possibly multiple-organ) suggestive of CF
• Avoid terms like “atypical” or “nonclassical” CF because there is no
consensus definition of these terms
• Recommendation unchanged but greater emphasis now given to the
importance of avoiding these imprecise, potentially confusing terms in
the US.
ACMG/ACOG, American College of Medical Genetics/American Congress of Obstetricians and Gynecologists.
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that CF is unlikely. In individuals who fall into the interme-
diate sweat chloride level, 30-59 mmol/L, genetic analysis is re-
quired. Further testing for CFTR function such as NPD and
ICMmay also be indicated but should be performed in a spe-
cialized center approved for such studies. Some infants with
a positive NBS and sweat chloride levels from 30 to 59 mmol/L
or even ≤29 mmol/L and inconclusive genetic testing may be
designated as CRMS/CFSPID. Further research is needed to
determine their prognosis, best practice, and frequency of
follow-up. ■
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Cystic Fibrosis Diagnostic Challenges over 4 Decades:
Historical Perspectives and Lessons Learned
Philip M. Farrell, MD, PhD1, Terry B. White, PhD2, Nico Derichs, MD3, Carlo Castellani, MD4, and Beryl J. Rosenstein, MD5
Objective Because cystic fibrosis (CF) can be difficult to diagnose, and because information about the genetic
complexities and pathologic basis of the disease has grown so rapidly over the decades, several consensus con-
ferences have been held by the US CF Foundation, and a variety of other efforts to improve diagnostic practices
have been organized by the European CF Society. Despite these efforts, the application of diagnostic criteria has
been variable and caused confusion.
Study design To improve diagnosis and achieve standardization in terms and definitions worldwide, the CF Foun-
dation in 2015 convened a committee of 32 experts in the diagnosis of CF from 9 countries. As part of the process,
all previous consensus-seeking exercises sponsored by the CF Foundation, along with the important efforts of the
European CF Society, were comprehensively and critically reviewed. The goal was to better understand why con-
sensus conferences and their publications have not led to the desired results.
Results Lessons learned from previous diagnosis consensus processes and products were identified. It was decided
that participation in developing a consensus was generally not inclusive enough for global impact. It was also found
that many efforts to address sweat test issues were valuable but did not always improve clinical practices as CF
diagnostic testing evolved. It also became clear from this review that premature applications of potential diagnos-
tic tests such as nasal potential difference and intestinal current measurement should be avoided until validation
and standardization occur. Finally, we have learned that due to the significant and growing number of cases that
are challenging to diagnose, an associated continuing medical education program is both desirable and necessary.
Conclusions It is necessary but not sufficient to organize and publish CF diagnosis consensus processes. Follow-
up implementation efforts and monitoring practices seem essential. (J Pediatr 2017;181S:S16-26).
“E very physician’s first duty is to diagnose—accurately and promptly. Diagnosis is the first step of treatment.”
1 Al-
though this principle of medical practice applies well to cystic fibrosis (CF), this relatively common genetic disease
has presented diagnostic challenges ever since autopsy-based diagnosis was first reported by Andersen2 in 1938,
leading to the recognition and naming of the disease. In fact, there has been a surprising degree of difficulty encountered world-
wide in establishing the diagnosis unequivocally. The advent of sweat electrolyte testing3 provided considerable clarity over di-
agnosis based on demonstration of pancreatic insufficiency after duodenal intubation, but healthcare providers continued to
be faced with uncertain cases and challenging diagnostic dilemmas. And, although the 5-decade-long quest to diagnose CF “ac-
curately and promptly” became more feasible with the advent of newborn screening (NBS),4 when evidence was published on
how benefits of NBS5 outweighed the manageable risks (as affirmed by both the Centers for Disease Control [CDC]6 and the
US CF Foundation7), NBS expanded, and new diagnostic challenges ensued.
A diagnosis of CF has traditionally relied on recognition of characteristic clinical signs and symptoms, but the increased use
of NBS and prenatal screening has resulted in diagnosis often before symptoms are recognized, with a consequent opportunity
to foster normal growth and development.
For example, in the US, approximately 64%
of new CF diagnoses now follow a positive
newborn screen.8 According to consensus
CDC Centers for Disease Control
CF Cystic fibrosis
CFSPID CF screen positive, inconclusive diagnosis
CFTR CF transmembrane conductance regulator
CRMS CFTR-related metabolic syndrome
DNWG Diagnostic Network Working Group
ECFS European CF Society
ICD International Statistical Classification of Diseases and Related Health Problems
ICD-9 International Statistical Classification of Diseases and Related Health Problems,
Ninth Revision
ICD-10 International Statistical Classification of Diseases and Related Health Problems,
Tenth Revision
ICM Intestinal current measurement
IRT Immunoreactive trypsinogen
NBS Newborn screening
NPD Nasal potential difference
NSWG Neonatal Screening Working Group
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guidelines developed by the CF Foundation in 2007 and pub-
lished in The Journal during 2008,9 individuals identified by
NBS can be diagnosed with CF by a sweat chloride value
≥60 mmol/L, by the identification of 2 CF-causing muta-
tions, or by the presence of 1 CF-causing mutation plus a clini-
cal finding in infants with an intermediate (30-59 mmol/L)
sweat test result. Although the vast majority of screened infants
can be unequivocally diagnosed with CF after a positive
newborn screen and sweat test,9,10 the decision is not clear-
cut in a significant number of individuals,11,12 leading to per-
sistent challenges13 and stress and confusion for both families14,15
and clinicians.16 This group, as well as symptomatic subjects
identified without NBS who have varying levels of symp-
toms and a variety of CF transmembrane conductance regu-
lator (CFTR) mutations, has been the focus of discussions in
the US and in Europe, with differing conclusions on both di-
agnosis and management.10,17-19 In addition, there has been a
lack of international harmony regarding terminology, leading
to confusion.20
Another recently recognized problem is that, despite the care-
fully developed CF Foundation consensus guidelines pub-
lished in 199821 and 2008,9 CF centers have not been applying
them consistently. For instance, in the US, approximately 20%
of new diagnoses in 2010-2012 were made after NBS but
without a confirmatory sweat test.11
Because of these issues, the US CF Foundation decided to
convene a CF diagnosis consensus conference in 2015, bring-
ing together CF specialists from around the world in an effort
to bring clarity to diagnostic algorithms, paying special atten-
tion to the diagnostic challenges presented subsequent to the
widespread implementation of NBS in the US and other coun-
tries. During the planning phase of the 2015 CF Diagnosis Con-
sensus Conference, it was decided that a detailed historical
review would be performed to assess previous consensus-
producing conferences with a goal of identifying reasons why
published guidelines have been misunderstood and/or imple-
mented inconsistently. The review focused on the processes and
products of efforts organized by the US CF Foundation and
generally published in The Journal.9,21 In addition, the important
contributions of the European CF Society (ECFS) were ex-
amined, especially the activities of their Diagnostic Network
Working Group (DNWG) and the Neonatal Screening Working
Group (NSWG). Thus, proceeding under the assumption that
knowledge of history is a precondition for better outcomes,
we reviewed and critiqued 3 previous CF Foundation diag-
nostic consensus conferences and current European prac-
tices and identified the lessons learned.
Initial Efforts of the CF Foundation to
Establish Diagnostic Criteria for US CF
Centers (1963-1976)
In 1963, a committee of 6 US experts was commissioned by
the US CF Foundation to write a “Guide to Diagnosis and Man-
agement of Cystic Fibrosis” for use by a growing network of
CF centers in the US.22 The timing of this 1963 publication
was related to the widespread introduction of routine sweat
testing using the method of Gibson and Cooke23 that was pub-
lished in 1959. During the ensuing years, a number of issues
developed about the safety and reliability of the sweat test. In
addition, novel, intriguing research appeared in the litera-
ture on “CF factors”24-26 and their applicability to diagnosis,
as well as potential opportunities for screening. This led to a
large multiworkshop conference27 organized in 1974 by the Na-
tional Institutes of Health and the US CF Foundation with an
American committee of 16 broad “experts” and 69 others par-
ticipating as “consultants.” Thus, the impetus for the consen-
sus conference in 1974 was a growing body of knowledge about
CF combined with difficulties encountered in applying the sweat
test. Even as the workshops proceeded, preliminary data were
appearing in the literature on an entirely new laboratory
method of facilitating the early diagnosis of CF through NBS
using meconium albumin analyses.28
Lessons Learned
The landmark 1974 conference led to a number of recom-
mendations (Table I) that still apply today, although some
Table I. 1976 Consensus: conclusions and recommendations for CF consensus-development process*
1 “Information on the value of early diagnosis and early treatment is urgently needed.”
2 All siblings should have diagnostic tests at CF centers.
3 Detailed long-term family studies are needed.
4 Studies need to be carried out on very young patients before the development of lung infections.
5 Communication and collaboration between investigators should be improved.
6 “The sweat test is an efficient diagnostic test when properly performed and when interpreted. . .in the light of the overall clinical picture.”
7 “The major limitations. . . are due to technical limitations in the stimulation and collection of sweat.”
8 “The quantitative pilocarpine iontophoresis test is recommended. . .corroborated by the clinical picture.”
9 “A system for quality control of sweat testing for cystic fibrosis should be developed.”
10 “To avoid burns. . . and electrical shocks. . .” several recommendations were made, including the importance of electrical current control, performing sweat tests
in CF centers, etc.
11 “There are no tests that meet established criteria for general screening in utero or any time thereafter.” (This conclusion changed soon thereafter in 1979 when
IRT was reported as a valid NBS test applicable to dried blood specimens.29)
12 “Neonates produce insufficient sweat to permit screening” by the sweat test before. . .about 4-6 wk.” (This conclusion was subsequently disproven.30)
13 “Research to develop a reliable and safe neonatal screening test and. . .antenatal test for CF is essential.”
14 “A screening test for the CF heterozygote is needed so that carriers can benefit from family-planning counseling.”
*Reprinted from Report of the Committee for a Study for Evaluation of Testing for Cystic Fibrosis27 with permission from Elsevier Inc.
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have been superseded by new knowledge, especially in our
understanding of CFTR genetics. Clearly, the major conclu-
sions and recommendations at that time centered on sweat
test confirmation of the diagnosis after symptoms had ap-
peared. However, limitations of sweat testing were acknowl-
edged; as the well-known CF physician-researcher Dr Paul di
Sant’Agnese stated, “the sweat test is only as good as the phy-
sician ordering it.”31 In addition, based on a study of out-
comes following diagnostic delays,32 some authorities such
as Dr Harry Shwachman early on felt NBS was essential to
achieving a diagnosis in time to improve outcomes. Other
lessons learned from this conference included the conclusion
that it was not appropriate to apply “CF factor” analyses or
any other incompletely developed tests to make a CF diagno-
sis. Indeed, premature applications of potential diagnostic
tests before validation and standardization should never be
recommended.
Discovery of the CFTR Gene Leads to New
Recommendations (1989-2000)
With the crucially important identification of the CFTR gene
in 1989,33-36 genetic analysis began to play an increasingly sig-
nificant role in diagnosis. There was recognition of an ex-
panded CFTR-associated phenotype (represented at that time
mostly by congenital bilateral absence of the vas deferens), and
development of new diagnostic techniques, such as nasal po-
tential difference (NPD) measurement.37 Attempts to catego-
rize patients led to a number of imprecise or inadequately
defined terms (such as classic/nonclassic CF, typical/atypical
CF, mild CF, and delayed CF). Although genetic knowledge
about CF and its epidemiology increased dramatically during
the decade after the CFTR discovery, there was uncertainty in
CF centers about: (1) how to apply genetic testing for diag-
nosis; (2) the disease-causing role of some mutations in the
rapidly growing list of mutations being identified; and (3)
whether or not prognosis could be predicted from genetic pro-
files. Faced with these new challenges, the US CF Foundation
convened another consensus conference in 1996 that focused
on assessing practical aspects of applying knowledge about
CFTR genetics and that produced a helpful set of revised con-
clusions, recommendations, and criteria. This effort involved
10 experts, all from North America, who based their recom-
mendations on updated genetic and NPD data. Published in
The Journal in 1998,21 the recommendations from this impor-
tant consensus conference attempted to bring order to the di-
agnostic landscape. The consensus at that time was that the
diagnosis of CF should be based on the presence of 1 or more
characteristic clinical features (Table II), a history of CF in a
sibling, or a positive NBS test result, plus laboratory evi-
dence of an abnormality in the CFTR gene or protein.
The overall conclusion was that acceptable evidence of a
CFTR abnormality included biological evidence of chloride
channel dysfunction (such as abnormal sweat chloride con-
centration, defined as sweat chloride >60 mmol/L; or abnor-
mal NPD) or identification of a CF disease-causing mutation38
in each copy of the CFTR gene. It was emphasized that “The
diagnosis of CF should be made only if there is an elevated
sweat chloride concentration (>60 mmol/L) on 2 separate oc-
casions in a patient with 1 or more clinical features consis-
tent with the CF phenotype or a history of CF in a sibling.”
However, it was also stated that:
The diagnostic criteria proposed here are not likely to cover
every possible clinical scenario, and there will be clinical di-
lemmas. . .Clinical judgment will continue to be essential in
patients who have typical or “atypical” clinical features but who
lack conclusive evidence of CFTR dysfunction. Such patients
will require close clinical follow-up along with laboratory re-
evaluation as appropriate.
Although NPD testing was not considered ready for routine
use, it was concluded that “For patients in whom sweat chlo-
ride concentrations are normal or borderline and in whom 2
CF mutations are not identified, an abnormal NPD measure-
ment recorded on 2 separate days can be used as evidence of
CFTR dysfunction.” Brief comments were also included on NBS,
which by 1991 had become valid and feasible based on the im-
munoreactive trypsinogen (IRT) test combined with DNA
analysis in some regions for CFTR mutations.39
Table II. 1998 Consensus: phenotypic features consistent with a diagnosis of CF*
1 Chronic sinopulmonary disease manifested by:
a. Persistent colonization/infection with typical CF pathogens including Staphylococcus aureus, nontypeable Haemophilus inﬂuenzae, mucoid and nonmucoid
Pseudomonas aeruginosa, and Burkholderia cepacia
b. Chronic cough and sputum production
c. Persistent chest radiograph abnormalities (eg, bronchiectasis, atelectasis, infiltrates, hyperinflation)
d. Airway obstruction manifested by wheezing and air trapping
e. Nasal polyps: radiographic or computed tomographic abnormalities of the paranasal sinuses
f. Digital clubbing
2 Gastrointestinal and nutritional abnormalities including:
a. Intestinal: meconium ileus, distal intestinal obstruction syndrome, rectal prolapse
b. Pancreatic: pancreatic insufficiency, recurrent pancreatitis
c. Hepatic: chronic hepatic disease manifested by clinical or histologic evidence of focal biliary cirrhosis or multilobular cirrhosis
d. Nutritional: failure to thrive (protein-calorie malnutrition), hypoproteinemia, and edema, complications secondary to fat-soluble vitamin deficiency
3 Salt loss syndromes: acute salt depletion, chronic metabolic alkalosis
4 Male urogenital abnormalities resulting in obstructive azoospermia (CBAVD)
CBAVD, congenital bilateral absence of the vas deferens.
*Reprinted from Rosenstein et al21 with permission from Elsevier Inc.
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Also at this time, the American College of Medical Genet-
ics, in conjunction with the American College of Obstetri-
cians and Gynecologists and the National Institutes of Health,
developed a panel of mutations for use in population screen-
ing for CF carriers, based on allele frequencies of CF muta-
tions in the US CF population.36,38 Even though the American
College of Medical Genetics guidelines were prepared for popu-
lation CF carrier screening, and not for the identification of
mutations in patients, genetic screening for carriers recog-
nized the growing importance of CFTR genetic analysis in the
CF diagnostic process.
Lessons Learned
This conference and the ensuing publication were timely, valu-
able contributions to medical practice in CF centers. However,
it soon became recognized that many CFTR mutations thought
to be CF-causing, were not associated with disease. Thus, the
recommendations from this conference and the American
College of Medical Genetics/American College of Obstetri-
cians and Gynecologists38,40 would need to be modified. Another
problem, which was recognized more slowly, was that the lack
of participation by European experts in the consensus process
contributed to a division on some issues such as terminol-
ogy. For instance, use of the term atypical has been, and
remains, integral in European CF practice.
The Advent of NBS Changes the Diagnostic
Strategy and Criteria (2001-2015)
In 1998, CF NBS was available in only 6 US states41 and certain
regional programs worldwide (such as Austria, Italy, the United
Kingdom, and Australia), and a CF diagnosis was suggested
by a positive NBS test result in fewer than 6% of new cases.42
However, this was soon to change. Data were published from
a randomized clinical trial in Wisconsin showing the benefits
of early diagnosis through NBS,43 and the CDC had become
interested in the evidence and special opportunity to capital-
ize on the network of 114 CF centers for confirmatory
diagnostic testing and follow-up care.44 At that time, approxi-
mately 500 CFTR mutations had been identified,45 with only
24 mutations classified as “CF-causing.”21 By 2007, CF NBS was
available in 34 states in the US46 and a growing number of Eu-
ropean countries10,47 and mandatory screening in every state
was imminent because of CDC6 and CF Foundation7 recom-
mendations. More than 1500 CFTR mutations had been iden-
tified, and there was greater awareness of the spectrum of
mutations in specific population groups as well as an in-
creased understanding of genotype–phenotype relation-
ships. The dramatic, and in fact unprecedented, implementation
of a NBS test that yielded genetic data led to more questions
and challenges related to diagnostic criteria.
Consequently, the US CF Foundation convened another CF
diagnosis consensus conference in 2007 and invited 18 par-
ticipants, including 4 of the 10 from the 1996-1998 confer-
ence. Although predominately from the US, there were 2
Canadians, an Australian, and a European CF geneticist with
NBS expertise. This group generated the US diagnostic guide-
lines in use before this publication (Table III) and recom-
mended the process summarized in Figure 1.9 Significant
differences from the 1998 recommendations included a de-
crease in the level of sweat chloride recognized as suggestive
of CF in infants (from 40 mmol/L in 199821 to 30 mmol/L in
20089) and the requirement in 1998 for a sweat chloride test
result >60 mmol/L on at least 2 occasions plus symptoms of
the disease, or history in a sibling. In 2008, a second sweat test
was not required for diagnosis if 2 CF-causing mutations were
identified, demonstrating the importance that genetic analy-
sis was having on diagnostic algorithms.
During the process of developing the 2008 guidelines, it was
recognized that NBS introduced a new complexity and diag-
nostic dilemma, namely infants with abnormal screening tests
because of elevated IRT levels but inconclusive sweat test and/
or DNA results. Rather than address this complex situation in
the diagnostic guidelines, it was decided that this issue of a “gray
zone,” affecting perhaps approximately 10% of infants with high
IRT levels and a single CFTR mutation,48 would be addressed
by the CF Foundation through a separate US consensus
Table III. 2008 US diagnostic guidelines*
Screened newborns: Infants with a positive newborn screen shall be diagnosed with CF if they have 1 of the following:
• sweat chloride ≥60 mmol/L
◦ CFTR mutation assessment is recommended; in the absence of 2 CF-causing mutations, sweat chloride value should be verified by repeat sweat test
• sweat chloride = 30-59 mmol/L† if they also have at least 1 of the following:
◦ 2 CF-causing mutations in trans
◦ clinical findings suggestive of CF, such as fecal elastase <200 mg/g or respiratory tract cultures revealing CF-associated pathogens
• sweat chloride ≤29 mmol/L‡ in the presence of 2 CF-causing mutations in trans
General population: Individuals shall be diagnosed with CF if they have 1 of the following:
• sweat chloride ≥60 mmol/L
• sweat chloride = 30-59 mmol/L§ if they also have at least 1 of the following:
◦ 2 CF-causing mutations (in trans, as stated in text9)
◦ significant clinical findings suggestive of CF, such as pancreatic insufficiency or respiratory tract cultures revealing CF-associated pathogen
• sweat chloride ≤39 mmol/L (after 6 mo of age) in the presence of 2 CF-causing mutations (in trans as stated in text9)
*Reprinted from Farrell et al9 with permission from Elsevier Inc.
†40-59 mmol/L in repeat sweat test after 6 mo of age.
‡≤39 mmol/L in repeat sweat test after 6 mo of age.
§40-59 mmol/L ≥6 mo of age.
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conference. An expert panel convened and, using a Delphi
method,49 recommended a new diagnostic term (CRMS for
CFTR-related metabolic syndrome) and management guide-
lines, published subsequently in The Journal.18 CRMS is the di-
agnosis used in the US to describe infants with elevated levels
of IRT, but with sweat chloride levels below CF diagnostic levels,
and fewer than 2 CF-causing mutations. Although this con-
dition is not a metabolic disorder, the designation “meta-
bolic syndrome” was established in part to have an International
Statistical Classification of Diseases and Related Health Prob-
lems (ICD), Ninth Revisions (ICD-9) medical code (277.9) for
US healthcare delivery system follow-up and billing pur-
poses. In fact, this consensus-producing effort led to the general
recognition that ICD coding was not included as part of the
diagnosis considerations in previous CF Foundation-sponsored
consensus conferences.
Despite the efforts to explain and apply CRMS as a diag-
nosis, this term has not been well accepted in Europe and some
other countries because of concern about its appropriateness
and a feeling that it was difficult for families to understand this
“syndrome label” as a descriptive term for a temporary diag-
nosis in an asymptomatic child requiring a further diagnos-
tic step (which is yet to be decided). Thus, a different term,
CFSPID, for CF screen positive, inconclusive diagnosis,17 was
developed in a Delphi process by the ECFS NSWG and intro-
duced recently in Europe as an alternative to CRMS.
During the planning phase of the 2015 CF Diagnosis Con-
sensus Conference, it was concluded that both CRMS and
CFSPID must be considered diagnoses that should be accom-
panied by a clinical management plan. Indeed, the original con-
sensus articles describing CRMS and CFSPID included action
plans for follow-up care.17,18 In addition, the CF Foundation
organized a separate consensus conference that was focused
on developing comprehensive care guidelines for infants di-
agnosed through NBS, extending to 2 years of age.50
Lessons Learned
The guidelines published in 2008 had significant impact as
NBS programs proliferated in the US (extending nationwide
by 2010) and also in other countries. However, the complexity
Positive IRT/DNA or IRT/IRT 5-14 days
AgeCF Newborn Screening Result:
CF Center Diagnostic Evaluation:
Outcomes:
CF Center Follow-up:
• DNA analysis if IRT/IRT
• Clinical Asessments
• Begin therapy aimed
to stay healthy
• Sweat test siblings
DNA analysis
• Using CFTR
multimutation
method
• Ancillary tests
1-2 months
2-6 months
Notification of parents and PCP ~2 weeks
Sweat Chloride Test* 2-4 weeks
30-59 mmol/L
Diagnosis of CF Possible CF
2 CF mutations† 0-1 CF mutation no DNA data
CF very unlikely‡
Repeat sweat
chloride test§
Figure 1. 2008 CF Foundation recommended diagnostic process for screened newborns. *If the baby is at least 2 kg and more
than 36 weeks’ gestation at birth, perform bilateral sweat sampling/analysis with either Gibson-Cooke or Macroduct method;
repeat as soon as possible if sweat quantity is less than 75 mg or 15 mL, respectively. †CF mutation refers to a CFTR mutant
allele known to cause CF disease. ‡The disease is very unlikely; however, if there are 2 CF mutations in trans, CF may be
diagnosed. §After a repeat sweat test, further evaluation depends on the results as implied above. PCP, primary care physician.
*Reprinted from Farrell et al9 with permission from Elsevier Inc.
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of the recommendations and the failure to incorporate the
CRMS consensus statements into the general diagnostic
guidelines resulted in 2 unlinked sets of recommendations
and caused confusion. An additional diagnostic term, CFTR-
related disorder, introduced by US authors in 2008,51 contrib-
uted to the confusion, as it was used in a variety of ways by
different authors before being precisely defined as a mono-
symptomatic entity by mainly European authors in 2011 after
2 consensus conferences.52 Once again, the very limited rep-
resentation of Europeans during the development of the 2008
CF Foundation guidelines led to less impact than antici-
pated. Another lesson learned was that the genetic data used
for diagnostic purposes must be defined more precisely, as
the explosion of information coming from the NBS pro-
grams demonstrated the wide array of phenotypic impacts
of different CFTR mutations.53,54 Finally, as these guidelines
were disseminated and explained, it became clear that some
confusion was attributable to the complexity and ambiguity
of cases arising from NBS programs; in retrospect, it would
have been wise to include case studies as examples of diag-
nostic challenges.
Consensus Recommendations and
Practices of the European CF Society
The ECFS has established both a DNWG and a NSWG, which
meet regularly and have published a variety of helpful ar-
ticles on CF diagnosis. The DNWG was organized in 2004 and
the NSWG in 2005. These groups have been responsible for
recommending diagnostic criteria, methods, and practices for
screened and nonscreened populations.10,17,19,47,55-57 To reach con-
sensus, they have used Delphi and other robust methods, in-
cluding a variety of surveys and multidisciplinary conferences.
Topics addressed by these ECFS groups include performance
and follow-up recommendations of NBS, standardization of
CFTR biomarkers such as NPD and intestinal current mea-
surement (ICM) for difficult cases, as well as characteriza-
tion of CFTR genotypes of unknown clinical relevance.
CF diagnostic algorithms were established by the ECFS in
2006 for the nonscreened population (Figure 2)10 and in 2009
for screened infants (Figure 3).19 Following the 2006
nonscreened algorithm can lead to 3 separate outcomes: “classic
CF,”“CF unlikely,” or “CFTR dysfunction.”A diagnosis of “classic
CF” is given to patients with sweat chloride levels >60 mmol/L
(as recommended in the 1998 CF Foundation consensus,21
rather than ≥60 mmol/L as recommended in subsequent US
guidelines9). “CF unlikely” is used to describe patients with
normal sweat chloride values (≤29 mmol/L) or intermediate
sweat chloride values (30-60 mmol/L for all ages), either 0 or
1 CFTR mutation and/or a normal NPD. Patients with inter-
mediate sweat chloride concentrations require further study;
NPD is recommended, and ICM may be considered to help
clarify the diagnosis. Both measures of CFTR function appear
to correlate well with CF genotype and phenotype58 and po-
tentially can be used to discriminate pancreatic-sufficient CF
from the individual without CF in the setting of intermediate
sweat chloride values.59,60 Both ICM and NPD require stan-
dardized techniques to be reliable, and the ECFS DNWG has
designed standardized operating procedures for ICM61 and
NPD62 that require validation in a multicenter setting.
In contrast to the potential outcome of “possible CF” de-
scribed in the 2008 CF Foundation diagnostic guidelines, the
ECFS algorithm recommends the use of NPD results to further
classify individuals with intermediate sweat chloride values and
less than 2 CF-causing CFTR mutations, potentially resulting
in the third, gray zone, category of “CFTR dysfunction” or
“nonclassic CF.”10 Subsequent validation of the European CF
diagnostic algorithm revealed that the “CFTR dysfunction”
group differs phenotypically from patients with intermediate
sweat chloride values in whom CFTR function based on NPD
testing was normal.19 Despite recommendation of the terms
“CFTR dysfunction” or “nonclassic CF” category in the 2006
ECFS algorithm, many European CF clinicians still use the term
atypical CF. This highlights the need for better consensus in
the currently ongoing update of the ECFS CF diagnostic guide-
line, which is being developed by Delphi consensus within the
DNWG and NSWG, and which is expected to include recent
European advances in using NPD and ICM as additional CFTR
biomarkers for difficult CF diagnoses.
An additional contribution from the ECFS came after the
results of 2 consensus conferences, which included world-
wide experts, were published by Bombieri et al52 describing a
“CFTR-related disorder” as “a clinical entity associated with
CFTR dysfunction that does not fulfil diagnostic criteria for
CF.” Examples of this would be certain monosymptomatic in-
dividuals with congenital bilateral absence of the vas defer-
ens, diffuse bronchiectasis, or recurrent pancreatitis. Diagnostic
algorithms for these groups44 are shown in Figure 4. NPD and
ICM values are not clear-cut in these individuals. The ECFS
recommends that individuals who cannot be diagnosed with
CF but are thought to be at risk of monosymptomatic disease
because of CFTR dysfunction (suggested by symptoms or labo-
ratory findings) should be categorized as having a “CFTR-
related disorder.”
The ECFS also has been responsible for 2 visionary “Garda
conferences” that have contributed significantly to the appli-
cation of CFTR genetic data in diagnostic processes and to the
use of “best practices” in NBS.55,63 In 2007, following the growing
number of CFTR sequence variations detected by molecular
assays and difficulties in understanding their actual signifi-
cance, ECFS convened a consensus conference aimed at sug-
gesting how to use and interpret mutation analysis in clinical
practice.63 An international group of CF clinicians and
geneticists gave an account of the distribution of mutations
and methods of analysis, addressed the role of genetic testing
for establishing the diagnosis of CF and for outcome predic-
tion, and provided recommendations on the bidirectional in-
formation flow between clinicians and molecular analysis
laboratories. The resulting 2008 state-of-the-art publication9
is now partially outdated in the sections on mutation
distribution, which is better understood today, and on genetic
analysis, which is going through a radical change thanks to next-
generation sequencing technologies. Conversely, discussions
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contained in other chapters retain their validity. The promi-
nence of sweat chloride testing as a diagnostic tool, the limited
role of mutation classes in predicting phenotype, and the short-
comings in reliably predicting the severity of pulmonary disease
based only on CFTR genotype had been suggested before but
reached a wider audience through the consensus publication.63
As an outcome of the 2007 Garda Conference, CFTR mu-
tations were clustered into 4 groups according to their predicted
diagnostic significance: (1) mutations that cause CF disease;
(2) mutations that result in a CFTR-related disorder (with a
partial overlap of groups 1 and 2); (3) mutations with no known
clinical consequence; and (4) mutations of unproven or un-
certain clinical relevance. In addition, suggestions were given
on criteria to use to assess the probability that a given se-
quence variation might be CF-causing. These definitions were
later adopted and adapted by the CFTR2 project.53,64
Clinical suspicion
CFTR DNA test
CF center
Sweat test
Repeat sweat test
Nasal PD
Consult
genetic lab
Consult
genetic lab
Mutatation scanning
of CFTR gene
Inconclusive
Consider FU (at CF center)
Consider
CF heterogeneity?
False + sweat test?
Consider alternative diagnosis
Appropriate investigations
and follow-up
Follow-up at CF center
CF unlikely CFTR dysfunction
– non classic CF
– WHO diagnostic list
Classic CF
<30 mmol/L 30-60 mmol/L >60 mmol/L
<30 mmol/L 30-60 mmol/L >60 mmol/L
if 0 mutation
0-1 mutation 2 mutations
0 mutation 1 mutation 2 mutations
Normal Inconclusive Abnormal
<30 mmol/L 30-60 mmol/L >60 mmol/L
CF center
Sweat test
Figure 2. 2006 ECFS recommended diagnostic process for nonscreened population. *Reprinted from De Boeck et al10 with
permission from BMJ.
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One year later, a second ECFS Consensus Conference,55 this
time prompted by the proliferation of CF NBS programs and
the heterogeneity of protocols and performances, outlined ben-
efits, by-products and costs of NBS, examined advantages and
disadvantages of different protocols, and suggested strategies
to inform families. Problems and uncertainties connected with
the identification of inconclusive cases elicited by NBS were
also discussed and later further elaborated on by the ECFS
NSWG. This in turn led to the use of the term CFSPID for as-
ymptomatic infants with an inconclusive diagnosis after posi-
tive NBS.17 There is ongoing ECFS activity on how, and for how
long, to follow up infants with CFSPID.
Lessons Learned
Investment by the ECFS to organize a combination of con-
sensus conferences and working groups on NBS and diagno-
sis has paid dividends worldwide. However, despite very
impressive data on the potential value of new, very sensitive
methods such as NPD and ICM, their dissemination has been
limited. It is especially surprising that the US has lagged behind
in the emerging field of evaluating CFTR functioning in situ
with NPD and ICM methods for improving our diagnostic ca-
pability in certain cases such as infants with intermediate sweat
chloride levels and inconclusive genetic data. Another lesson
learned is that the Delphi consensus process, although
considered fairly robust, is quite time consuming. Finally, it
appears that ECFS-generated products that we regard as “Eu-
ropean” may not apply to some aspects of diagnosis and ter-
minology (ie, atypical is not used throughout Europe even
though it is favored in many countries).
ICD-Associated Healthcare Delivery
Challenges and Recommendations for
Using ICD, 10th Revision Codes
Diagnostic consensus conferences, with the exception of the
conference convened to define CRMS,18 have lacked atten-
tion to the use of the ICD system. However, the ICD system
was created by the World Health Organization to be “the in-
ternational standard for defining and reporting diseases and
health conditions. . .It allows the world to compare and share
health information using a common language.”65 Thus, en-
suring that ICD codes are understood and used appropri-
ately in the many complex clinical scenarios encountered by
CF caregivers internationally is vital to achieving clinical re-
search objectives and optimizing access to and quality of care.
Recognizing the need to encourage the common and correct
use of ICD codes by CF caregivers, the issue was included during
the development of recommendations from the 2015 US CF
Diagnostic Consensus Conference.
The ICD system is updated on a regular basis. Revision of
the ICD-9 codes for the ICD, 10th Revision (ICD-10) system
began in 1983, was completed in 1992, and implemented in
the US on October 1, 2015. The delay was due to a variety of
issues including the complexity of ICD-10, the arduous trans-
formation processes involving both computer software up-
grades and paperwork revisions, training needs, the rigorous
regulatory requirements in the US, and the opposition of the
American Medical Association. The next update of the code,
to ICD, 11th Revision, is due to be completed by 2018.
ICD-10 codes recommended for use in individuals with CF
or CRMS/CFSPID can be found in the article in this Supple-
ment by Farrell et al.66 Although some CF specialists were
engaged in the ICD-10 development process, the degree of in-
fluence was limited. Despite the creation of over 16 000 codes
in the ICD-10 system, there is no code for a CFTR-related dis-
order, nor was there one in ICD-9. This unfortunate situa-
tion can be attributed to the timing of ICD-10 development
vis-à-vis the definition of a CFTR-related disorder in 2011.52
Lessons Learned
International consensus is important to clarify our under-
standing of CF pathology and improve the care for individu-
als affected by CFTR dysfunction. The ICD coding system
is an international language that must be used to enable
clinical data to be reported accurately across member nations.
A discussion of current ICD codes should be considered
at future diagnosis consensus conferences, to enhance global
understanding and ensure accurate diagnosis and research
results.
> Cut-off < Cut-off
NBS Negative
NBS NegativeNBS Positive
IRT at Birth
CF
Diagnosis
Referral to CF Center
for Clinical Evaluation
and Follow-up
Referral to CF Center
for Further Investigations
and Follow-up
(see figure 6)
Inconclusive
Diagnosis
False NBS
Positve*
Sweat Test
CI > 60 mmol/L CI 30-59 mmol/L CI < 30 mmol/L
Intermediate
Tiers
(see figure 4)
Figure 3. 2009 ECFS recommended diagnostic process for
screened newborns. (Note that references to figures in this il-
lustration refer to those in the original 2009 article.) *Re-
printed from Castellani et al55 with permission from Elsevier
Inc.
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Discussion
The US CF Foundation current diagnosis recommendations
arose from 3 essentially concurrent consensus exercises
published in 2008-2009, to be applied as an integrated
“package.”9,18,50 The ECFS recommendations, emanating from
their Diagnostic Network and Neonatal Screening Working
Groups, have also contributed significantly to recommenda-
tions for diagnostic practices. Unfortunately, despite best in-
tentions, the 2008 recommendations have been misunderstood
by some CF specialist leaders and have not been applied con-
sistently, leading to less-than-optimal outcomes for the CF
population.
To improve the design, uptake, and proper use of new rec-
ommendations, a review was conducted of the past several
decades of experience in creating CF diagnosis guidelines. A
number of valuable lessons were learned, and 3 lessons in
particular were used to inform the design of the 2015 CF di-
agnosis consensus process. First, although European recom-
mendations have contributed to US decisions, criteria and
terminology have varied, as reflected by the use of similar but
not identical nomenclature for CRMS and CFSPID, and by the
differential use of CFTR biomarkers such as NPD and ICM
to clarify a difficult CF diagnosis. This problem was ad-
dressed by inviting more European participation than ever
before, both during the conference itself, and afterward during
open review periods while the report was being prepared. The
second lesson, that the recommendations were misunder-
stood and inconsistently applied is being addressed by the de-
velopment of an implementation strategy. Finally, the lesson
of confusion and errors resulting from incorrectly applied ICD
codes was addressed by consultation with an ICD-coding expert
and inclusion of the pertinent codes in the main diagnosis con-
sensus document.66 It is hoped that these efforts to under-
stand and correct past oversights will improve development,
uptake, and application of the 2015 diagnosis consensus
guidelines. ■
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Applying Cystic Fibrosis Transmembrane Conductance Regulator
Genetics and CFTR2 Data to Facilitate Diagnoses
Patrick R. Sosnay, MD1, Danieli B. Salinas, MD2, Terry B. White, PhD3, Clement L. Ren, MD4, Philip M. Farrell, MD, PhD5,
Karen S. Raraigh, MGC6, Emmanuelle Girodon, MD7, and Carlo Castellani, MD8
Objective As a Mendelian disease, genetics plays an integral role in the diagnosis of cystic fibrosis (CF). The
identification of 2 disease-causing mutations in the CF transmembrane conductance regulator (CFTR) in an indi-
vidual with a phenotype provides evidence that the disease is CF. However, not all variations in CFTR always result
in CF. Therefore, for CFTR genotype to provide the same level of evidence of CFTR dysfunction as shown by direct
tests such as sweat chloride or nasal potential difference, the mutations identified must be known to always result
in CF. The use of CFTR genetics in CF diagnosis, therefore, relies heavily on mutation interpretation.
Study design Progress that has been made on mutation interpretation and annotation was reviewed at the recent
CF Foundation Diagnosis Consensus Conference. A modified Delphi method was used to identify consensus state-
ments on the use of genetic analysis in CF diagnosis.
Results The largest recent advance in CF genetics has come through the Clinical and Functional Translation of
CFTR (CFTR2) project. This undertaking seeks to characterize CFTR mutations from patients with CF around the
world. The project also established guidelines for the clinical, functional, and population/penetrance criteria that
can be used to interpret mutations not yet included in CFTR2’s review.
Conclusions The use of CFTR genetics to aid in diagnosis of CF requires that the mutations identified have a
known disease liability. The demonstration of 2 in trans mutations known to always result in CF is satisfactory evi-
dence of CFTR dysfunction. However, if the identified mutations are known to be associated with variable out-
comes, or have unknown consequence, that genotype may not result in a CF phenotype. In these cases, other
tests of CFTR function may help. (J Pediatr 2017;181S:S27-32).
The diagnosis of cystic fibrosis (CF) in this and previous consensus statements relies on both a clinical presentation aswell as evidence of CF transmembrane conductance regulator (CFTR) dysfunction.1-3 As a genetic disease, CF is definedby mutation in the gene that codes for CFTR. Therefore, the presence of deleterious mutations in both copies of the
CFTR gene does satisfy the diagnostic criteria for CF. It is important to keep in mind, especially in the evaluation of rare mu-
tations, that the genetic evidence of CFTR dysfunction is indirect and must be inferred from what is known about the muta-
tion. Even before the gene was identified, tests that measure the direct consequence of dysfunctional CFTRwere shown to differentiate
CF from non-CF.4 This established the measurement of sweat chloride concentration as the “first-line”method to describe CFTR
dysfunction, and it remains integral to CF diagnosis. However, there are circumstances such as newborn screening (NBS) in
which sweat testing is impractical or impossible. As a result, CFTR genotyping has become an equally important part of CF
diagnosis. The introduction of CFTR-modulating therapies that are specific to certain mutations also emphasizes the need for
genotyping and mutation characterization.5
Initially,CFTR genotyping was done in individuals with clear phenotypic mani-
festations of CF who demonstrated CFTR dysfunction through sweat chloride mea-
surement. Therefore, if a mutation was detected in the CFTR gene in a sample
from an individual with CF, it was presumed to be CF-causing. This was accu-
rate for most well-recognized mutations (such as c.1521_1523delCTT [legacy:
F508del], c.1652G > A [legacy: G551D], or c.1624G > T [legacy: G542X]), but several
important examples were recognized in which variants identified in CFTR were
not independently causal of CF.6,7 Also, the number of variants in CFTR ex-
panded rapidly as genetic analysis was performed on more patients with CF and
CF Cystic fibrosis
CFMD CF Mutation Database
CFTR CF transmembrane conductance regulator
CFTR2 Clinical and Functional Translation of CFTR
MVCC Mutations of varying clinical consequence
NBS Newborn screening
UNK Mutation of unknown significance
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in the general population. To address the need for the anno-
tation of CFTR variants, the US CF Foundation assembled an
international research group tasked with defining criteria for
disease liability and annotating the mutations seen in pa-
tients with CF entered in registries. This research group, the
clinical and functional translation of CFTR (CFTR2) team, has
made an important contribution and has better informed
genetic analysis as a part of CF diagnosis.
In this report, we outline the use of CFTR genetic analysis
in the diagnosis of CF and other related conditions. The in-
terpretation of CFTR genotyping will focus on the categories
of mutations as described by the CFTR2 team. The CFTR2
analysis is a comprehensive annotation of mutations among
patients with CF, but there are several important instances in
which genetic analysis does not allow a definitive CF diagno-
sis, or in which information other than CFTR2 should be con-
sidered. For example, the use of genetic criteria in diagnosis
is insufficient for mutations that are known to be associated
with CF in some individuals but no phenotype in others, and
for the manymutations not yet characterized by CFTR2. There-
fore, the diagnostic challenge of difficult-to-interpret geno-
types will remain.
Mutation Annotation
The initial repository for CFTR variants, termed the CF Mu-
tation Database (CFMD),8 began in 1990, shortly after the
CFTR gene was identified. The CFMD content was as-
sembled through voluntary contributions from research labo-
ratories, genetic testing facilities, and clinicians. It is a
comprehensive collection of variation in the CFTR gene, with
graphic and text search features that incorporate both legacy-
mutation naming, as well as more recent naming rules that
are consistent across the genetic community9,10 (Appendix;
available at www.jpeds.com). The database in some cases con-
tains phenotypic information that was included with the sub-
mission. For example, it may report that a given mutation
was noticed in an individual with infertility. Although this
information might be helpful for rare mutations, these single
cases do not always reflect the true disease liability of the mu-
tations. The first reported case of a mutation may be the only
one noted, even if subsequent occurrences of the mutations
have differing phenotypes. Therefore, assessing the disease li-
ability of CFTR variants based solely on whatever data have
been submitted to CFMD is of limited usefulness toward CF
diagnosis.
Although the CFMD constitutes an excellent existing re-
pository of information on nucleotide variation in the CFTR
gene, it was clear that a new approach was essential to com-
prehensively and consistently address the phenotypic and func-
tional implications of CFTR variants. The CFTR2 project has
assembled data from national registries of patients with CF,
as well as large clinical databases from countries without a na-
tional registry, to collect, quantify, and describe the muta-
tions reported in individuals with CF.11 These registries and
datasets are largely from Europe, North America, and Austra-
lia, but also contain representation from the Middle East, Asia,
and South America. The mutations seen among this group of
individuals with CF can be ranked by frequency to prioritize
the analysis and annotation of mutations seen most com-
monly. Mutations are categorized as CF-causing if they meet
clinical, functional, and population/penetrance criteria (Table I).
Mutations are categorized as mutations of varying clinical con-
sequence (MVCC) if they do not meet clinical and/or func-
tion criteria. Categorizing a mutation as non-CF-causing
Table I. Categories of mutations, as defined by CFTR2
Clinical criteria Functional analysis Population/penetrance
CF-causing Mean sweat chloride
≥60 mmol/L in patients with
the mutation present in trans
with a known CF-causing
mutation*
Mutation of the type expected to produce no protein
(nonsense, frameshift, canonical splice)†
OR
Functional evidence of:
• <10% wild-type CFTR mRNA present
• <10% wild-type CFTR protein folding/processing
• <10% wild-type CFTR-specific chloride
conductance
Evidence suggests completely penetrant for CF:
• Not seen in the nontransmitted allele in fathers of
offspring with CF
• Allele frequency in the population with CF higher
than in the general population
MVCC Variant may or may not meet
CF-causing criteria
Variant may or may not meet CF-causing criteria Lack of CF phenotype in some individuals with
mutation in trans with CF-causing mutation
Variant does not satisfy both clinical and functional criteria above (but may satisfy one or
the other, or may satisfy neither)
Non-CF-causing Clinical evidence not considered Variant must not meet CF-causing criteria Evidence that the variant is nonpenetrant:
• Allele frequency in the population with CF lower
than allele frequency in the general population
• Observed as the nontransmitted allele in trans
with a CF-causing mutation in the father of
offspring with CF
Unknown Analysis incomplete
OR
Unable to assign a disease liability characterization
mRNA, messenger RNA.
*If too few patients with sweat chloride data, pancreatic function data are used.20
†Not all mutations that cause premature terminations will result in nonsense-mediated decay and no protein (ie, those with terminations in the last exon); in which case, laboratory-based func-
tional analysis is required.
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requires a different approach. Clinical criteria are not consid-
ered because it is likely that the patients’ phenotypes result from
an unidentified variant. Instead, characterization of non-CF-
causing requires functional analysis and strong evidence from
the general population that these variants are not fully pen-
etrant for CF (that is, they do not result in CF when present
in trans with a CF-causing mutation). A fourth category listed
in Table I is unknown; the CFTR2 annotation project is
ongoing, and analysis has not been completed for allCFTR vari-
ants, particularly those that occur at extremely low frequency.
Assigning mutations to these categories of disease liability
has the benefit of simplifying genetic interpretation. It is con-
sistent with current recommended practices for variant an-
notation by the American College of Medical Genetics, while
keeping specificity toward the mutations’ likelihood of causing
CF (as opposed to any phenotype, which may not meet the
definition of CF).12 The following potential shortcomings of
this classification hierarchy deserve consideration because they
elucidate scenarios in which CFTR molecular genetic analy-
sis may be less helpful in making a CF diagnosis or cases where
the context of additional research may be needed.
The Penetrance of Variants Classified as Varying
Consequence May Differ
For example, the variant c.3454G > C (legacy: D1152H) is well
known to be associated withmilder CF disease in some cases.13-15
In comparison, the variant c.[350G > A;1210 − 12[7]] (legacy:
R117H;7T) also is associated with milder disease but has been
shown to have many more individuals that possess this variant
with a CF-causing variant who do not have disease.16
There Is No Special Designation for Mutations
Primarily Associated with CFTR-Related Disorders
The recognition of individuals with CFTR mutations and a
CFTR-related phenotype who do not meet the diagnostic cri-
teria for CF has led to the definition of CFTR-related disorders.17
These individuals may have isolated male infertility, recur-
rent pancreatitis, or bronchiectasis. There are CFTR variants
that more frequently (but not exclusively) result in these milder
phenotypes.18,19 In CFTR2, these variants have been classified
as either MVCC or non-CF-causing. Prior reviews of the use
of genetics in CF have assigned mutations to categories in a
similar fashion as CFTR2 but include a category of muta-
tions leading to CFTR-related disorders.21,22 However, the
authors of those reviews concede that many of the muta-
tions assigned in the CFTR-related disorder category may also
be included in another category. CFTR2 is focused more spe-
cifically on individuals with CF, and defining the disease li-
ability relative to CF.
CFTR2 Is Not Comprehensive
Although the CFTR2 project is a comprehensive systematic an-
notation of disease liability, there is a great deal of published
literature on mutations not yet included in CFTR2. This may
occur for populations under-represented in CFTR2. Other re-
search may be of considerable help, especially for mutations
reported as “unknown” by CFTR2.
Penetrance
The genetic term“penetrance” refers to the proportion of people
with a given genotype who will exhibit symptoms of a con-
dition. For CF, this can be defined as the proportion of people
with a specific mutation combination, (specifically, the indi-
vidual mutation under analysis plus any known CF-causing
mutation on the other allele) who will satisfy the diagnostic
criteria for CF. Mutations or genotypes that always lead to CF
are said to be 100% penetrant. The most common example
of a mutation with 100% penetrance is F508del; this means
that every person with the genotype F508del/F508del is ex-
pected to have CF. Other mutations, such as the more vari-
able D1152H, are less than 100% penetrant for CF because not
all people with this mutation, even in combination with a CF-
causing mutation like F508del, will have CF. In this respect,
a given mutation is expected to have different penetrance for
CF- vs CFTR-related disorders.
Assessing penetrance requires an understanding of the fre-
quency of individuals who have a given genotype but do not
have CF (and are, therefore, not represented in CFTR2). There
has been great progress in public repositories of genetic varia-
tion, which allows better estimates of the allele frequency of
a given variant in general (presumably healthy and unaf-
fected) populations. As part of the penetrance analysis for the
CFTR2 assignment of disease liability, the allele frequency in
individuals with CF is compared with the allele frequency in
the general population as estimated using data from the 1000
genomes browser.23,24 Mutations such as G551D are more
common among individuals with CF. Therefore, the relative
prevalence of patients with CF with this mutation can be ac-
curately estimated by applying the Hardy-Weinberg prin-
ciple to the allele frequency in European populations. For
mutations such as c.2991G > C (legacy: L997F), the allele fre-
quency in the general population is much higher than among
individuals with CF. This suggests that many individuals carry
this allele, in trans with a CF-causing allele, are not entered
into registries of patients with CF, and are, therefore, not re-
flected in CFTR2. However, this comparison of the general to
the population with CF does not include individuals who may
have phenotype (such as infertility) because of L997F but are
not entered into a registry of patients with CF.
Use of Genetics in CF Diagnosis
The US Cystic Fibrosis Foundation 2015 Diagnosis Consen-
sus Committee voted to adopt the guidelines shown in Table II
regarding the use of molecular genetic tests to aid in demon-
strating CF diagnosis.3
Although it was not specifically designated in the consen-
sus statements, it is the opinion of the authors that CFTR
genotyping should be performed for all individuals diag-
nosed with CF, even if physiologic tests establish the diagno-
sis. The reason for this, beyond better understanding of the
genetic epidemiology of this disease, is that currently avail-
able (and, presumably, future) therapies are able to modulate
February 2017 SUPPLEMENT
S29Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses
specific CFTR mutations. Genotyping errors are more likely
to occur in NBS (state-run laboratories doing a large number
of tests) than in genetic testing done for clinical purposes.
Therefore, depending on the laboratories’ quality metrics, repeat
genotyping may be indicated to confirm the genotype iden-
tified through NBS.
In the event that an individual being considered for CF has
a genotype that is not annotated by CFTR2, other literature
should be consulted. If other research is lacking or equivocal,
the clinician will need to rely more heavily on other tests to
demonstrate CFTR dysfunction, such as sweat chloride testing
or physiologic CFTR testing through nasal potential differ-
ence or intestinal current measures. Some specific genotype
combinations and recommendations are described in Table III.
Genetic Tests for CFTR
As the use of genetic testing inmedical practice has expanded,
testing for more variation has become less expensive. Tradi-
tionally, testing for CFTR mutations was done by panel tests
that detect a given number of mutations (usually 5-150 mu-
tations). These panels can be customized to better detect local
variants seen in the local populations. Sequencing is a com-
prehensive check of all nucleotides in the coding region of the
gene and typically also includes noncoding regionswhere known
mutations exist.Sequencingnow is increasingly performedusing
“next-gen” technology. One application of this technology in-
volves only reporting mutations with well-established disease
liability as abnormal in the initial screening report, but with
the ability to“go back”and reveal variants of uncertain disease
liability if the clinician believes the clinical scenario warrants
this.27 Sequencing is more sensitive, but may not detect mu-
tations in the noncoding region and also may not detect large
deletions or duplications in the gene. Deletions and duplica-
tions can specifically be tested for by separate tests such asmul-
tiplex ligation-dependent probe amplification. Deletions and
duplications may be detected by certain next-gen platforms,
but this practice will vary by testing laboratory.28
Table II. 2015 CF Foundation diagnosis consensus conference recommendations for diagnosis of CF using CFTR2
Statement
numbers Consensus statements
11 The latest classifications identified in the CFTR2 project25 should be used to aid with CF diagnosis:
• CF-causing mutation: individuals with 2 copies on separate alleles will likely have CF (clinical sweat confirmation needed)
• Mutation of varying clinical consequence (MVCC): a mutation that in combination with a CF-causing mutation or another MVCC mutation may
result in CF
• Uncharacterized mutation/mutation of UNK: mutation that has not been evaluated by CFTR2 and may be disease causing or of variable clinical
consequence or benign
• Non-CF-causing mutation: individuals with 1 or more are unlikely to have CF (as a result of that allele)
12 In individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, the identification of 2 CF-causing mutations
(defined by CFTR2) is consistent with a diagnosis of CF. Sweat chloride testing is necessary, though, to confirm the diagnosis.
13 The absence of detection of 2 CF-causing CFTR mutations does not exclude a diagnosis of CF.
Table III. Effects on diagnosis recommendations of different categories of CFTR mutations in the presence of a CF-
causing mutation (in trans)
CFTR genotype
Recommendations for interpretationAllele 1 Allele 2
CF-causing
mutation
Variant not characterized by
CFTR2 (or categorized as
“unknown”)
This category includes mutations not annotated by CFTR2. Therefore, this genotype may or may not result in CF,
depending on the disease liability of the uncharacterized variant. In some cases, there may be existing literature on
the variant. If so, the same criteria used by CFTR2 can be used to define the pathologic potential for that variant.
The literature on the variant should include clinical evidence (described in well-phenotyped patients with CF),
functional evidence (either predicted to result in no protein, tested for RNA or protein levels, or tested for chloride
conductance), and finally, population evidence. The population evidence can be investigated by looking for the
variant in public databases such as 1000 genomes23 or the Exome Aggregator Consortium.26 A high allele
frequency of the variant in these public databases would suggest that it is not fully penetrant.
Mutation of varying clinical
consequence
The likelihood that this genotype will result in CF will depend on the penetrance of the mutation with varying clinical
consequence. In most cases, that is not well known. The clinical scenario becomes the key determinate of the
diagnostic label. This can become challenging, especially if this genotype is detected in a newborn (eg, Extended
Genetic Testing as Part of NBS in California). Because lung and pancreatic phenotypes progress over time, a clinical
scenario that meets CF criteria may not occur until later in life.
No variant identified The key to interpreting a result in which only one variant identified is evaluating the extent of genetic testing. If only a
panel containing common mutations was used, there may be an unidentified mutation. If there is suspicion from
either clinical criteria or from CFTR physiologic testing, extended CFTR analysis should be performed. Sequencing
and deletion duplication testing have a very high negative predictive value, but cannot completely exclude the CF.
Non-CF-causing The non-CF-causing mutations in CFTR2 were all identified in patients believed to have CF (enough to be entered in a
registry). This occurred because the individual: (1) does not actually have CF, and the diagnosis is incorrect; (2) has
mild organ system manifestations that do not typically meet diagnostic criteria for CF, but may be an example of a
CFTR-related disorder; or (3) has CF, but 1 of the causative variants has not been identified (and the non-CF-
causing variant is inappropriately assumed the culprit). This (2 mutations on the same chromosome) would be an
example of a complex allele.
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Complex alleles, in which multiple variants are present on
the same chromosome, present an added diagnostic chal-
lenge. In some cases, disease liability is well recognized, but this
is not often the case. For the mutation c.350G > A (legacy:
R117H), it is well established that differing intron 9 (legacy
intron 8) modifiers affect the severity and penetrance of this
allele.6,29 Another example of a complex allele is one contain-
ing the common variant L997F. Individuals who carry this and
c.350G > T (legacy: R117L) on the same allele have a more
severe phenotype than those carrying just L997F alone.30When
multiple mutations are detected and there is suspicion of a
complex allele, testing of the parents or siblings is needed to
determine which variants are inherited together.
In general, genetic tests designed to identify the presence of
one of a defined panel of CFTR mutations can be designed
to be highly specific as they test for only CFTR variants that
are known to cause CF. The sensitivities of these panels depend
on how well the selected variants reflect the population being
tested. Sequencing (and deletion/duplication testing) in-
creases the sensitivity of the assay, but it is less specific because
it may identify a CFTR variant that is uncharacterized or one
that is known to be associated with varying clinical conse-
quences. No genetic testing is completely infallible, and clini-
cal suspicion should always take precedence.
Example: Extended Genetic Testing as Part of NBS
in California
Because of the racial diversity in California, traditional NBS
algorithms that rely on standardized panels of CFTR muta-
tions were not sensitive enough to meet state NBS standards.
In 2007, California initiated a CF NBS program that uses a
3-tiered approach: (1) a high immunoreactive trypsinogen
level in a newborn’s dried bloodspot; (2) which triggers use
of a panel of 40 mutations selected from the mutations found
in local CF clinics; (3) and then CFTR sequencing is per-
formed for newborns with only 1 mutation identified from
the California panel.31 A consequence of this approach has
been the detection of MVCC and (especially in the Hispanic
community) previously unrecognized CFTR mutations that
have not yet been classified.32 Thus, the program has identi-
fied large numbers of infants with a positive newborn screen
who do not fulfill current diagnostic criteria for CF, and who
have mutations with as-yet-unknown likelihood of causing
disease.
Of the 2 124 050 infants screened in the period from 2004
to 2011, 174 infants were diagnosed with CF on the basis of
2 panel mutations. Another 674 infants displayed 1 Califor-
nia panel mutation, with a second mutation found through
CFTR sequencing. In 98 of these individuals, the genotype was
determined to be non-CF-causing. In follow-up, these infants
had no signs or symptoms related to CF, and none of them
presented with high sweat chlorides or pancreatic insuffi-
ciency by 2 to 6 years of age.33 In 60 infants, the mutation iden-
tified by sequencing was known to be CF-causing, and these
individuals were diagnosed with CF. The remaining infants were
grouped for further study according to the predicted effects
of the second mutation: MVCC (n = 78), mutations of
unknown significance (UNK; n = 244), and intron 9 5T vari-
ants (splicing efficiency mutation, n = 194).
In 2-4 years of follow-up, a small but significant percent-
age of children from the MVCC (4/78, 5%) and UNK (27/
244, 11%) groups had been diagnosed with CF because of
either having sweat chloride level ≥60 mmol/L or developing
pancreatic insufficiency. These data highlight the challenge
of uncharacterized mutations in screening: some unknown
or uncharacterized mutations may cause CF, and others
have evidence of being benign. The 5T variants are under
analysis.
These outcomes highlight the potential benefit and chal-
lenges of using CFTR sequencing in NBS, which has ex-
panded knowledge of CFTR variants in populations in which
CF is uncommon but under-recognized. Sequencing will iden-
tify mutations that have no disease annotation or are associ-
ated with varying clinical consequences (MVCC).When used
in screening, this will result in large numbers of patients with
CRMS/CFSPID (Another article in the Supplement provides
additional information on this topic.34) Because some chil-
dren may develop different CF symptoms over the course of
their lifetime, this presents the opportunity to detect disease
before it occurs. However, the added sensitivity is countered
by the distinct challenges resulting from the greater need for
CF clinics to follow more children, and the potential conse-
quences of over-labeling or “medicalizing” these asymptom-
atic children is not known. Because the prognosis for children
in theMVCCandUNKgroups described above is still not clear,
further study is needed to better recognize features that will
predict disease (or lack thereof) over the lifetime. Until this is
done, sequencing is not a universal solution to establishing a
CF diagnosis.
Discussion
The majority of individuals with CF can be diagnosed readily
with sweat testing and withCFTR genetic analysis showing well-
recognized CF-causing mutations. Genetic analysis can be
difficult to interpret if mutations identified are rare and
uncharacterized or are known to be associated with varying
clinical consequences. The CFTR2 project has characterized
mutations using clinical, functional, and population/penetrance
criteria. Although in the final analysis the clinician’s judg-
ment must prevail, the genotypic information provided to the
clinician is increasingly helpful, both in making the diagno-
sis and in choice of life-changing therapies that are becom-
ing available for many individuals with CF. ■
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Appendix
Mutation Terminology
Both the terms “mutation” and “variant” are commonly used
to describe a genetic difference from what is typically seen in
a population. These terms have different meanings in some con-
texts (“mutation” often describes a deleterious change, whereas
“variant” does not) but are also frequently used interchange-
ably. To prevent confusion and misinterpretation, multiple
groups now recommend the use of the terms “variant” or “se-
quence alteration” to describe a DNA change, therefore, avoid-
ing the negative connotation of the term“mutation.”However,
most clinicians are more familiar and comfortable with “mu-
tation”; thus, for the purposes of this report, this term will be
used to describe any DNA change. Additional descriptors such
as “CF-causing mutation” or “mutation of unknown signifi-
cance” will be applied when known.
TheCFTR gene was discovered before there was an attempt
to standardize gene numbering and mutation nomenclature
across all genes; thus, the original numbering and mutation
naming system became outdated once the Human Genome
Variation Society recommended standardizing these
practices.8 The CF community had already adopted a“legacy”
numbering and nomenclature (eg, F508del, G551D, or
3849+10kbC->T). However, genetic testing laboratories gen-
erally report mutations using standardized Human Genome
Variation Society terminology (F508del = c.1521_1523delCTT,
G551D = p.Gly551Asp, or c.1652G>A, and 3849+10kbC->T =
c.3717+12191C>T). The “c” refers to coding DNA nucleotide
number, and the “p” refers to amino acid number. Although
this can create confusion, resources such asCFTR220 andCFMD8
can be consulted to translate mutations into different naming
conventions.
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Richard B. Parad, MD, MPH5, Margaret Rosenfeld, MD, MPH6, Olaf Sommerburg, MD7, Frank J. Accurso, MD8,
Jane C. Davies, MBChB, FRCPCH, MD9, Michael J. Rock, MD1, Don B. Sanders, MD, MS10, Michael Wilschanski, MBBS11,
Isabelle Sermet-Gaudelus, MD, PhD12, Hannah Blau, MBBS13, Silvia Gartner, MD14, and Susanna A. McColley, MD15
Objective Cystic fibrosis (CF) can be difficult to diagnose, even when newborn screening (NBS) tests yield posi-
tive results. This challenge is exacerbated by the multitude of NBS protocols, misunderstandings about screening
vs diagnostic tests, and the lack of guidelines for presumptive diagnoses. There is also confusion regarding the
designation of age at diagnosis.
Study design To improve diagnosis and achieve standardization in definitions worldwide, the CF Foundation
convened a committee of 32 experts with a mission to develop clear and actionable consensus guidelines on
diagnosis of CF with an emphasis on screened populations, especially the newborn population. A comprehensive
literature review was performed with emphasis on relevant articles published during the past decade.
Results After reviewing the common screening protocols and outcome scenarios, 14 of 27 consensus
statements were drafted that apply to screened populations. These were approved by 80% or more of the
participants.
Conclusions It is recommended that all diagnoses be established by demonstrating dysfunction of the CF
transmembrane conductance regulator (CFTR) channel, initially with a sweat chloride test and, when needed,
potentially with newer methods assessing membrane transport directly, such as intestinal current measurements.
Even in babies with 2 CF-causing mutations detected via NBS, diagnosis must be confirmed by demonstrating
CFTR dysfunction. The committee also recommends that the latest classifications identified in the Clinical and
Functional Translation of CFTR project [http://www.cftr2.org/index.php] should be used to aid with CF diagnosis.
Finally, to avoid delays in treatment, we provide guidelines for presumptive diagnoses and recommend how to
determine the age of diagnosis. (J Pediatr 2017;181S:S33-44).
Cystic fibrosis (CF) is the most common life-threatening autosomal reces-sive disease in the US, occurring in approximately 1 in 4000 newborns.1-3Since 1989, it has become well known that CF is an ion channel disorder
caused by mutations in the gene for the CF transmembrane conductance regu-
lator (CFTR).4 There are more than 2000 mutations identified to date,5 approxi-
mately 10%-15% of which have so far been confirmed to be CF-causing alleles.6
There has been a surprising degree of difficulty encountered worldwide in estab-
lishing the diagnosis in a minority of cases and because of this, healthcare pro-
viders continue to be faced with uncertain cases and challenging diagnostic
dilemmas. Although the diagnosis of CF has traditionally relied on recognition
of characteristic clinical signs and symptoms, the increased use of prenatal popu-
lation screening for maternal CF carrier status, prenatal ultrasound screening (that
CF Cystic fibrosis
CFFPR CF Foundation Patient Registry
CFSPID CF screen positive, inconclusive diagnosis
CFTR CF transmembrane conductance regulator
CRMS CFTR-related metabolic syndrome
FE Fecal elastase
ICM Intestinal current measurement
IRT Immunoreactive trypsinogen
NBS Newborn screening
NPD Nasal potential difference
PAP Pancreatitis-associated protein
PFT Pulmonary function test
VHIRT Very high IRT
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might reveal meconium ileus,meconium peritonitis, bowel ob-
struction, or echogenic bowel), and newborn screening (NBS)
has resulted in the routine diagnosis of asymptomatic or mini-
mally symptomatic infants and a consequent opportunity to
foster their normal growth and development. Since 2010 when
nationwide CF NBS began in the US because of endorse-
ments by the US Centers for Disease Control7 and the CF
Foundation,8 the proportion of newly diagnosed patients iden-
tified through screening has progressively increased. In fact,
in the US, approximately 64% of new CF diagnoses now follow
positive NBS.
According to consensus guidelines developedby theCFFoun-
dation in 2007 and published in The Journal in 2008,9 indi-
viduals identified byNBS can be diagnosed with CF by a sweat
chloride value ≥60 mmol/L, or a level of 30-59 mmol/L if they
have 2 CF-causing mutations in the CFTR gene. Although the
vast majority of screened infants can be unequivocally diag-
nosedwith CF by high levels of sweat chloride following a posi-
tive newborn screen,9,10 the decision is not clear-cut in a
significant number of individuals.11-13 Unclear diagnoses lead
to treatment delays, persistent challenges,14 and stress and con-
fusion for both families15,16 and clinicians.17 This groupof infants,
with varying levels of symptoms and a variety of CFTR mu-
tations, has been the focus of discussions in the US and in
Europe, with somewhat differing conclusions on both diag-
nosis and management.18,19 In addition, there has been a lack
of international harmony regarding terminology, leading to con-
fusion reflected in a recent article, entitled “Comparing the
American and European diagnostic guidelines for cystic fi-
brosis: same disease, different language?”20
Although treatment advances over the past several decades
have raised themedian predicted survival age from themidteens
in the 1970s to more than 40 years of age today in the US21
and many countries in Europe,22,23 and more than 50 years in
Canada24 and in addition new CFTRmodulator therapies offer
great promise,25 achieving optimal outcomes for all ages depends
on timely and accurate diagnosis.26,27 Continued improve-
ment in predicted survival requires careful attention to diag-
nostic recommendations. Despite efforts to reach and sustain
a consensus on diagnostic criteria, however, it has become in-
creasingly clear during the past few years that CF Founda-
tion guidelines published in 2008 are not being used consistently
and are considered obsolete by many clinicians.14
During the process of developing the 2008 guidelines, it was
recognized that CF NBS introduced a new complexity and di-
agnostic dilemma, namely infants with abnormal screening tests
because of elevated immunoreactive trypsinogen (IRT) levels
but inconclusive sweat tests and/or DNA results. Some infants
with a high IRT, for example, can display an initial sweat chlo-
ride level below the lowest accepted value for a potential CF
diagnosis (30 mmol/L), even in the presence of 2 CF-causing
mutations.12,28 More common, however, are infants with high
IRT levels and sweat chloride levels below CF diagnostic levels
who have fewer than 2 CF-causing mutations.12 This latter sce-
nario has led to a new diagnostic term andmanagement guide-
lines, published in The Journal,19 in an article that created the
term CFTR-related metabolic syndrome (CRMS).
In an effort to resolve the current diagnostic challenges fol-
lowing a positive CF NBS result, participants in the 2015 Di-
agnosisConsensusConference included the following objectives
in their mission: to develop revised guidelines for NBS-linked
diagnosis, aswell as for babies born after positive prenatal testing
(ie, positive fetal diagnostic testing, including sweat test re-
quirements and use of genetic data). Consensus recommen-
dation statements that apply to the screened population,
developed as a result of this conference29 are presented inTable I.
The Many Potential Meanings of a Positive
CF NBS Test
A positive CF newborn screen is a result that demands prompt
follow-up to identify infants with CF. However, CF NBS pro-
grams vary considerably in design, and the type of NBS al-
gorithm used to produce a positive screening result affects the
positive predictive value, follow-up, and diagnostic processes.
All CF NBS programs begin with detection of a high IRT
level in a dried blood specimen from the newborn. In the US,
this is routinely followed either by a second IRTmeasurement
(IRT/IRT) or by use of a variety of CFTR mutation panels
(usually 23-40 mutations30) (IRT/DNA). IRT/IRT is used fol-
lowing approximately 10% of all US births, but its use is de-
clining, because of lower sensitivity,31 delayed completion,32 and
higher false-negative rate33 compared with IRT/DNA NBS al-
gorithms. A variation of the IRT/DNA method, called IRT/
IRT/DNA, requires the demonstration of persistent
hypertrypsinogenemia for 1-2 weeks beforeDNA is analyzed.34
The time to diagnosis may be longer than in IRT/DNA pro-
grams, but a study suggests the IRT/IRT/DNA screen is more
sensitive and detects fewer carriers.34
Once a positive CF NBS result has been found, sweat chlo-
ride testing must be performed to establish a CF diagnosis
(Table I, statement 3). Some CF NBS programs in the US that
use IRT/IRThave added sweat testing, combined selectivelywith
DNA analysis, for follow-up to the biomarker screening.
However, requiring sweat testing of all infants with positive
IRT/IRT tests can be logistically problematic, such as when the
infant does not live close to an accredited sweat test facility.
Performing a sweat chloride test in infants receiving neonatal
intensive care, who are more likely to have high IRT values
because of nonspecific pancreatic stress,35 can also be chal-
lenging, either because they are preterm or <2 kg in weight
(Table I, statement 2), are on supplemental oxygen, or cannot
leave the intensive care unit for the test. In these cases, CFTR
mutation analysis can play a role in the initial evaluation even
in CF NBS programs that measure biomarkers alone.
Most USCFNBS programs now include some formof DNA
analysis in a second or third tier of screening.36 The type of
analysis performed depends on state laws and demographics
of the population being screened,37 but usually involves a panel
of 23-40 of the most common CF-causing mutations. Some
CF NBS programs subject the DNA to a more comprehensive
genetic analysis.38-40 Although a more detailed analysis can
improve the detection of CF in nonwhite populations,41 it can
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also result in the detection of many more infants with unclear
diagnostic results.13
An approach taken by some US CF NBS programs to
improve sensitivity is the institution of a “safety net.” (The term
“failsafe” is also used,36 although it must be cautioned that false-
negative screening tests will still occur.) Safety net design differs
between programs. In CF NBS programs using DNA analysis
as a second tier of screening, if the DNA suggests CF, the infant
is referred for diagnostic confirmation by sweat test. However,
even if the second-tier DNA screen does not detect a panel mu-
tation, infants with very high IRT (VHIRT) values may still
be referred for diagnostic sweat chloride testing. These CF NBS
programs include algorithms such as IRT/DNA/VHIRT,42
IRT/IRT1↑/DNA,43 or IRT/DNA/IRT.44 In all cases, sensitiv-
ity and specificity of algorithms using VHIRT must be evalu-
ated, as has been done in New York.42
The use of VHIRT as a safety net also has been used
elsewhere, including France45 and the United Kingdom.46 In
the United Kingdom, the national NBS program uses a
safety net for infants with a VHIRT value but no mutations
identified on a limited mutation panel. The United Kingdom
approach is to undertake a repeat IRT measurement on a
sample obtained on day 21 of life. If the IRT value remains
elevated at this stage, the NBS is reported as positive, and the
infant referred for diagnostic assessment. This safety net
approach has been useful for identifying infants with CF
from a diverse ethnic population but at the expense of
reducing positive predictive value. The adoption of various
safety net algorithms is being considered by at least 9 Euro-
pean nations (Olaf Sommerburg, personal communication,
October 2015).
Because of diverse political and demographic circum-
stances, there are at least 32 separate CF NBS programs in
Europe,using a host of different screening algorithms.47-53While
still using IRT as the first tier of screening, some European pro-
grams have incorporated a second biomarker, pancreatitis-
associated protein (PAP), into their CF NBS algorithms.
Although issues have surfaced regardingPAPcut-off values,47,52,54
there are significant advantages of adding PAP analysis as a
second tier of screening, including decreased recognition of
carriers.55,56However,using PAP analysismay also result in lower
sensitivity. Methods to enhance sensitivity depend on the al-
gorithm being used. While in France, Sarles et al52 decreased
the PAP cut-off values recently to reach sufficient sensitivity,
programs inGermany incorporated a failsafe strategy in which
not only infants with high IRT and high PAP are referred for
sweat testing, but also infants with low PAP values are re-
ferred for sweat testing if they display ultrahigh IRT levels
(IRT/PAP-failsafe).48 Pure biochemical IRT/PAP protocols nev-
ertheless show a poor positive predictive value.More than two-
thirds of all European CF screening programs use DNA, in
accordance with the EuropeanCF Society recommendations,57
Programs can still benefit from the use of PAP when com-
bined with genetic analysis as a third tier as demonstrated by
Vernooij-van Langen et al51 in 2012. Those protocols show not
only sufficient sensitivity but also a positive predictive value
comparable to that of IRT/DNA programs. Because of this ex-
perience, IRT/PAP/DNA protocols will be implemented as a
Table I. 2015 CF Foundation diagnosis consensus conference recommendations related to diagnosis of CF in the screened
population*
Statement
numbers* Consensus statements
2 Newborns with a positive CF newborn screen, to increase the likelihood of collecting an adequate sweat specimen, should have the test performed
bilaterally and when the infant weighs >2 kg, and is at least 36 wk of corrected gestational age.
3 Newborns greater than 36 wk gestation and >2 kg body weight with a positive CF newborn screen, or positive prenatal genetic test, should have sweat
chloride testing performed as soon as possible after 10 d of age, ideally by the end of the neonatal period (4 wk of age).
4 In infants with presumptive CF identified through NBS, CF treatment should not be delayed while efforts to establish a diagnosis of CF are initiated.
6 In individuals presenting with a positive newborn screen, clinical features consistent with CF, or a positive family history, a diagnosis of CF can be made if
the sweat chloride value is ≥60 mmol/L.
7 Individuals who are screen-positive and meet sweat chloride criteria for CF diagnosis should undergo CFTR genetic testing if the CFTR genotype was not
available through the screening process or is incomplete.
8 In individuals with a positive newborn screen, a sweat chloride <30 mmol/L indicates that CF is unlikely.
10 Individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, and sweat chloride values in the intermediate range
(30-59 mmol/L) on two separate occasions may have CF. They should be considered for extended CFTR gene analysis and/or CFTR functional analysis.
12 In individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, the identification of 2 CF-causing mutations (defined
by CFTR2) is consistent with a diagnosis of CF. Sweat chloride testing is necessary, though, to confirm the diagnosis.
13 The absence of detection of 2 CF-causing CFTR mutations does not exclude a diagnosis of CF.
14 If further CF functional testing is needed (NPD and ICM), it should be performed in a validated reference center with trained staff certified by the CF
Foundation TDN or ECFS Clinical Trial Network.
15 In individuals with a positive newborn screen but variable or uncharacterized CFTR mutations (<2 CF-causing mutations), the diagnosis of CF can be made
by demonstrating CFTR dysfunction (a sweat chloride ≥60 mmol/L or CF-typical NPD or ICM).
18 The definition of CRMS/CFSPID is an infant with a positive NBS test for CF and either:
• A sweat chloride <30 mmol/L and 2 CFTR mutations, at least 1 of which has unclear phenotypic consequences
OR
• An intermediate sweat chloride value (30-59 mmol/L) and 1 or 0 CF-causing mutations
19 Children designated as CRMS/CFSPID should undergo at least 1 repeat sweat chloride test at CF centers with suitable expertise, such as an accredited CF
center.
20 Children designated as CRMS/CFSPID should have clinical evaluation performed by CF providers to identify the minority that may develop clinical
symptoms.
CTN, clinical trial network; ECFS, European CF Society; TDN, therapeutics development network.
*Adapted from Farrell et al.29
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national screening program from 2016 and 2017 in Germany
and in France, respectively. In a post hoc analysis, the effect of
an ultrahigh-IRT safety net was demonstrated for the German
IRT/PAP/DNA CF NBS program (Olaf Sommerburg, per-
sonal communication, October 2015). In this NBS program,
a high IRT leads to PAP analysis as the second-tier screen, and
elevated PAP leads to the third-tier screen, that is, analysis for
31 CF-causing mutations. Data obtained from 372 906 neo-
nates screened from 2008 to 2015 in southwest Germany were
used to compare the potential impact of an ultrahigh IRT safety
net that could trigger either sweat testing or DNA analysis in
the absence of an elevated PAP level. If ultrahigh IRT trig-
gered sweat testing, approximately 345 infants would undergo
this diagnostic procedure. If ultrahigh IRT led instead to re-
quired DNA analysis, only 79 infants would subsequently
undergo sweat testing. In either case, 71 infants with CFwould
be detected.
The diversity of CFNBS algorithms leads inevitably to a spec-
trum of risk for CF subsequent to a positive screen result. The
likelihood of a “positive CF newborn screen” resulting in a di-
agnosis of CF can vary hugely, from close to 100% (as may
occur if 2 CF-causing mutations are identified) to around 1%
(as may occur in infants with positive NBS results because of
VHIRT42). Some infants present for follow-upwithout any sup-
porting genetic information,whereas others may have had ex-
tensive genetic analysis performed.Regardless of the algorithm
used, it must be emphasized that CF NBS is not a diagnostic
test, and whether or not the baby has CF must be determined
in follow-up care by diagnostic testing. As stated above, the
essential component of this determination is the sweat test; the
identification of a physiological abnormality not only sup-
ports the positiveNBS result butmay also help the family accept
the diagnosis.58 Clearly, the CF diagnosis is a serious one, and
the sweat test provides an important safeguard to avoid mis-
labeling babies because of identity errors, or laboratory errors
in IRT or DNA analysis.59,60 Furthermore, the sweat test will
be performed on siblings,61 and comparison data can be in-
valuable. Even though there may appear to be less need of a
sweat test in the presence of meconium ileus because meco-
nium ileus provides obvious evidence of a physiological defect,
a sweat test revealing elevated chloride should still be the cri-
terion to confirm the diagnosis. There have been many in-
stanceswhere aneonatologist or surgeondidnotproperly inform
the parents of an infant with meconium ileus about the high
probability of CF, leading them to unrealistic expectations.
Thus, the next step in the follow-up of a positive NBS or
prenatal test that suggests CF must be determination of the
sweat chloride concentration. However, its interpretation and
any additional tests needed to further explore the possibility
of the CF diagnosis depend on the NBS algorithm used.
Confirming CF Diagnosis after Positive
Newborn Screen without Detection of
CF-Causing Mutations
Some positive results from a CF newborn screen do not include
a DNA screen (for example, those using an IRT/IRT screen);
in this case, a sweat chloride test is directed, and the nature
of the follow-up is determined by the chloride levels found
(Table I, statements 6, 8, 10). If the sweat chloride level is
≥60 mmol/L, the infant has CF andCFTR genetic testing should
be done (Table I, statement 7).
In most cases, if no CF-causing6 mutations are found in a
CF NBS program that includes DNA analysis, the infant would
be considered screen-negative. A safety net (such as very high
or ultrahigh IRT), however, could be triggered to direct a sweat
chloride test, with follow-up again determined by the chlo-
ride levels found (Table I, statements 6, 8, 10).
Confirming CF Diagnosis after Positive
Newborn IRT/DNA Screen with Detection of
2 CF-Causing Mutations
Even with the identification of 2 CF-causing mutations
(Table I, statement 11), the next step in a diagnostic work-
up must be sweat chloride analysis (Table I, statement 12).
Regardless of increased understanding of CFTR genetics,
experts continue to emphasize the need for proof of CFTR
dysfunction to complete the CF diagnosis.14,62 Some CF NBS
programs demonstrate very high adherence; in France, for
example, sweat test results are reported for up to 95.4% of
infants with 2 CF-causing mutations (excluding those with
meconium ileus),63 but the same is not true for all CF NBS
programs.58 A review of diagnostic practices in the European
Union showed that only 13 of 26 CF NBS programs reported
routinely including sweat testing for infants with 2 CF-
causing mutations.58 Four programs never conducted sweat
testing in these infants, whereas it was sometimes conducted
in 6 other programs. Analysis of data in the US CF Founda-
tion Patient Registry (CFFPR) suggests a similar lack of
adherence to this guideline: nearly 24% of US patients with
2 CF-causing mutations do not have associated sweat chlo-
ride results.11 Although the policy of a CF NBS program may
be to recommend sweat chloride confirmation, the responsi-
bility for performing the test resides with the primary care
provider and the CF clinician assuming care. If the decision
is made by the diagnostician to assign a diagnosis of CF
without sweat chloride testing, the CF NBS program is left
without these data, as are the CF patient registries.
Improving adherence may require a better understanding
of the potential challenges in sweat testing young infants and
improved performance of sweat test procedures: (1) the
sweat test itself remains challenging because of higher rates
of insufficient sweat (quantity not sufficient) in neonates;
(2) the diagnosis of CF already seems confirmed to some
parents when they arrive with the baby at a CF center; (3)
the presence of intermediate sweat chloride levels in babies
with 2 CF-causing mutations can cause confusion in the
family and primary care providers; (4) it may be difficult to
order a sweat test if it has been postponed and a CF diagno-
sis has been presumptively made and recorded in a medical
chart; (5) sweat test results do not impact follow-up modali-
ties in these infants; (6) sweat test results, unlike genetic
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analysis, do not provide utility for personalized medicine;
(7) because of the high costs of analytic devices, sweat
chloride testing often is not performed in countries that
have limited resources or consider CF rare; and (8) reimburse-
ment for sweat testing may be problematic; in many areas of
the world, including some of the US, the sweat test is not
part of NBS funding, and health insurance companies may
not pay for the test, and certainly not for a repeat sweat test,
if they believe it is unnecessary.
Despite these issues, it is clear that sweat tests can be
performed successfully in most infants during the first month
of life.44,64 Rock and Farrell64 reported that patients diag-
nosed in Wisconsin following positive CF NBS from 2004 to
2014 had sweat testing performed at a mean age of 21 days
(SD of 16 days) and a median age of 16 days. There were 2
infants whose sweat testing was delayed, which skewed the
data distribution (an infant who had meconium ileus with
surgery and prolonged hospitalization, with sweat test
at 55 days of age, and an infant born prematurely at
34 weeks’ gestation, who was identified as a homozygous
c.1521_1523delCTT [legacy: F508del] patient with birth weight
of 2126 g and whose sweat test was delayed until 100 days of
age to ensure a sufficient quantity of sweat). This study used
the Gibson-Cooke method. Other data show similar, if not
better results regarding adequate sweat quantity with the
Macroduct collector (Wescor Inc, Logan, Utah).65
It is important to explore ways to improve adherence. Re-
quiring sweat test results for entry into the European and US
CF Foundation data registries might emphasize the need for
the information for diagnosis. Thus, beginning in 2017, the
CF Foundation will require that a sweat chloride value be
entered for enrollment of a newly diagnosed patients in the
CF registry.
In addition to the sweat test, CFTR gene analysis on DNA
obtained directly from the infant should ideally be per-
formed as part of the diagnostic evaluation, even if a genotype
was reported as part of the newborn screen (Table I, state-
ment 2). This recommendation is new but is appropriate in
the expanding era of CFTR modulator therapy in which the
genotype must be known unequivocally. Although this group
of infants has 2 reported CF-causing mutations, some CFTR
mutations (such as c.3717 + 12191 C→T [legacy: 3849 + 10kB
C→T] and c.3454G>C [legacy: D1152H]) are known to
result in an increased probability of a sweat chloride level
well below 60 mmol/L, even into the “normal” range, in
individuals with CF.66-70 In the case of certain other muta-
tions, a more in-depth genetic analysis may be useful. For
example, if the c.350G>A mutation (legacy: R117H) is iden-
tified, exploration of the polyT status and possibly TG repeats
is essential because of their effects on both function and
penetrance.71-73 Such in-depth genetic analysis is not always
done as part of the diagnostic evaluation following CF NBS.
However, because the polyT tract is highly significant in
individuals with R117H, it should be added to the diagnostic
evaluation to better identify, early on, infants with CF vs
those who should be categorized as CRMS/CF screen posi-
tive, inconclusive diagnosis (CFSPID), with a risk of converting
to a CF diagnosis74 (Appendix, case study 1; available at
www.jpeds.com). There are also uncommon instances of 2
CF-causing mutations occurring in cis60,75; in this scenario,
the sweat test would be normal and additional genetic analy-
sis including parental testing could explain the result and
prevent medicalization of this healthy infant.
Confirming CF Diagnosis after Positive
Newborn Screen with Detection of
1 CF-Causing Mutation
Not all infants with CF will have 2 CF-causing mutations de-
tected (Table I, statement 13). Because of the lack of clarity
on the disease liability of various CFTR mutations, the sweat
test is an especially crucial part of the diagnostic algorithm for
this group of infants (Table I, statements 10, 15), but inter-
pretations can be difficult. The mutation effects are not always
clear-cut because of the presence of modifier genes, or envi-
ronmental or epigenetic influences: the same mutations may
be associated with CF in some patients, but with CRMS/
CFSPID in others.18
In general, in this group of infants, a sweat chloride level
≥60 mmol/L is clearly indicative of CF (Table I, statement
15) and a sweat chloride level <30 mmol/L indicates CF is
unlikely (Table I, statement 8). A sweat chloride level of
30-59 mmol/L, however, should lead to a second sweat test
(Table I, statement 19). Often, this second sweat test will
produce resolution of the intermediate screening test result,
with a decrease to <30 mmol/L resulting in discharge from
the program as healthy, or an increase to ≥60 mmol/L as
diagnostic of CF. However, in some instances the sweat
chloride levels remain intermediate and inconclusive. In this
scenario (1 detected CF-causing mutation), extended
genotyping, clinical evaluation by a CF specialist by 2 months
of age, and another sweat chloride test repeated by 6 months
of age are recommended to seek resolution.18,19 Asymptom-
atic infants who continue to display intermediate sweat
chloride levels (30-59 mmol/L) and whose genetic analysis
does not provide clarity (<2 CF-causing mutations) should
be categorized as CRMS/CFSPID and followed at a CF care
center (Table I, statements 18 and 20). (More details on
frequency of CRMS/CFSPID, appropriate diagnostic evalua-
tion, and outcomes can be found in the report by Ren
et al.74) Some CF NBS programs may use nasal potential
difference (NPD) or other tests to clarify CFTR physiological
dysfunction, particularly if insufficient sweat can be col-
lected for analysis.
Although it is appropriate from the perspective of both phy-
sician and patient to label newborns who screen positive with
intermediate sweat chloride values and <2 CF-causing muta-
tions as CRMS/CFSPID, when patients display a clear history
of CF-like lung disease plus intermediate sweat chloride and
abnormal NPD/intestinal current measurement (ICM), they
need CF management and must be diagnosed with CF.
Infants whose newborn screen has identified 2 CFTR mu-
tations with ≤1 known to be CF-causing and who display
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normal sweat chloride levels should also be categorized as
CRMS/CFSPID and followed (Table I, statement 18).
Infants who are screen positive with 1 CF-causing muta-
tion but who produce insufficient sweat for analysis should be
retested as described in Farrell et al29 (Appendix, case study
2).
Additional Tests
A small percentage of infants who are eventually diagnosed
with CF do not meet definitive CF diagnostic criteria at the
time of their first evaluation following a positive CF NBS result.
Typically, in this group, sweat chloride levels do not provide
the information needed to properly identify CF. Extended geno-
type (or any genotype) results may not be available initially,
and even with the substantial progress of the past decade, will
not be able to resolve all cases because of extremely rare alleles
with insufficient clinical data or partially penetrant alleles with
variable clinical consequences that cannot be predicted. Thus,
we must turn to other possible biomarkers to provide an un-
derstanding of the level of CF risk for these families as well
as appropriate care for the patients. Embracing a wide array
of biomarkers may help clinicians face the challenge of defin-
ing the risk of CF for children with inconclusive genetic data.
Gathering information about these biomarkers in early child-
hood would help evaluate the penetrance of CFTR variants and
describe the full spectrum of disorders associated with CFTR
mutations, extending our knowledge about how CFTR vari-
ants (and other genes) contribute to disease beyond our current
understanding of CF.
Fecal Elastase (FE)
Demonstration of low FE levels <200 mg/g (in the absence of
diarrhea) has been proposed as an indicator of pancreatic in-
sufficiency and a diagnostic marker for CF. FE values fluctu-
ate through the first 12 months of life. In a study76 of 61 infants
diagnosed with CF through NBS, 48 infants (79%) had initial
FE <200 mg/g; 13 of these 48 infants (27%) had a least 1 FE
value >200 mg/g over the next several months before resolv-
ing into levels <200 mg/g, and 4 of 48 infants (8%), on the other
hand, displayed pancreatic-sufficient levels >200 mg/g by >9
months of age. In addition, 13 infants (21%) had initial FE
>200 mg/g; 10 of these (77%) had pancreatic sufficiency at the
end of the first year of life.
FE may be useful as an interimmeasure in those infants with
pancreatic insufficiency who have“quantity not sufficient” sweat
test results, permitting appropriate treatment until repeat sweat
testing is successful. This strategy has been used in Switzerland.77
However, despite the early enthusiasm for this biomarker,78,79
FE is of limited value in diagnosing CF definitively, as many
individuals with CF retain normal levels of FE.76,80 It also has
been disappointing when used to try to determine which
infants, categorized as CFSPID from a newborn screen, will
eventually be diagnosed with CF.81 When FE levels were mea-
sured over the first 24 months of life in a cohort of 36 infants
with CFSPID, all but one remained >200 mg/g, and none of
the babies later diagnosed with CF displayed low FE levels, re-
maining pancreatic sufficient (Tanja Gonska, personal com-
munication, October 2015).
Trypsinogen
Trypsinogen levels are already used to identify infants at high
risk for CF and may be used to better advantage. Serum tryp-
sinogen levels were serially examined over the first 36 months
of life in 82 infants categorized as CFSPID and 80 infants di-
agnosed with CF.81 Overall, infants with CFSPID had signifi-
cantly lower NBS IRT than did infants with CF. Furthermore,
nine of the 82 (11%) infants with CFSPID were subsequently
diagnosed with CF, and these patients had significantly higher
serial serum trypsinogen levels than did those infants who re-
mained in the group with CFSPID. Thus, serial trypsinogen
levels may contribute useful information.
NPD and ICM
As in the 1996-1998 and 2007-2008 CF Foundation consen-
sus development processes, the overwhelming importance of
demonstrating CFTR dysfunction to confirm a CF diagnosis,
combined with the limitations of sweat tests, creates great
appeal for other CFTR functional assays. This is especially
true for those assays providing added value from an in vivo
strategy and a drug responsiveness component that increases
sensitivity.
Measurements of CFTR (and the epithelial sodium channel)
activity in nasal epithelium readily distinguish the healthy young
infant from one with CF. In fact, NPD, when attempted in
babies with intermediate sweat chloride levels by very expe-
rienced, skilled operators, can provide reliable results. In 1 study
of 11 children (aged 3.5 ± 1.5 years) with nondiagnostic sweat
chloride values, NPD testing was able to demonstrate normal
CFTR function in 7 of the children; only 1 showed NPD in-
dicative of pathology (the test could not be completed in 3 chil-
dren because of poor cooperation) (Michael Wilschanski,
personal communication, October 2015). Another study of
NPD conducted in 23 young children (aged 3 months to 4
years) with high IRT values, 1 CF-causing mutation identi-
fied and intermediate sweat chloride levels demonstrated a con-
nection between NPD results and clinical outcome.82 Although
NPD results were not interpretable in 2 of the children, 13 of
the 21 remaining children (62%) had NPD scores in the CF
range; 2 CFTR mutations were subsequently found in all 13
patients, and 9 of the 13 had developed chronic lung disease
at follow-up. Of the 8 children (38%) with normal NPD scores,
only 2 children had 2 CFTR mutations (both of which are as-
sociated with a wide spectrum of phenotypes), and none had
developed a CF-like lung disease at follow-up. Repeated sweat
test results were obtained in 5 of these 8 children; all had sweat
chloride values <60 mmol/L. A CF diagnosis was ruled out in
6 of the 8 children.
However, NPD is not possible or reliable in every situa-
tion, and analysis of CFTR function in the intestine (ICM)may
be considered, aided by the fact that CFTR is highly ex-
pressed in intestinal epithelia, offering high specificity and sen-
sitivity for the test.83,84 Like NPD, ICMmeasurements must be
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conducted in specific high quality reference centers with ex-
perienced, very skilled personnel.85,86 ICM can be used to
confirm a diagnosis of CF in the context of intermediate sweat
chloride levels.87,88 Ion transport in the intestine is a very sen-
sitive measure of CFTR function: only 10% of wild-type CFTR
is necessary to prevent intestinal pathology in CF, and a very
small gain in CFTR expression (from 1% to 5% of wild-
type) results in large gains in chloride secretion (from 5% to
25% of wild-type levels).83 Because of this sensitivity, ICM can
be used to better characterize variants of unknown disease
liability.
Combining results from ICM and NPD, when available,
can provide an even clearer picture of the spectrum of CFTR
function, from CF-causing to healthy levels (Isabelle Sermet-
Gaudelus, personal communication, October 2015). If the ICM
is normal, other pathologies, such as immunodysregulation
polyendocrinopathy enteropathy X-linked syndrome, should
be considered.
NPD and ICM have the potential to be useful as surrogate
outcomes because they are in vivo/ex vivo measurements and
may play a useful supplementary role for the diagnosis of CF
(Table I, statement 15). However, they are not sufficiently vali-
dated at present to recommend routine use and are not avail-
able on a wide scale because of the expertise and experience
required to obtain reliable measurements (Table I, statement
14). Nevertheless, these are increasingly attractive, advanced
research methods that will help us better understand the nature
of the spectrum of CF disease and CRMS/CFSPID. And, with
more routine use in European CF centers, greater applica-
tion will undoubtedly occur.
Despite these advances, some infants still provide a diag-
nostic challenge. Thus, long-term follow-up evaluations of
children with various levels of CFTR function are needed to
determine the best approach for diagnosis and management
of children without the signs and symptoms of established,
unequivocal CF. The best approach may involve sensitive
functional tests such as NPD and ICM tests in combination
with genotype-phenotype studies (such as correlation with
the CFTR2 database6) and data collected from CF registries.
Clinical/Respiratory Evaluations in Uncertain
Cases
Clinical evaluations for respiratory pathology are of little value
in cases of uncertain CF during infancy. Signs and symptoms
are unlikely and nonspecific, although chronic cough should
raise suspicion.An infant pulmonary function test (PFT) that
demonstrates gas trapping or reduced forced expiratory flows
could be of value, but the measurement is not standardized,
the capability of performing an infant PFT is not widely avail-
able, and other obstructive lung problems (such as wheezing)
can produce similar PFT results.89 Lung clearance index using
the SF6 method for infants is sensitive, but again, not widely
available (N2washout is not currently developed for infants).90-92
Chest radiographs are worthwhile, but the changes are often
subtle and nonspecific.Chest computed tomography scans per-
formed in infants diagnosed with CF following NBS through
the Australian Respiratory Early Surveillance Team for CF in-
tensive surveillance program revealed 29.3% with bronchiec-
tasis by 3months of age,93 althoughfindings differed in aUnited
Kingdom cohort.94 This finding is in keeping with earlier ob-
servations from autopsy-based studies.95 However, a study of
chest computed tomography in asymptomatic infants with CF
suggested that this imaging is usually not warranted because
the changes during infancy are typically very mild.94 Thus, in
uncertain cases, the radiation burden and risks of anesthesia
are unlikely to be balanced by benefit.
Induced sputum or bronchoalveolar lavage performed in
children with CF aged 3 to 7 years may reveal evidence of bac-
teria common in CF, including Pseudomonas aeruginosa,
Stenotrophomonas maltophilia, and Staphylococcus aureus.96 To
understand the significance of culturing CF-typical bacteria
in this population, respiratory samples collected over the first
2 years of life in children with either CF (n = 23) or non-CF
chronic suppurative lung disease (n = 124) were compared by
retrospective analysis (Hannah Blau, personal communica-
tion, October 2015). At the time of the first culture, there was
no significant difference between the bacterial species cul-
tured from children with CF compared with those cultured
from children with other lung diseases. However, when all
sputum culture results from the first 2 years were analyzed, cul-
tures from children with CF were significantly more likely to
contain P aeruginosa, Enterobacter species, Escherichia coli,Kleb-
siella oxytoca, and Serratia species than were control cultures.
P aeruginosa-positive cultures were found in 32/124 (about
26%) of the children with non-CF lung disease compared with
17/23 (74%) children with CF, although chronic P aeruginosa
infection was rare in either case. The conclusion from this ret-
rospective analysis is that cultures from induced sputum may
provide a useful disease marker in the infant with suspected
CF.
Consensus Statements on Diagnosing CF
in Screened Populations
Taking into account the available evidence, the 2015 CF Foun-
dation Consensus Committee agreed upon the statements
shown in Table I for diagnosing screened populations. Sweat
tests, CFTR mutation analysis, and the ancillary tests de-
scribed above may all prove valuable for establishing or con-
firming a CF diagnosis in children with positive prenatal testing
or neonatal screening. The European CF Society Standards of
Care state that the majority of infants with a confirmed di-
agnosis after NBS should be seen by the specialist CF team by
35 days of age and no later than day 58,62 whereas the recom-
mended US standard of care specifies diagnosis by 2-4 weeks
without specifying care at a CF center.9 Therefore, to ensure
timeliness, follow-up evaluations needed to decide CF status
should be completed within 2-4 weeks of age when infants are
hopefully still in a preclinical stage. Even by 2 weeks, however,
malnutrition may be present,97,98 and there is a risk of poten-
tially fatal electrolyte depletion and hyponatremic dehydration99
(Appendix, case study 3). Hence, it is important in some cir-
cumstances to make a presumptive diagnosis of CF to enable
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appropriate treatment and follow-up while pursuing diagnos-
tic confirmation (Table I, statement 4).
Once a diagnosis is established, genetic counseling
should be offered to families of all infants with CF or
CRMS/CFSPID.18,19,57,100 In other words, all families of CF NBS
positive newborns should receive genetic counseling, whether
the infant turns out to be a carrier or is truly affected. Rec-
ommendations have been published on methods of genetic
counseling.101,102
Enrollment into the US CF Foundation
Patient Registry
The US CF Foundation Patient Registry was created in 1966
to collect data on health outcomes, clinical care and demo-
graphic characteristics of people with CF who receive care at
CF Foundation-accredited care centers.103 Clear, reliable data
must be entered into the CFFPR and other registries to
permit quality analysis of CF NBS programs and clinical
outcomes of all those with CF. Entering diagnostic informa-
tion under consistent guidelines is critically important for all
patients diagnosed with the disease, including those diag-
nosed immediately following a positive newborn screen, as
well as those diagnosed at a later age, such as those with a
false-negative newborn screen, or those who had a positive
newborn screen and a negative initial sweat test. It is impor-
tant to accurately record dates, test results, and treatment
from the initial contact. Because CFFPR consent often is not
obtained until the patient has been seen at the CF center for
1 or more visits, it is essential to ask families for consent as
soon as possible to allow retrospective data (ie, before consent)
to be entered in the registry, subject to institutional review
board approval. Appropriate guidelines for data entry on
consented patients diagnosed following prenatal screening
or NBS are presented below.
Guidelines for Date of Confirmation of CF
Diagnosis following Prenatal Testing
Prenatal testing showing 2 CF-causing CFTR mutations (in
trans, as confirmed by parental testing) is generally adequate
for a presumptive diagnosis of CF. In most cases, prenatal
testing is done when both parents are known carriers either
because of population screening with cascade testing or as a
result of testing because of a positive family history. However,
because of varying prenatal testing and reporting protocols,
infants with prenatal diagnosis should have the date of
diagnosis listed as the date of birth (ie, diagnosed at 1 day of
age). In addition, infants with positive prenatal testing results
should always have a sweat test performed for confirmation
of the diagnosis.
Guidelines for Date of Presumptive Diagnosis
in CF NBS
It is important to provide a date of presumptive diagnosis
for the purpose of evaluating timeliness of diagnosis and
treatment by CF centers in conjunction with NBS programs.
An infant can be presumed to have CF in any of the
following clinical circumstances: (1) positive CF NBS test
result reveals 2 CF-causing CFTR mutations; (2) CF NBS test
is positive based on a specific state’s algorithm, and there are
clinical features consistent with CF, such as growth failure or
malabsorption; or (3) infant has meconium ileus, with or
without a positive CF NBS test.
In each of these cases, confirmation of diagnosis should
proceed as quickly as possible, but treatment should not be
delayed while awaiting diagnostic confirmation.
Guidelines for Date of Confirmation of CF
Diagnosis Subsequent to NBS
A sweat test should be performed in all cases of presumptive
diagnosis, as soon as possible. It may be delayed because of
illness, prematurity, or, rarely, other circumstances (eg, geo-
graphic or weather-related) but should not otherwise be
delayed. A CF diagnosis is considered confirmed only if: (1)
sweat chloride is ≥60 mmol/L; (2) CF-causing CFTR muta-
tions are identified and the sweat chloride value is ≥30 mmol/
L; (3) 2 variable or uncharacterized CFTR mutations are
identified and physiological testing such as NPD or ICM
reveal CFTR dysfunction, and the sweat chloride value is
≥30 mmol/L; (4) 2 CF-causing CFTR mutations are identi-
fied from a blood specimen obtained directly from the
affected infant during follow-up—a genotype report from
the NBS program is not sufficient because of the risk of
errors (parental testing may be required in some circum-
stances to verify that 2 mutations are in trans,60 in cases
where genotype and CFTR functional testing results are at
variance [eg, normal sweat value and 2 CFTR mutations are
present]); or (5) NPD or ICM values typical of CF are
present (CF-typical values must be defined by an experi-
enced center performing the test).
Guidelines for Date of Confirmation of CF
Diagnosis Because of “Diagnostic Drift” or
Because of Genetic Reclassification
A change to a CF diagnosis most often occurs when an infant
initially categorized as CRMS/CFSPID develops clinical signs
or symptoms of CF. In these cases, the CFFPR entry should
note the date of clinical diagnosis of CF, as well as the date of
the onset of clinical or laboratory findings that led to the change
in diagnostic category (such as an increase in sweat chloride
into the diagnostic range, or infection with P aeruginosa).
Rarely, children may move from the CRMS/CFSPID cat-
egory to a CF diagnosis because of a new recognition of the
pathologic consequences of their CFTR alleles. In these cases,
the CFFPR entry should be updated to the date for reclassi-
fication of their genotype.
The guidelines described above should enhance the quality
of data in the CFFPR. Other CF registries may wish to con-
sider these recommendations. It would be ideal to have inter-
national harmony and consistency in the global CF registries.
Perhaps the proper use of International Statistical Classifica-
tion of Diseases and Related Health Problems, 10th Revision codes
on an international scale, reflecting a clear application of
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diagnostic categories created by consensus, would contribute
to harmony.
Educational Resources
The diagnosis of CF has become increasingly complex, as CFTR
mutations resulting in a wide spectrum of dysfunction have
been increasingly identified. To address this challenge and help
educate CF centers and care providers in CF diagnosis, efforts
will be put in place to facilitate implementation. Additional
educational resources are also available (Table II).
Conclusions
Prompt diagnosis of CF is vital for optimizing outcomes. The
widespread use of CF NBS has enabled the diagnosis of CF
in most affected infants before obvious clinical signs, but di-
agnosis can be difficult. To take advantage of burgeoning knowl-
edge of the impact of various CFTR mutations and recent
studies on cohorts with unclear CF diagnoses, the CF Foun-
dation convened a committee of experts from around the world
to update consensus guidelines on diagnosis of CF with an em-
phasis on screened populations. The committee concluded that
all diagnoses should be established by demonstrating CFTR
dysfunction—by sweat chloride test where possible, or poten-
tially by other methods such as NPD or ICM where neces-
sary. Even in babies with 2 CF-causing mutations detected by
NBS, diagnosis must be confirmed by demonstrating CFTR
dysfunction. Guidelines for making a presumptive diagnosis
were also developed. Following the recommendations for
screened populations should provide clarity to CF care pro-
viders and families, and ensure treatment is provided when
needed, while avoiding medicalization of healthy infants. ■
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Appendix
Case Study 1
A 1-week-old female infant presents to the pediatrician for a
first visit following an uneventful pregnancy and normal
vaginal delivery. She has been steadily improving in the time
that she breastfeeds and is currently now at birth weight
after being several ounces down at her discharge on day 2.
Parents are concerned that she sneezes and has some nasal
stuffiness. The physical examination is within normal
limits.
She was born in a state that uses IRT/DNA for CF NBS and
was positive for 2 mutations: c.350G>A mutation (legacy:
R117H) and c.1521_1523delCTT (legacy: F508del). The polyT
intron analysis revealed 7T/7T.
What is the recommended next step by the pediatrician for
the evaluation of this infant?
A. Referral to a CF center for evaluation and sweat chloride testing
B. Observe for 1 y and refer to CF center if clinical symptoms
suggestive of CF develop
C. Send for detailed genetic analysis of CF gene
D. Send for sweat testing at accredited laboratory and observe for 1 y
of life with referral to CF center if symptoms develop
A—correct
A sweat test is obtained at an accredited laboratory, and sweat chloride value is
33 mmol/L. The infant was seen at an accredited CF center where a negative
history was obtained, and she had a normal physical examination.
What is the most likely diagnosis of this infant at this
time?
A. CF
B. CRMS/CFSPID
C. Atypical CF
D. CFTR-related disorder
B—correct
The diagnosis of CRMS or CFSPID is given after a positive newborn screen and: a
sweat test value less than 30 mmol/L and 2 CFTR mutations, at least 1 of
which has unclear phenotypic consequences; or an intermediate sweat
chloride value (30-59 mmol/L) and 1 or no CF-causing mutations. In this infant,
the R117H with 7T is the mutation that is unclear in its clinical significance but
in a few patients has been associated with the development of symptoms
consistent with CF. The term CRMS/CFSPID is reserved for those screen-
positive infants without clinical features consistent with CF. Following
consensus guidelines from 2008 would have resulted in considering this infant
not to have CF, and no follow-up would be recommended. The new guidelines
are specific that this infant should receive an evaluation and education at an
accredited CF center. This is a significant shift in guidance.
Children designated as CRMS/CFSPID should undergo at least 1 repeat sweat
chloride test at a CF center with suitable expertise, such as an accredited CF
center. This is often done when the infant is 6 months of age. Some centers
repeat again at 2 years of age.
These infants and children may benefit from continued clinical evaluation by CF
providers at the accredited CF centers along with regular care from their
primary care providers to monitor for signs and symptoms of CF. A minority of
these infants may develop changes in their physiologic testing along with
clinical symptoms that ultimately lead to a diagnosis of CF.
Guide to initial diagnosis in cases where 2 mutations have
been identified through NBS or no genes identified in IRT/
IRT CF NBS algorithm:
Mutation 1 Mutation 2
Sweat Cl−
<30 mmol/L
Sweat Cl−
= 30-59 mmol/L
Sweat Cl−
≥60 mmol/L
CF-causing CF-causing CF CF CF
CF-causing MVCC CRMS/CFSPID CRMS/CFSPID CF
CF-causing Unknown
significance
(not in
CFTR2)
CRMS/CFSPID CRMS/CFSPID CF
Not available Not available CF unlikely CRMS/CFSPID CF
Case Study 2
A 1-week-old male infant presents for his first visit to the
primary care physician. He was born at 34 weeks’ gestation
and was screen-positive because of high IRT and 1 CF-
causing mutation, F508del, on his CF newborn screen test.
During this visit, he is noted to be feeding well and is a few
ounces over his birthweight of 4 pounds (1.8 kg). His history
is negative for respiratory symptoms, and there is no family
history of cystic fibrosis.
His physician refers him to the local hospital for a sweat
chloride test as per protocol. At 9 days of age, the test is
completed, and results in quantity not sufficient for testing
(QNS).
What is the next step for this infant?
A. Repeat testing when he is corrected 36 wk of age and is 2 kg in
weight
B. Repeat testing at an accredited laboratory
C. Repeat testing when tolerating feedings and is well hydrated
D. All of the above
D—correct
The sweat test was performed when his weight reached 2 kg and was normal
with a sweat chloride value of 12 mmol/L. The infant is considered to be a
carrier for CF.
What should be done next for this infant?
A. Discuss the testing results with the parents and refer for genetic
counseling
B. Repeat the sweat test at 6 mo of age
C. Send for expanded genetic mutation analysis
D. Refer all siblings for sweat testing to verify the negative result
A—correct
Newborns with a positive CF NBS test should be tested when at least 36 wk
gestation and 2 kg body weight. Testing should be completed no later than
10-28 d of age at an accredited laboratory in a healthy full term newborn with
a positive CF NBS test.
In this case, the carrier state was detected by CF NBS testing. The incidence of
carrier testing has been found to be decreased in those states that use the
sequence of IRT/IRT/DNA testing. Genetic counseling is recommended for the
families of all infants that screen positive for CF including those with carrier
status.
It is important to recognize that CF NBS testing, except perhaps for those areas
that use IRT/expanded DNA testing, is not designed to detect the carrier state.
A negative NBS test in the majority of cases does not exclude that the infant is
a carrier of CF.
Case Study 3
A female infant was born at 38 weeks’ gestation with a birth
weight of 2.8 kg to African American parents. Prenatal screen-
ing for CFTR carrier status revealed that the mother carried
a common disease-causing CFTR mutation—c.1652G>A
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(legacy: G551D). The father was tested via a 23-mutation panel
(American College of Obstetricians and Gynecologists) that
detected common mutations and was found to have no
mutations.
The infant had a positive CF NBS test with an elevated IRT
and was positive for 1 mutation—G551D. She was followed
by her primary care physician, and at 2 weeks of age, she was
found to be breastfeeding well but the weight had decreased
to 2.3 kg. A sweat test was ordered and had QNS for analysis.
At 4 weeks of age, she was seen again and weighed 2.2 kg, and
a repeat sweat test was again QNS.A third sweat test at 6 weeks
of age was positive with results of 89 and 94 mmol/L.
She was then seen at a CF center and was started on
pancreatic enzyme replacement therapy, albuterol, and chest
physiotherapy. Further testing was completed. Fecal pancre-
atic elastase was low at <15 mg/g. She was found to have her
mother’s mutation as well as a rare second disease-causing
mutation that her father had not been tested for during
prenatal testing. Slow weight gain was then established during
a subsequent visit to the CF center and her primary care
physician.
At 3 months of age, the infant presented to an emergency
department for poor feeding. She was noted to have a 3-day
history of reduced oral intake and irritability without cough
or rhinorrhea. Over the previous 24 hours, she had eaten very
little by mouth and had only 2 wet diapers. On physical ex-
amination, she was afebrile but lethargic and had dry tacky
mucous membranes. Her weight was at the first percentile for
age. Her chest was clear, and her abdomen was soft and
nontender.
The most likely etiology of the current findings in this infant
with CF is:
A. Chronic malnutrition
B. Acute pulmonary exacerbation of CF
C. Distal intestinal obstruction syndrome
D. Electrolyte abnormalities
D—correct
This infant presents with acute changes in behavior and feeding suggestive of
electrolyte abnormalities; she had not been prescribed supplemental salt, a
recommendation of the CF Foundation clinical practice guidelines for infants
with CF. A basic metabolic panel showed Na+ 119 mEq/L (134-146); K+
1.9 mEq/L (4.2-6.4); Cl− <60 mEq/L (98-108); HCO3− 49.6 mEq/L (23-30). An
electrocardiogram revealed first degree atrioventricular block and a prolonged
QTc interval. She was hospitalized in the intensive care unit for 1 wk and was
hospitalized for a total of 4 wk.
This case illustrates risk factors for delayed diagnosis after a positive CF NBS.
Because the infant was from a racial minority with a lower incidence of CF, and
because her mother was a carrier of a CFTR gene mutation but her father was
found to have a “negative” carrier test, her initial positive NBS test was thought
to be reflective of a carrier status. Even though sweat testing was ordered
within an appropriate time interval, the QNS values were thought to be due to
inadequate weight gain, and she was not evaluated for the possibility that
pancreatic insufficiency was the underlying cause of this poor postnatal weight
gain.
Her diagnosis was delayed until after the first month of life and, in addition, salt
was not prescribed. She subsequently developed a severe, life-threatening
electrolyte imbalance and notably this occurred during the winter in a cold
climate. In infants with a positive newborn screen and poor growth, it is
appropriate to make a “presumptive diagnosis” of CF, perform appropriate
diagnostic studies, and treat empirically with pancreatic enzyme replacement
therapy and salt until the diagnosis can be either confirmed or ruled out.
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Cystic Fibrosis Transmembrane Conductance Regulator-Related
Metabolic Syndrome and Cystic Fibrosis Screen Positive,
Inconclusive Diagnosis
Clement L. Ren, MD1, Drucy S. Borowitz, MD2, Tanja Gonska, MD3, Michelle S. Howenstine, MD1, Hara Levy, MD4,
John Massie, MBBS, FRACP, PhD5, Carlos Milla, MD6, Anne Munck, MD7, and Kevin W. Southern, MBChB, PhD8
Objective An unintended consequence of cystic fibrosis (CF) newborn screening (NBS) is the identification of
infants with a positive NBS test but inconclusive diagnostic testing. These infants are classified as CF transmem-
brane conductance regulator-related metabolic syndrome (CRMS) in the US and CF screen positive, inconclusive
diagnosis (CFSPID) in other countries. Diagnostic and management decisions of these infants are challenges for
CF healthcare professionals and stressful situations for families. As CF NBS has become more widespread across
the world, increased information about the epidemiology and outcomes of these infants is becoming available. These
data were reviewed at the 2015 CF Foundation Diagnosis Consensus Conference, and a harmonized definition of
CRMS and CFSPID was developed.
Study design At the consensus conference, participants reviewed published and unpublished studies of CRMS/
CFSPID and used a modified Delphi methodology to develop a harmonized approach to the definition of CRMS/CFSPID.
Results Several studies of CRMS/CFSPID from populations around the world have been published in the past
year. Although the studies vary in the number of infants studied, study design, and outcome measures, there have
been some consistent findings. CRMS/CFSPID occurs relatively frequently, with CF:CRMS that ranges from 3 to
5 cases of CF for every 1 case of CRMS/CFSPID in regions where gene sequencing is not used. The incidence
varies by NBS protocol used, and in some regions more cases of CRMS/CFSPID are detected than cases of CF.
The majority of individuals with CRMS/CFSPID do not develop CF disease or progress to a diagnosis of CF. However,
between 10% and 20% of asymptomatic infants can develop clinical features concerning for CF, such as a respi-
ratory culture positive for Pseudomonas aeruginosa. Most studies have only reported short-term outcomes in the
first 1-3 years of life; the long-term outcomes of CRMS/CFSPID remain unknown. The European CF Society defi-
nition of CFSPID and the CF Foundation definition of CRMS differ only slightly, and the consensus conference was
able to create a unified definition of CRMS/CFSPID.
Conclusions CRMS/CFSPID is a relatively common outcome of CF NBS, and clinicians need to be prepared to
counsel families whose NBS test falls into this classification. The vast majority of infants with CRMS/CFSPID will
remain free from disease manifestations early in life. However, a small proportion may develop clinical features
concerning for CF or demonstrate progression to a clinical phenotype compatible with a CF diagnosis, and their
long-term outcomes are not known. A consistent international definition of CRMS/CFSPID will allow for better data
collection for study of outcomes and result in improved patient care. (J Pediatr 2017;181S:S45-51).
During the development of the 2008 cystic fibrosis (CF) diagnosis consen-sus guidelines, it was recognized that the increased implementation ofnewborn screening (NBS) had led to a new and complex diagnostic
dilemma of infants with abnormal NBS tests but inconclusive sweat tests and/or
DNA test results.1 Rather than address this complex situation in the diagnostic
guidelines, a separate CF Foundation consensus conference was convened to address
CF Cystic fibrosis
CFFPR CF Foundation Patient Registry
CFSPID CF screen positive, inconclusive diagnosis
CFTR CF transmembrane conductance regulator
CFTR-RD CFTR-related disorder
CRMS CFTR-related metabolic syndrome
ECFS European CF Society
IRT Immunoreactive trypsinogen
NBS Newborn screening
PCP Primary care provider
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this issue. An expert panel used the Delphi method and created
a new diagnostic term, CF transmembrane conductance regu-
lator (CFTR)-related metabolic syndrome (CRMS) and rec-
ommendations for its management.3 CRMS is the term used
in the US to describe infants with elevated immunoreactive
trypsinogen (IRT) levels, but with insufficient sweat chloride
or genetic data to support a diagnosis of CF.Although this con-
dition is not a metabolic disorder, the designation metabolic
syndrome was established in part to have an International Sta-
tistical Classification of Diseases and Related Health Problems,
Ninth Revision medical code (277.9) for US healthcare deliv-
ery system follow-up and billing purposes. However, CRMS
has not been accepted in Europe and some other countries
because of concern about the appropriateness of the term and
a feeling that it was difficult for families to understand. Thus,
a similar term, CF screen positive, inconclusive diagnosis
(CFSPID), was developed in a Delphi process4 by the Euro-
pean CF Society (ECFS) Neonatal Screening Working Group
and introduced recently in Europe as an alternative to CRMS.5
The planning committee for the 2015 Diagnosis Consensus
Conference recognized that with the increasing use of CFNBS
worldwide,CRMS andCFSPIDhave become important aspects
of theCFdiagnostic process.Therefore, the conference included
a session to review recently published and unpublished data on
populationswithCRMS andCFSPID.An important goal of the
conference was to develop a consensus to unify the definition
of CRMS and CFSPID that could allow for collection of data
from populations around the world and increase our under-
standing of the epidemiology and outcomes of CRMS/CFSPID.
At the conclusion of the conference, consensus recommenda-
tionswere crafted andagreeduponby electronic survey (Table I).
Harmonization of US and ECFS Terminology
In the US, the expert consensus panel specifically created a term
that did not imply the infant has CF, whereas still acknowl-
edging that these infants required follow-up by CF specialists.3
CRMS (International Statistical Classification of Diseases and
Related Health Problems, 10th Revision code E88.89) was defined
as an infant with hypertrypsinogenemia at birth who is as-
ymptomatic, and who has either: (1) persistently intermedi-
ate sweat chloride levels (30-59 mmol/L if age <6 months or
40-59 mmol/L if age ≥6 months) and fewer than 2 CF-
causing CFTR mutations; or (2) sweat chloride concentra-
tion <30 mmol/L and 2 CFTR mutations with 0 to 1 known
to be CF-causing.
In Europe and some other countries, especially when
international coding is not required for healthcare delivery,
expert consensus differed slightly on how to define this
group. In the initial ECFS consensus process,4 it was recom-
mended that these infants should not have a designation, but
in the second exercise 5 years later,5 it was clear that the
majority of respondents believed a designation was needed.
In the subsequent voting exercise (including CRMS as an
option), there were 2 clear favorites: CF inconclusive diagno-
sis and CFSPID. An expert panel decided to amalgamate the
2 terms, and CF screen positive, inconclusive diagnosis
(CFSPID) reached high levels of agreement in the subse-
quent round of the Delphi exercise, creating a category for
infants who are asymptomatic, with hypertrypsinogenemia
at birth,5 and have either: (1) 0 or 1 CFTR mutations, plus
intermediate sweat chloride (30-59 mmol/L); or (2) 2 CFTR
mutations, at least 1 of which has unclear phenotypic conse-
quences, plus a normal sweat chloride (<30 mmol/L).
The differences between the definitions of CRMS and
CFSPID are minor and resolved by the improved character-
ization of CFTR mutations as disease-causing by the CFTR2
project. The CF Foundation recognizes that CFSPID is a term
that may be helpful in describing this complex situation to
parents and families. However, the term CRMS will continue
to be required for entry of this group of individuals into the
US healthcare system. Recognizing the 2 groups as 1 will
Table I. Consensus recommendations related to CRMS/CFSPID
Statement
numbers* Consensus statements
16 The term CRMS is used in the US for healthcare delivery purposes and CFSPID is used in other countries, but these both describe an inconclusive
diagnosis following NBS.
17 The term CRMS/CFSPID is reserved for individuals who screen positive without clinical features consistent with a diagnosis of CF.
18 The definition of CRMS/CFSPID is an infant with a positive NBS test for CF and either:
• A sweat chloride <30 mmol/L and 2 CFTR mutations, at least 1 of which has unclear phenotypic consequences
OR
• An intermediate sweat chloride value (30-59 mmol/L) and 1 or 0 CF-causing mutations
19 Children designated as CRMS/CFSPID should undergo at least one repeat sweat chloride test at CF centers with suitable expertise, such as an
accredited CF center.
20 Children designated as CRMS/CFSPID should have clinical evaluation performed by CF providers to identify the minority that may develop clinical
symptoms.
21 Children designated as CRMS/CFSPID can be considered for extended CFTR gene analysis (sequencing and/or deletion duplication testing), as well as
CFTR functional analysis (NPD/ICM) testing to further define their likelihood of developing CF.
22 The decision to reclassify children designated as CRMS/CFSPID as CF is an integrated decision that should take into account functional assessment of
CFTR (sweat chloride, and possibly NPD/ICM), CFTR genetic analysis, and clinical assessment by the CF clinicians caring for the patient.
23 Genetic counseling should be offered to families of individuals followed for CRMS/CFSPID, including a discussion of the risk in future pregnancies.
24 Research recommendation: Infants with a designation of CRMS/CFSPID (by definition) do not have clinical features consistent with a diagnosis of CF
and further research is needed to determine the prognosis and best practices for frequency and duration of follow-up.
ICM, intestinal current measurement; NPM, nasal potential difference.
*Adapted from Farrell et al.2
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facilitate global collection of data from these individuals and
improve our understanding of this population.
Infants will be designated as CRMS/CFSPID if they present
a positive CF NBS test plus: (1) sweat chloride <30 mmol/L
and 2 CFTR mutations with 0-1 CF-causing CFTR muta-
tions; or (2) sweat chloride 30-59 mmol/L and <2 CF-causing
CFTR mutations.
CFTR mutations that have been shown to be non-CF-
causing should not be considered when applying the defini-
tion. Also, note that infants with CRMS/CFSPID who have
sweat chloride levels of 30-59 mmol/L may have 0, 1, or 2 CFTR
mutations, as long as they do not have 2 CF-causing mutations.
Risks and Benefits of Labels
There are risks to classifying infants with CRMS/CFSPID, in-
cluding anxiety in parents and families, and increased health-
care costs because of extensive and potentially expensive
diagnostic evaluations. Currently, despite guidelines, there are
different practices regarding the extent, detail, and frequency
of these evaluations. A detailed work-up, including DNA se-
quencing and additional tests, such as nasal potential difference
measurements and intestinal currentmeasurements,may resolve
the diagnosis of CF in some cases, but certainly many cases
will continue to remain inconclusive, despite extensive testing.
Overall, however, creation of a category for these infants is
considered beneficial because it allows these infants who cannot
be clearly diagnosed with CF but may remain at risk of CF to
be followed so that treatment, if needed, can be initiated quickly
for optimal outcomes. Further, it allows for epidemiologic
studies to be performed that will help define the disease risk
and outcomes for this group of individuals.
To provide additional guidance, the consensus conference
reviewed recent data from Europe, Canada, Australia, and the
US on frequency of occurrence and outcomes of infants cat-
egorized as CRMS/CFSPID. These studies were used to gen-
erate recommendations for further testing in CRMS/CFSPID,
including genetic and ancillary CFTR functional studies that
may help diagnose CF or identify infants likely to develop clini-
cal features of CF (Table I).
Prevalence, Clinical Features, and
Outcomes of CRMS/CFSPID
Nutritional indices in this population are generally good. An
analysis of data on infants with CRMS reported during 2010-
2012 to the US CF Foundation Patient Registry (CFFPR)
showed that almost all infants with CRMS in the CFFPR had
pancreatic-sufficiency, consistent with other recent studies of
CRMS.6 However, a higher-than-expected rate of respiratory
cultures may be positive for bacteria typically associated with
CF6-9; for example, in the CFFPR study, 11% of the infants in
the group with CRMS had at least 1 positive Pseudomonas
aeruginosa respiratory culture during the first year of life, a pro-
portion higher than that reported in the population without
CF, underlining the need for these infants to be followed.6 Al-
though it is important to ensure that these infants are moni-
tored, the application of a CF diagnosis should be made with
much thought, taking into account the implications for the
infant and family with increased healthcare costs and raised
anxiety. Follow-up requires a careful balance between surveil-
lance and readiness to diagnose with CF and appropriately treat.
Several recent studies (Table II) have provided information
about CRMS/CFSPID prevalence and outcomes and longitu-
dinal studies show that these infants do have a small risk of
developing CF over time. The results of these studies, de-
scribed briefly below, can help provide guidance on determin-
ing how this group should best be monitored.
CRMS/CFSPID Characteristics in US CF
Foundation Patient Registry
TheCFFPR collects data from all the accredited CF care centers
in the US. In 2010, CRMS was added as a diagnostic category,
Table II. Summary of recent studies of CRMS/CFSPID
Ren et al6 Levy et al7 Kharrazi et al10 Groves et al11 Ooi et al8
Study design Prospective cohort Prospective cross-sectional Prospective cohort Retrospective case control Prospective case control
Location US Wisconsin California Australia Multinational
Duration of follow-up (y) 1 20+ 5 14* 3
CF 1540 300 373 225‡ 3101
CRMS 309 57 553 29§ 82
CF:CRMS 5:1 5.2:1 0.67:1 7.8:1 1.8:1
CRMS→CF N/A N/A 20 14¶ 9†
CRMS→CF % N/A N/A 3.7% 48% (38%) 10.9%
Increased sweat chloride ≥60 mmol/L N/A Initial <30, n = 14 (27%)
Initial 31-59, n = 38 (73%)
22 (3.2%) 4 (14%) 3 (33%)
P aeruginosa % 10.7% 39% N/A 78.6% 14.6%
S maltophilia % 9.4% N/A N/A N/A 4.9%
Pancreatic insufficiency 14 (4.5%) 0 3 4 (13.8%) 0
F508del/R117H 26.1% 36/57 (63%)** N/A 4 (28.5%) 19.5%
N/A, not applicable.
*28% Lost to follow-up.
†Diagnosed as CF through reclassification of a second disease-causing mutation or increased sweat Cl−.
‡Number of infants with CF inferred based on reported annual rate of new diagnoses and timespan of study.
§CRMS definition was slightly different from CRMS/CFSPID.
¶Diagnosed through clinical signs and symptoms of respiratory disease or PI. Eight were diagnosed through respiratory symptoms.
**R117H(7T) as their second mutation with a class 1, 2, or 3 mutation as the first.
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and Ren et al6 reported the outcomes in infants with CRMS
from 2010 to 2012. A total of 1540 infants met the diagnostic
criteria for a CF diagnosis in that timeframe, and 309 met the
criteria for CRMS (5:1). However, 40.8% of infants that fit a
strict CRMS definition were actually classified as CF by the re-
cording CF center, and 13 states entered a CF diagnosis inap-
propriately for at least 10%of their infants.Based on definitions
established in the guidelines, 8 infants placed into the CRMS
category should actually have been diagnosed with CF. It may
be possible that clinical data not entered into the Registry af-
fected the decision to classify an infant as CF. However, it is
also possible that there is some confusion or disagreement with
consensus guidelines. A more consistent approach to classifi-
cation is important to reduce variations in CRMS/CFSPID in-
cidence that canhave a significant impact on registry data quality
and epidemiology research efforts.
Growth andnutritional indices in the groupwithCRMSwere
normal, but some infants had positive respiratory cultures for
CF associated pathogens, such as P aeruginosa (10.7%) and
Stenotrophomonas maltophilia (9.4%). The genotype c.1521
_1523delCTT (legacy: F508del)/c.[350G>A;1210-12[7]] (legacy:
R117H;7T)was present in 26%of infantswithCRMS, reflecting
the variable phenotype associated with the R117H mutation.
There weremoreHispanic and non-White infants in the group
withCRMS comparedwith the groupwithCF (19.1%vs 12.5%
and 11.7% vs 6.5%, respectively). The relatively higher pro-
portion of Hispanic infants in the groupwith CRMS, however,
could be due to the large numbers of infants reported with
CRMS fromCalifornia,which has a large Hispanic population
and uses anNBS algorithmwith a greater probability of CRMS
detection. The CFFPR higher proportion of African Ameri-
can infants in the group with CRMS could reflect the fact that
AfricanAmerican infants tend to have higher IRT levels,12 and
CF itself is less common in the African American population,
leading to a higher number of false-positive NBS tests.
CRMS/CFSPID in Wisconsin
Investigators from Wisconsin reported their experience with
CF and CRMS in a cohort of 376 patients.7 Most of these pa-
tients were diagnosed through NBS, but some were referred
from neighboring states or came to attention through clini-
cal features suggestive of CF. These patients were divided into
3 groups: CF, CRMS, and CFTR-related disorder (CFTR-RD).13
CFTR-RD was defined as an infant or child with clinical fea-
tures of CF in a single organ system and who had: (1) an in-
termediate sweat chloride concentration and/or 2 CFTR
mutations of which no more than 1 was known to cause CF;
or (2) a sweat chloride concentration below the upper limit
of normal for age. There were 300 patients with CF (80% of
the total), 57 infants with CRMS (15%), and 19 patients with
CFTR-RD (5%). The median IRT level was significantly higher
in the group with CF compared with the groups with CRMS
and CFTR-RD (171 ng/mL vs 94 ng/mL in CRMS and 106 ng/
mL in CFTR-RD; P < .001). Similarly, the mean sweat chlo-
ride concentration was also higher in patients with CF
compared with these other groups (105 mmol/L vs 35 mmol/L
for CRMS and 43 mmol/L for CFTR-RD; P < .001). Patients
with CF were significantly more likely to have pancreatic in-
sufficiency (83% vs 0%; P < .001), failure to thrive (28% vs 2%;
P < .001), and a respiratory culture positive for P aeruginosa
(80% vs 39%; P < .001). Fourteen of the infants with CRMS
had a sweat chloride concentration <30 mmol/L; mutation
analysis revealed that 10 infants had F508del on 1 allele and
13 had R117H-7T/9T.
CRMS/CFSPID in California
The large, diverse California population provides additional
insight into the population with CRMS.10 California uses a 40-
mutation genetic panel, specific to the state’s population, in
all infants with high IRT. Infants with 2-panel mutations are
screen positive. Infants with only 1 California-panel muta-
tion identified undergo gene scanning and sequencing, and only
those with 1 or more additional CFTR mutations are consid-
ered to have a positive newborn screen. From 2007 to 2012, a
total of 2 573 293 newborns were tested; 345 were diagnosed
with CF (20 of whomwere initially considered to have CRMS);
553 were categorized as CRMS (not including the 20 who were
later given a CF diagnosis), and 1617 were designated healthy
carriers. In addition, 28 infants were later diagnosed with CF
following false-negative NBS results. Thus, in California, there
was a rate of approximately 2 infants with CF for every 3 infants
diagnosed with CRMS.
It is likely that the gene sequencing required by the Cali-
fornia program is at least partially the cause of the identifi-
cation of large numbers of infants categorized as CRMS, and
it is useful to examine whether this results in an overall benefit
to population health. Some of the infants are labelled as CRMS
because of the presence of novel CFTR mutations whose
disease-causing potential is unclear. Over the first 3 years of
the California NBS program, 55 novelCFTR variants were iden-
tified in the 524 infants with 2 mutations detected.14 Of the
424 infants with adequate follow-up, novel CFTR variants were
detected about equally in the group of infants diagnosed with
CF (14/110, 12.7%) during the 3-year study compared with
those who stayed in the group with CRMS (28/279, 10%). Thus,
in this population, the detection of novel CFTR variants re-
sulted in the identification of 14 additional children with CF
at the “cost” of adding another 28 children to the CRMS cat-
egory who may not eventually become symptomatic. Further
analysis of these infants has shown as expected that infants with
a non-CF-causing CFTR mutation have benign outcomes, but
that those with mutations of varying clinical consequences can
potentially develop CF.15,16 It is likely that factors other than
CFTR play a role in this, but these are unclear at this point
and only large long-term studies will provide clarity.
In the first 5 years of the California NBS program, progres-
sion from CRMS to a CF diagnosis because of clinical pre-
sentation has occurred in a relatively limited number of infants:
In 20 infants with CRMS (5.8%), a diagnosis of CF was made
due to 1 or more clinical symptoms, including failure to thrive/
gastrointestinal involvement, respiratory involvement, or P
aeruginosa infection (n = 7; 29%). Two of the 24 patients (8%)
eventually had sweat chloride >60 mmol/L levels just above the
diagnostic cut-off.10
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CRMS/CFSPID in Australia
In New South Wales, Australia, infants are categorized as
CFSPID if they have a high IRT on NBS, 1 copy of F508del,
and an intermediate sweat chloride concentration of 30-
59 mmol/L. A retrospective long-term follow-up of 29 infants
in this group revealed approximately one-half (n = 14) were
eventually diagnosed with CF and referred to as “delayed CF,”
although the course of CF was milder compared with NBS-
positive CF cases.11 From this study, the estimated risk of a
future CF diagnosis is 48%,much higher than that found else-
where in the literature (8%-15%).However,many of the infants
were diagnosed as delayed CF based on nonspecific respira-
tory symptoms, such as cough.
At the 2015 CF Diagnosis Consensus Conference, investi-
gators fromVictoria, Australia, presented their experience in-
volving 111 infants with positive NBS results (high IRT, 1 CFTR
mutation) and sweat chloride concentration of 30-59 mmol/
L. The clinical practice at that time (1994-2014) was to perform
clinical assessment at 4-6 weeks of age, fecal elastase measure-
ment, and extended CFTRmutation analysis. The infants were
seen again at 6-12 months of age, and sweat testing was re-
peated. Infants with sweat chloride concentration <40 mmol/
L, only 1 CFTR mutation found, and no clinical features of CF
were considered carriers and referred for genetic counseling
only. Infants with clinical features of CF or with a diagnostic
sweat chloride concentration (≥60 mmol/L) or in whom a
second CF-causing mutation was found were referred for CF
care. Individuals who continued to display sweat chloride con-
centration of 30-59 mmol/L, or found to have a second CFTR
mutation of unknown significance or indeterminate clinical
features, were not considered to have CF and were referred for
annual clinical assessment, with a repeated sweat test ordered
when they reached 5 years of age.Over the 20-year study period,
15 children received a diagnosis of CF and 96 were deter-
mined to be healthy carriers. In the group of individuals with
intermediate sweat chloride concentrations, the higher the value,
the more likely the individual would eventually receive a CF
diagnosis. The Victoria experience showed that the vast ma-
jority of these children never received a CF diagnosis, but a
small minority did.
CRMS/CFSPID in Canada and Verona, Italy
A prospective, longitudinal study was performed in collabo-
ration between Canada and the CF center inVerona, Italy. They
identified 1-2 subjects with CFSPID for every 3 infants with
CF. A study reported on the first 3 years’ health outcomes of
82 individuals categorized as CFSPID compared with the health
outcomes of 80 infants with CF diagnosed through NBS.8 CFTR
mutation rates did not differ between the CF and CFSPID
groups; extensive gene analysis showed that 2 CFTR muta-
tions were present in 96.3% of individuals in the group with
CFSPID, compared with 92.5% in the group with CF. P
aeruginosa and Staphylococcus aureus were isolated in 12% and
40%, respectively, of subjects with CFSPID. Although this was
significantly less than in patients with CF (31% P aeruginosa
and 71% S aureus), the frequency is higher compared with a
healthy non-CF population.17,18 In the CFSPID group, there
was a slight increase in sweat chloride concentration through-
out the first 2-3 years of life. In 9 of the 82 children in the group
with CFSPID (11%), CF was eventually diagnosed through ab-
normal sweat chloride results, reclassification of their CFTR
mutations as CF-causing, or a combination. Infants that con-
verted from the CFSPID category to a CF diagnosis had sig-
nificantly higher serial sweat chloride levels (P < .0001) and
serum trypsinogen (P = .009) levels than did individuals who
remained in the CFSPID group. The authors demonstrated that
sweat testing at age 2 years provided the clearest differentia-
tion between infants who were likely to develop a positive sweat
test and be reclassified as having CF compared with those who
were unlikely to do so.
CRMS/CFSPID in France
The French CF NBS algorithm utilizes a 30-mutation genetic
screen, specific to their population, in all high-IRT infants.
Between 2002 and 2014, over 10 million babies were screened.
A total of 1765 infants met the diagnostic criteria for a CF di-
agnosis in that timeframe, and 280 met the criteria for CFSPID
based on the available US definition of CRMS (CF:CFSPID,
6.3:1.0). R117H was identified in 58% of infants labeled
CFSPID, all with a polypyrimidine variant in intron 8 T7 in
cis. The estimated risk of a future CF diagnosis has not been
yet evaluated. A prospective nutritional, pulmonary, and di-
agnosis assessment of a national matched cohort CF/CFSPID
is underway.
Recommendations for Follow-Up of Infants
with CRMS/CFSPID
Following a review of data presented at the consensus con-
ference, recommendations for follow-up of CRMS/CFSPID
infants were developed by electronic survey of the consensus
committee (Table I). The committee determined that when an
infant is classified as CRMS/CFSPID, a clear explanation must
be given to the parents and primary care provider (PCP).3
Genetic counselling should be offered to the family. The chil-
dren should undergo at least 1 repeat sweat chloride test at the
CF center, and extended CFTR genetic analysis. In addition,
second-tier CFTR functional analysis (nasal potential differ-
ence or intestinal current measurement) can be considered and
performed by centers with expertise in these tests. Other clini-
cal assessments, such as measurement of fecal elastase activ-
ity, can be performed as clinically appropriate. Parents and PCPs
should understand that children classified as CRMS/CFSPID
must be followed by a specialized CF care physician because
some will develop manifestations of CF disease (Appendix;
available at www.jpeds.com). However, there are currently not
enough data to help stratification of the individuals at risk for
developing CF disease. CF care centers should follow strict in-
fection control guidelines for infants with CRMS/CFSPID to
minimize exposure to individuals with CF and, thus, poten-
tial transmission of pathogens. Although guidelines for man-
agement of CRMS/CFSPID have been published, they are based
on limited data.3,4
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It was apparent to the consensus committee that further re-
search is needed to determine the prognosis and best prac-
tices for frequency and duration of follow-up of the infant with
CRMS/CFSPID. To facilitate this, parents should be advised
on the need to provide consent to include data on their infants
in patient registries.
Discussion
In the past few years, several studies of CRMS and CFSPID
have been reported from across the world. Although they vary
in terms of patient characteristics, sample size, and study design,
some common themes have emerged. CRMS/CFSPID is a rela-
tively common outcome of CFNBS, and CF clinicians and PCPs
need to be prepared to counsel families with these infants. The
majority of these infants do not go on to develop clinical CF,
but in some infants, the diagnosis of CF is eventually made
through an increase in the sweat chloride concentration into
the CF diagnostic range, or through reclassification of an in-
fant’s CFTR mutation as disease-causing based on increased
knowledge of CFTR genetics. In addition, infants may be di-
agnosed subsequent to the development of clinical features that
are concerning for CF. Because respiratory symptoms, such as
cough and wheeze, are very common in infants and young chil-
dren without CF, interpreting their significance in children with
CRMS/CFSPID is challenging. To avoid potential transmis-
sion of CF-related respiratory pathogens, exposure of infants
with CRMS/CFSPID to individuals with CF should be mini-
mized during medical evaluation and follow-up.
Current studies suggest that most of the infants with CRMS/
CFSPID do not develop disease symptoms in a 3-year follow-
up period. However, there is a lack of longer term outcome
data. Experiences from diagnosing adolescents and adults with
CF or a CFTR-related disorder suggest that disease symp-
toms on these individuals can become apparent later in life.
Studies of large cohorts of infants with CRMS/CFSPID are es-
sential to better understand the relationship between CRMS/
CFSPID, CF, and CFTR-RD and to provide more information
to CF caregivers to counsel families of these infants. Families
need to be well-informed of the increased risk for these infants
as they grow. Some infants with CRMS/CFSPID may develop
respiratory symptoms and acquisition of CF-typical respira-
tory pathogens. However, because of lack of data, we cur-
rently do not know how many of those will go on to develop
CFTR-RD or CF.
A harmonized definition will facilitate research into the fre-
quency and clinical outcomes of these infants, which should
address a number of concerns:
• Will these patients remain free of significant symptoms, or
will they demonstrate increasing pathology, “phase shifted”
by a few decades?
• What factors are involved or promote this development and
progression of pathology?
• Do the current recommendations for management, includ-
ing testing and follow-up, provide the optimal balance
betweenmonitoring and detecting development of CF disease
while not over medicalizing infants with CRMS/CFSPID?
• Should the CF care team adopt a more proactive approach
for this infant or is the reactive approach advocated in current
recommendations appropriate?
• What is the psychological impact of designating a poten-
tially healthy individual with CRMS/CFSPID?
• What is the cost to the healthcare system of follow-up for
infants with CRMS/CFSPID, and how should this be con-
sidered in the financing of CF NBS?
• When can we release an individual from a designation of
CRMS/CFSPID? Even if they are asymptomatic as infants and
children?
• What is the true risk of these infants developing single-
organ disease as an adult consistent with a designation of
CFTR-RD?
These important questions need answers if we are to monitor
this group of children optimally. However, this consensus con-
ference focused on diagnosis and definitions, not manage-
ment. Thus, although the definitions of CRMS and CFSPID
should be harmonized as described above, no recommenda-
tions on management were made at the consensus confer-
ence other than follow-up diagnostic testing.We appreciate that
current management of CRMS/CFSPID may differ between
the US and other countries. CF Foundation guidelines for the
management of infants with CRMS were published in 2009,
and it is likely that they will be revised in the near future to
reflect the additional knowledge gained since that time. ■
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Appendix
Case Study
The parents of an infant boy are notified that he screened posi-
tive for CF by their state department of health and presented
to your pediatric office at 10 days of age for evaluation. Your
state follows an IRT/DNA testing protocol and the screening
results note that after an elevated IRT he was positive for 1 mu-
tation: c.1521_1523delCTT (legacy: F508del).
The infant was born following a full-term uncomplicated
pregnancy with a birth weight of 3.2 kg. The family history is
negative for CF.His neonatal period was normal, and he passed
meconium soon after birth.
Your examination reveals a negative history and a normal
examination. His current weight is 6 ounces over his birth
weight, and he is breastfeeding without concerns.
A sweat test is obtained at 2 weeks of age, and the labora-
tory notifies you that it is in the intermediate sweat chloride
range at 32 mmol/L.
What is the most likely initial diagnosis of this infant?
A. CF
B. CRMS/CFSPID
C. Negative NBS test
D. CF carrier
B – correct
What should you do as the next step for care of this infant?
A. Observe and repeat sweat test at age 2 years
B. Observe for one year and refer to CF center if clinical symptoms
suggestive of CF develop
C. Referral to a CF center for evaluation and testing
D. Send for chest radiograph and a throat swab for CF pathogens
C – correct
The definition of CRMS/CFSPID applies to this infant with a positive NBS,
1 CF causing mutation and an intermediate sweat test. The next step,
referral to an accredited CF center, will initiate an evaluation by a CF
provider, and very importantly, begin education regarding this complex
NBS diagnosis for the parents and family of this patient. If the findings
in the history and physical examination are normal, the center may elect
to observe the infant and plan on a repeat sweat chloride test in several
months. Genetic counseling would be recommended.
Often, further genetic testing with an expanded CF mutation panel is
obtained at this visit or a subsequent visit and will help determine the
presence of other CF-causing mutations not identifiable on the limited
state screening panel. The center will usually follow the infant at regular
intervals over the first several years, closely watching for signs and
symptoms suggesting CF. Further testing will be completed as prompted
by signs and symptoms or any changes on the subsequent sweat test that
would indicate a potential change in physiologic status.
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Diagnosis of Cystic Fibrosis in Nonscreened Populations
Patrick R. Sosnay, MD1, Terry B. White, PhD2, Philip M. Farrell, MD, PhD3, Clement L. Ren, MD4, Nico Derichs, MD5,
Michelle S. Howenstine, MD4, Jerry A. Nick, MD6, and Kris De Boeck, MD7
Objective Although the majority of cases of cystic fibrosis (CF) are now diagnosed through newborn screening,
there is still a need to standardize the diagnostic criteria for those diagnosed outside of the neonatal period. This
is because newborn screening started relatively recently, it is not performed everywhere, and even for individuals
who were screened, there is the possibility of a false negative. To limit irreversible organ pathology, a timely diag-
nosis of CF and institution of CF therapies can greatly benefit these patients.
Study design Experts on CF diagnosis were convened at the 2015 CF Foundation Diagnosis Consensus Con-
ference. The participants reviewed and discussed published works and instructive cases of CF diagnosis in indi-
viduals presenting with signs, symptoms, or a family history of CF. Through a modified Delphi methodology, several
consensus statements were agreed upon. These consensus statements were updates of prior CF diagnosis con-
ferences and recommendations.
Results CF diagnosis in individuals outside of newborn screening relies on the clinical evidence and on evidence
of CF transmembrane conductance regulator (CFTR) dysfunction. Clinical evidence can include typical organ pa-
thologies seen in CF such as bronchiectasis or pancreatic insufficiency but often represent a broad range of severity
including mild cases. CFTR dysfunction can be demonstrated using sweat chloride testing, CFTR molecular genetic
analysis, or CFTR physiologic tests. On the basis of the large number of patients with bona fide CF currently followed
in registries with sweat chloride levels between 30 and 40 mmol/L, the threshold considered “intermediate” was lowered
from 40 mmol/L in the prior diagnostic guidelines to 30 mmol/L. The CF diagnosis was also discussed in the context
of CFTR-related disorders in which CFTR dysfunction may be present, but the individual does not meet criteria for CF.
Conclusions CF diagnosis remains a rare but important condition that can be diagnosed when characteristic
clinical features are seen in an individual with demonstrated CFTR dysfunction. (J Pediatr 2017;181S:S52-7).
Since the identification of cystic fibrosis (CF) as a pathologic entity in 1938,
1 diagnosis has been based on the appearance
of signs and symptoms of the disease. For many decades, diagnosis occurred in infancy or early childhood, although by
the 1960s, the disease was occasionally being identified in adults,2-4 who were usually pancreatic-sufficient. The identi-
fication of the gene for the CF transmembrane conductance regulator (CFTR) in 19895-7 and subsequent discovery of mutations
that can alter quantity and/or function of the protein to varying degrees,8 as well as the recognition of modifier genes,9 have led
to demonstration of a wider spectrum of CF in individuals of all ages and ethnicities.10 It is now clear that in individuals with
residual function CFTR mutations, clinical manifestation of CF may develop later in life.11 Furthermore, although the advent
of widespread newborn screening (NBS) has dramatically changed the diagnosis for many infants born in the last decade or so,
more than one-third of all US diagnoses in 2014 were not a result of NBS.12 Criteria to establish a diagnosis of CF outside of NBS
are needed because CF NBS is neither universal nor foolproof; false negatives can and do occur.12,13 Thus, although physicians
today may have less clinical suspicion as a result of CF NBS, a diagnosis of CF or related entities must remain a consideration
in anyone who displays signs and symptoms of the disease, regardless of age, race,
or whether they may have undergone NBS.
Diagnosis of the Nonscreened Individual
The process for diagnosis of CF in individuals that present with clinical symp-
toms rather than a positive newborn screen does not differ greatly from that
CF Cystic fibrosis
CFTR CF transmembrane conductance regulator
CFTR2 Clinical and functional translation of CFTR
CT Computed tomography
FEV1 Forced expiratory volume in the first second
ICM Intestinal current measurement
NBS Newborn screening
NPD Nasal potential difference
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recommended by earlier diagnosis consensus criteria13 (flow
chart representing the diagnostic process recommended for all
populations by the 2015 CF diagnosis consensus committee14).
There is growing recognition that CF can present at any age,
and in any race or ethnicity. In making the diagnosis, an ap-
propriate clinical presentation needs to be linked with evi-
dence of CFTR dysfunction. Since earlier consensus statements,
several advances have evolved our experience with both the
clinical presentation (as we have recognized a broader spec-
trum of CF and CFTR-related disorders) and with our un-
derstanding of the molecular and cellular pathophysiology of
CFTR dysfunction (increased genetic annotation and im-
proved physiologic testing of CFTR). This article will place those
advances in the context of CF diagnosis in the era of ex-
panded CF therapeutics.
As part of the US CF Foundation Diagnosis Consensus Con-
ference, convened in Phoenix, Arizona, in October 2015, the
criteria for CF diagnosis were reviewed. This review included
recent advances in changes to diagnosis for screened individu-
als, as well as for nonscreened. A summary of the conference
was organized according to consensus statements and voted
on by participants in the conference, as well as opened to public
comment. The summary review and other articles can be
viewed as part of this Supplement.14-18 The consensus state-
ments pertaining specifically to nonscreened individuals are
listed in Table I.
Steps to Establish CF Diagnosis
When the diagnosis of CF is being considered outside of the
NBS context, the presenting signs and symptoms (Table II) play
an important role in defining likelihood of CF. An individual
with multiple typical-organ systemmanifestations of CF (bron-
chiectasis, sinus polyps, and pancreatic insufficiency) has a
higher probability of having CFTR dysfunction as the expla-
nation of their phenotype compared with someone with only
atypical manifestations of CF (eg, isolated symptoms such as
chronic cough or sputum production without bronchiecta-
sis, recurrent pancreatitis) that may have alternative explana-
tions. Therefore, diagnosis of CF can be heavily influenced by
the pretest probability or how well the phenotype is consis-
tent with CF as we understand it now.
Coincident with the consideration of presenting signs and
symptoms for CF, the clinician must also compare these with
Table I. 2015 CF Foundation diagnosis consensus conference recommendations related to diagnosis of CF in nonscreened
populations*
Statement
numbers* Consensus statements Comments
25 For individuals presenting with CF symptoms, the same diagnostic
criteria recommended for the screened population for sweat chloride
testing, CFTR genetic analysis, and CFTR functional testing should be
used to confirm a CF diagnosis.
This represents a change in the cut-offs for sweat chloride testing. In
previous statements, an “unlikely CF” sweat chloride was
<40 mmol/L;19 at present it is <30 mmol/L. See “Change in Sweat
Chloride Range Definitions” section.
26 The diagnosis of CFTR-related disorder has been defined as a
monosymptomatic clinical entity (CBAVD/pancreatitis/bronchiectasis)
associated with CFTR dysfunction that does not fulfill the diagnostic
criteria for CF.
This draws on the international effort to characterize this clinical
scenario. See “Alternative Diagnoses” section.
27 Clinicians should avoid the use of terms like classic/nonclassic CF,
typical/atypical CF, delayed CF because these terms have no
harmonized definition and could be confusing for families or
caregivers.
The European CF Society Diagnostic Network Working Group has
maintained a nonclassic or atypical CF label.20,21 See “Alternative
Diagnoses” section for discussion.
CBAVD, congenital bilateral absence of the vas deferens.
*Adapted from Farrell et al.14
Table II. Clinical signs/symptoms that may signify CF
Presenting conditions Common as first presentation of CF Uncommon as first presentation of CF*
Family history Sibling or parent with CF Parent of a child diagnosed with CF
Sinus Chronic sinusitis, nasal polyps
Lower respiratory Bronchiectasis, chronic or recurrent lower airway infection
(especially Pseudomonas infection)22
ABPA, nontuberculous mycobacterial infection, asthma, chronic
obstructive pulmonary disease
GI/lumen Meconium ileus, distal intestinal obstruction syndrome Abnormal motility, rectal prolapse
GI/hepatobiliary Pancreatic insufficiency, recurrent pancreatitis Elevated liver enzymes, ecchymosis, cirrhosis, prolonged neonatal
jaundice, fat soluble vitamin deficiencies (may present as ecchymosis,
anemia, edema, night-blindness, skin rash)
Reproductive Male infertility because of obstructive azoospermia (CBAVD) Female infertility
Other Hyponatremic dehydration,failure to thrive Pseudo-Bartter syndrome, aquagenic wrinkling of skin, digital clubbing
ABPA, allergic bronchopulmonary aspergillosis; GI, gastrointestinal.
*Many of the uncommon presentation clinical features are not uncommon in patients with CF (ABPA, nontuberculous mycobacterial infection, abnormal motility, clubbing, vitamin deficiencies),
however, they are uncommon as isolated presenting complaint that ultimately is due to CF. Atypical mycobacterial infection has more commonly led to a diagnosis of CF in adults.23,24
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alternative diagnoses. Comprehensive lists of alternative di-
agnoses are beyond the scope of this article and will differ
according to the specific clinical presentation and the age of
the patient. For example, an individual presenting with
bronchiectasis will have a different differential diagnosis
(immune deficiency, prior infection, ciliary dyskinesia, etc)
than an individual with primarily pancreatitis (alcohol tox-
icity, gallstones, hypertriglyceridemia, etc). To evaluate other
potential etiologies, the clinician may rely on tests that better
characterize the presenting signs and symptoms, or that test
for a specific alternative diagnosis. Those tests may include:
(1) pulmonary function tests; (2) high-resolution chest com-
puted tomography (CT); (3) respiratory tract cultures from
sputum or bronchoalveolar lavage; (4) fecal fat quantifica-
tion or elastase antibodies; (5) pancreatic imaging; (6) fat-
soluble vitamin levels; (7) genital evaluation in males to
evaluate for the bilateral absence of vas deferens; and (8)
exclusionary testing for ciliary dyskinesia, immunodeficien-
cies, recurrent pancreatitis, celiac disease, and inflammatory
bowel disease.
Informed with a pretest probability that compares the like-
lihood of CF vs an alternative explanation, the clinician will
interpret genetic analysis and tests for CFTR function (sweat
chloride testing, nasal potential difference [NPD], or intesti-
nal current measurement [ICM]) to support or refute a CF
diagnosis. Often, when a patient is referred for CF evalua-
tion, some of these tests may have already been performed. A
clinician would best interpret these tests in the context of a
reasoned pretest probability. The tests of CFTR function may
point in a clear single direction (eg, if the sweat chloride
is >60 mmol/L and 2 CF-causing CFTR mutations are found,
vs an alternative scenario of only 1 mutation found, and the
sweat chloride and NPD are normal). Challenges arise if those
CFTR tests do not provide a definitive answer. Examples of this
could include an intermediate sweat chloride level (30-59mmol/
L), the detection of at least 1 CFTR mutation of varying or
uncertain clinical consequence, or NPD/ICM that cannot be
interpreted as positive or negative. In these circumstances, the
clinician may refer to their pretest probability. It is impor-
tant to note that diagnostic challenges should not delay po-
tentially beneficial treatments.
Change in Sweat Chloride Range
Definitions
A major change that resulted from the 2015 Diagnosis Con-
sensus Conference was the adoption of a lower sweat chloride
level as the upper limit of normal. The 2008 diagnosis
consensus19 recommended the use of ≥60 mmol/L chloride
in the sweat as diagnostic of CF, with levels from 30 to
59 mmol/L as intermediate sweat chloride values in infants
under 6 months of age, or 40-59 mmol/L in individuals over
6 months of age. After reviewing evidence accumulated in
the interim (eg, Augarten et al,25 Highsmith et al,26 and
Collaco et al27), the 2015 Diagnosis Consensus Conference
Committee, however, now recommends the use of 30-
59 mmol/L as representing the intermediate sweat chloride
level for all ages.
The basis for a sweat chloride level of <60 mmol/L in
individuals who are diagnosed with CF because of a prepon-
derance of clinical symptoms can be attributed in large part
to the occurrence of CFTR mutations that do not result in a
total loss of chloride channel activity. The Clinical and
Functional Translation of CFTR (CFTR2) was established to
determine the clinical and functional impact of various
CFTR mutations.8 Phenotype and genotype information are
collected from patient registries, and disease-liability of each
CFTR mutation is evaluated through a combination of in
vivo (sweat chloride) and in vitro data (functional activity
identified in cell-based systems). The CFTR mutations are
sorted into 4 categories: (1) CF-causing (defined as resulting
in CF when 2 copies are present in an individual); (2) a
mutation of varying clinical consequence (defined as a mu-
tation that, in combination with a CF-causing mutation or
another mutation of varying clinical consequence may result
in CF); (3) a mutation of unknown clinical consequence
(defined as one that has not been evaluated by CFTR2); and
(4) a mutation that is non-CF-causing (defined as not causing
CF when present). Thus, consulting the CFTR2 database to
determine the disease liability categories represented by an
individual genotype may offer better insight into the ques-
tionable cases.
Table III provides an example of the clinical data accumu-
lated in CFTR2, and shows the clinical characteristics of
patients in CFTR2 with a diagnosis of CF, but who have a
sweat chloride of <60 mmol/L. In general, these patients
with intermediate sweat chloride concentrations have been
diagnosed at an older age and have milder manifestations of
disease. These data show some of the clinical manifestations
likely in individuals with CF who are homozygous for
c.1521_1523delCTT (legacy: F508del), the most common
CF-causing mutation, but who have a nondiagnostic sweat
chloride. It was on the basis of the 746 individuals with CF
in CFTR2 with a sweat chloride between 30 and 40 mmol/L
that the consensus committee supported a change of the
lower limit of the “intermediate” range to 30 mmol/L from
40 mmol/L. A consequence of this is that individuals present-
ing with symptoms of CF and a sweat chloride level between
30 and 40 mmol/L who were previously considered unlikely
Table III. Association of lung function in patients with
high, intermediate, or low sweat chloride values8
Sweat
chloride
Patients*
(n)
F508del†
homozygous (n)
Mean FEV1%
predicted
Mean
age (y)
41-59 mmol/L 3278 192 85.5 16.3
30-40 mmol/L 746 35 87 16.1
<30 mmol/L 52 40‡ 88 16.1
*CFTR2 contains anonymized data on 88 664 patients with CF, gathered from 41 countries.
†Legacy name for the mutation c.1521_1523delCTT.
‡Although this may include some patients truly homozygous for F508del, the CFTR2 team be-
lieves this more likely represents errors either in genotyping or in sweat values.
THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 181S
S54 Sosnay et al
to have CF, could be reconsidered as having a possible
diagnosis of CF under the current guidelines. Of course, in
subjects with a sweat chloride from 30 to 40 mmol/L, the
physician must still rely on other criteria to establish or
exclude a CF diagnosis. In general, this highlights that regard-
less of the test cut-offs used, CF diagnosis in nonscreened
individuals needs to appropriately consider all diagnostic
test results in the context of the clinical scenario.
Alternative or Unresolved Diagnoses
CFTR-Related Disorders
An important advance since the publication of the last US CF
Foundation diagnostic consensus criteria is a better defini-
tion of CFTR-related disorders.28 This is simply defined as a
clinical entity associated with CFTR dysfunction, that does not
fulfill diagnostic criteria for CF.28 It has been particularly as-
cribed to clinical entities such as congenital bilateral absence
of the vas deferens, recurrent pancreatitis, and disseminated
bronchiectasis. This traditionally has been diagnosed in adults.
An argument can be made that an individual with bronchi-
ectasis as a manifestation of CFTR-related disorder should be
labeled as CF.However, because there are many causes of bron-
chiectasis (including various immunodeficiencies, primary
ciliary dyskinesia, and sequellae of pneumonia), the identifi-
cation of a single CF-causing mutation, as exists in the parents
of an individual with CF, is not uncommon. The clinician must
be cautioned not to conclude too readily that a symptom is
the result of CFTR dysfunction. Rather, it would be prudent
simply to treat the individual following CF guidelines while
the diagnosis is being resolved.
It also has been recognized that variance in the CFTR gene
may play a contributing role in bronchiectasis and other organ
pathologies. For example, among individuals with bronchi-
ectasis, there is a higher than general-population incidence of
CFTR mutations,29-33 including mutations with only minor
effects on CFTR function that are not classified as CF-causing,
and that are seen commonly in the population. Similar genetic
analysis showsCFTRmutations in patients with congenital bi-
lateral absence of the vas deferens,34-37 chronic sinusitis,38 and
pancreatitis.39,40
At this point, the distinction between CFTR-related disor-
ders and conditions in which CFTR mutation or mutations
are contributing to complex traits is blurred. Individuals that
are carriers (only 1 mutated CFTR allele) may present with a
manifestation of reduced CFTR function (for example, chronic
sinusitis).38 The clinical entity of CFTR-related disorder is an
important recognition that CFTR variationmay impact a much
wider segment of the population, beyond those with the life-
shortening Mendelian disease. However, in light of newly ap-
proved and future CFTR modulating therapies that can result
in significant improvements in quality and length of life, it will
be worth identifying the disease liability of an individual geno-
type, to determine whether the CFTR mutations may be the
primary (or modifiable) cause of the phenotype. This will need
to be studied with epidemiologic comparison of the genome
of individuals with and without traits potentially related to
CFTR dysfunction.41
Cases in Which a CF Diagnosis Cannot be
Resolved
It would be useful to place CFTR-related disorders and complex
traits in which CFTR may be playing a role, into an algo-
rithm for CF diagnosis. In cases in which there is a clinical sus-
picion for CF, but sweat chloride testing, CFTR mutation
analysis, and physiologic testing cannot rule in or rule out CF,
the clinician is left with a decision. Ultimately in these cases,
if the physician believes CF therapies or CF follow-up would
benefit the patient, that should outweigh equivocal,
nondiagnostic, test results.
The goal must be to achieve optimal treatment, especially
of lung disease, rather than to engage in an ongoing debate
about the best diagnostic label. The European CF Society Di-
agnostic Network Working Group has advocated for the use
of the term “atypical” CF.20,21 Although these cases may not
follow the “typical” path of CF, patients who do not display 2
CF-causing mutations or do not have diagnostic sweat chlo-
ride test results can still have severe, life-limiting respiratory
disease.42,43 In fact, there are no CFTR mutations that can be
exclusively characterized as“atypical”mutations (although some
mutations may trigger more risk than others44). Thus, the di-
agnosis consensus committee has agreed (not universally) to
recommend against the use of the terms atypical or border-
line CF. Most, although not all, of the committee has con-
cluded that if a CF clinician feels CF therapies and follow-up
would benefit the individual and other potential diagnoses are
ruled out, the CF diagnosis is appropriate. This certainly is in-
fluenced by the third-party payers in the US that may be more
likely to cover expensive care if a CF diagnosis is used. Re-
gardless, in individuals diagnosed with CF as an adult or with
milder presentations, appropriate counseling should include
that the life expectancy estimates derived from mostly pa-
tients with CF diagnosed early in life are less applicable in their
situation.
Inconclusive Result after CF NBS
It is important to note that the uncertain diagnostic category
that can result from positive newborn screens that do not meet
criteria for CF (ie, CF-related metabolic disorder/CF screen
positive, inconclusive diagnosis) does not apply to anyone pre-
senting with CF-like symptoms.14,18 However, individuals iden-
tified in NBS that do not have CF frequently have mutations
that are seen more commonly in individuals with CFTR-
related disorders.45 Some of these individuals identified in NBS
may go on to develop a CFTR-related disorder later in life.
Future study of the likelihood of developing these condi-
tions is needed, but this will require long-term follow-up. In
the meantime, counseling parents of CFTR-related meta-
bolic syndrome/CF screen positive, inconclusive diagnosis
infants about this possibility is an important component of
NBS programs. Clinicians considering CF in a nonscreened
setting should ask questions about NBS history.
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Special Considerations Regarding Adult
Diagnosis
In the period from 1995 to 2005, there were 9766 new CF di-
agnoses, of which 811 (8.3%) were in adults, with a mean age
of 34 years at the time of diagnosis.42 Some examples of adult
diagnoses can be found in the case studies shown in the
Appendix (available at www.jpeds.com).Most adults (70.6%)
present with commonly described respiratory symptoms, such
as Pseudomonas lung infections and reduced lung function.
Despite the delayed appearance of symptoms, the causes of
death do not differ significantly from those experienced by pa-
tients diagnosed in childhood, with the vast majority of both
caused by respiratory failure (87% following childhood diag-
nosis, 85% following adult diagnosis).43 The importance of rec-
ognizing these later presentations of CF is that there is
tremendous opportunity to intervene in progressive lung
disease.Unlike asymptomatic babies who are diagnosed through
NBS, these patients (or their parents) are actively seeking a di-
agnosis to facilitate treatment. A CF diagnosis often comes as
a relief in these individuals.46 Beyond this, establishing the di-
agnosis is critical to help these individuals access the special-
ized care, genetic counseling, and drugs they need.Without a
CF diagnosis, there may be challenges getting insurance to pay
for necessary therapies. The “diagnostic odyssey” is pro-
longed, and further unnecessary testing and uncertainty will
ensue.
Discussion
Given the multitude of different organ systems that can be in-
volved in CF, establishing a diagnosis in an individual pre-
senting with symptoms does not lend itself well to protocols
or algorithms, such as those used in newborn screening. The
central tenant that an individual with a clinical scenario (symp-
toms, signs, and/or family history) and evidence of CFTR dys-
function (sweat test,CFTR genotype, CFTR physiologic testing
with NPD or ICM) has CF is true regardless of the situation,
but in nonscreened individuals, the diagnosis demands dif-
ferent clinician recognition and judgment. NBS has been a tre-
mendous improvement in CF detection, but it will never
eliminate the need to consider CF as a clinical diagnosis in in-
dividuals who were not screened or who were not identified.
CF was recognized as a clinical entity before the genetic cause
was determined. However, as the range of genetic variations
identified in CFTR has expanded, so too must our under-
standing of the clinical entity. The clinician must now look
beyond traditional presentations to consider milder cases of
CF and situations in which CFTR dysfunction is playing a role
in lung, gastrointestinal, or reproductive tract disorders. It is
the goal of the CF community to refine these diagnostic cri-
teria in a way that gets CF care and therapeutic advances to
those that would benefit themost from them, but also to inform
the clinician to help all those in whom the disease should be
considered. ■
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Appendix
Case Study 1
A 51-year-old male presents with a lifelong history of a
productive cough and chronic rhinosinusitis. As a child, he
was hospitalized on several occasions for dehydration and
was unable to perform strenuous exertion in hot weather. As
an adult, he suffered from recurrent pulmonary and sinus
infections that failed to resolve without antibiotic treatment.
He was unable to have children, and a semen analysis re-
vealed azoospermia. He does not complain of constipation
or diarrhea and tolerates a full diet. Prior evaluation by a
pulmonologist demonstrated an obstructive pattern of airflow
limitation, and he was diagnosed with asthma. On 2 occa-
sions, a sputum culture was positive for a mucoid strain of
Pseudomonas aeruginosa. There was no history of CF within
his extended family.
A chest CT scan was significant for upper lobe bronchiec-
tasis, worse on the right side. Pulmonary function tests
showed a forced expiratory volume in the first second (FEV1)
of 57% predicted. Analysis of CFTR function demonstrated
sweat chloride values of 80 and 82 mmol/L. Full CFTR
sequencing confirmed the presence of c.350G>A (legacy:
R117H) and c.1585-1G>A (legacy: 1717-1G>A) with an
intron 8 poly (T) variant 5T and 7T. Extensive ancillary
testing for other causes of bronchiectasis were nondiagnostic.
Which of the following statements is correct?
A. He is unlikely to have CF because he is too old, lacks a family history,
and does not have symptoms of pancreatic insufficiency
B. His bronchiectasis is likely the result of recurrent childhood respiratory
infections
C. He meets diagnostic criteria for CF
D. He meets the diagnostic criteria for CFTR-related metabolic syndrome
and is unlikely to develop full CF
C – correct
This case is an example of a typical presentation for a CF diagnosis made in
adulthood because of the presence of 1 or more residual-function CFTR
mutations. With a background of obstructive azoospermia, by his sixth decade
of life the patient has developed moderately severe bronchiectasis, chronic
infection with typical CF pathogens, and extensive sinus disease. Failure to
present with pancreatic insufficiency is common in adult-diagnosed patients,
but he is at risk to lose pancreatic function over time. The diagnosis is
confirmed by the presence of 2 disease-causing CFTR mutations and a sweat
chloride <60 mmol/L. Although R117H is often mild when combined with intron
8 poly (T) variant 7T, it is much more severe when paired with the 5T, which is
reflected by the relatively high sweat chloride values.
Even though postinfectious bronchiectasis remains common worldwide, it is rare
in the US or Europe, and is essentially a diagnosis of exclusion. It would be
incorrect to label this case CFTR-related metabolic syndrome, as he was not
identified through NBS, and he fulfils all criteria for CF.
What is the next appropriate step for this patient?
A. He should be referred to an accredited CF center
B. He should receive comprehensive CF care including airway clearance,
suppression of P aeruginosa, evaluation of sinus disease, and CF
modulator treatment with ivacaftor should be initiated
C. Genetic counseling should be offered to the patient, siblings, and
extended family members as appropriate
D. All of the above
D – correct
The patient should have access to CF center care, including all of the
therapies listed above. In this case, he had an outstanding response to
treatment, in particular ivacaftor. Genetic counseling is also an important
consideration. Even if the patient does not have children, his siblings each
have a 50% chance of being carriers.
Case Study 2
A 40-year-old woman presents with persistent productive
cough. She reports that her cough has increased in intensity
over the years. She has had a history of frequent upper respi-
ratory infections, feels that these illnesses last much longer than
in other family members, and often requires oral antibiotics
for resolution of symptoms. She has symptoms of chronic si-
nusitis and rhinorrhea but has not pursued formal evalua-
tion. She reports symptoms of intermittent diarrhea and
constipation but without frank steatorrhea. She has never had
pancreatitis and does not limit fat intake in her diet. She reports
that her sister was given the diagnosis of CF and died in her
40s of progressive respiratory failure because of bronchiecta-
sis. Her sister had chronic infection of her airways with P
aeruginosa and had suffered a precipitous decline in her health
following childbirth. The patient reports that her sister’s phy-
sicians described her sweat chloride results as “borderline,” and
she had only 1 CFTR mutation identified on screening.
At presentation, her initial sputum culture demonstrated
methicillin-sensitive Staphylococcus aureus, P aeruginosa, and
Mycobacterium avium complex. A chest CT scan was signifi-
cant for upper lobe predominant varicose, cylindrical bron-
chiectasis, with moderate mucoid impaction and air trapping.
A sinus CT confirmedmoderately severe pansinusitis. Her FEV1
was 68% predicted. Analysis of CFTR function demon-
strated sweat chloride values of 54 and 54 mmol/L. Full CFTR
sequencing of the entire coding regions as well as common
intronic mutation sites demonstrate only 1 copy of
c.1521_1523delCTT (legacy: F508del), with an intron 8 poly(T)
7T 11TG and 9T 10TG. There were no large sequence dupli-
cations or deletions.
She was initiated on inhaled tobramycin for 1 month, and
P aeurginosa was successfully eradicated. Subsequent cul-
tures have continued to grow methicillin-sensitive Staphylo-
coccus aureus. TheMycobacterium avium complex has not been
recovered since the initial visit, but she has had many posi-
tive cultures forMycobacterium abscessus. Airway clearance was
initiated with a therapy vest in combination with dornase alfa
and hypertonic saline. After 3 years, her FEV1 has improved
to 76%, with improved radiographic changes, decreased cough,
and less frequent upper respiratory infections.
Which of the following statements is correct?
A. She is only a CF carrier because full CFTR gene sequencing did not
demonstrate 2 CF-causing mutations
B. She does not meet diagnostic criteria for CF because her sweat
chloride is <60 mmol/L
C. The absence of detection of 2 CF-causing mutations does not
exclude a diagnosis of CF
D. Both A and B
C – correct
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This case demonstrates the role of clinical judgment in establishing the CF
diagnosis in certain individuals. The patient presents with a disease
phenotype consistent with CF, combined with a strong family history in a
first-degree relative. With currently available analysis, only a single CFTR
mutation can be identified, but her sweat chloride test is grossly abnormal,
although below the standard diagnostic cut-off. As our understanding of
CFTR structure, function and regulation continues to grow, it is likely that
at some point a second gene defect will be discovered in this individual,
but in the meantime she should be given the diagnosis of CF and provided
access to CF center care.
Which of the following statements is correct?
A. A sweat chloride of 54 mmol/L is typical of a carrier of a single copy of
F508del
B. NPD testing is necessary to establish a CF diagnosis
C. She can be assigned the diagnosis of CF based on clinical presentation,
family history and demonstrated CFTR dysfunction
D. She does not have CF and neither did her sister
C – correct
In general, CF carriers will not have an abnormal sweat chloride. NPD testing
could confirm the degree of CFTR dysfunction assessed by the sweat chloride
testing, but it should not delay the institution of CF therapies. The strong family
history should not be dismissed unless a more plausible hereditary cause of
bronchiectasis can be proven in this case. Her sweat chloride of 54 mmol/L is
entirely consistent with her clinical presentation at this point in life.
Case Study 3
A 20-year-old woman presents with recurrent hemoptysis and
a productive cough since age 11 years. She has had a history
of many respiratory infections, and her episodes of bleeding
have become more frequent and severe. She has chronic si-
nusitis and nasal polyps. She has symptoms consistent with
typical steatorrhea and is underweight. She has never had pan-
creatitis. She denies a family history of CF.
At presentation, her initial sputum culture demonstrated
P aeruginosa and methicillin-sensitive Staphylococcus aureus.
A chest CT scan was significant for mild upper lobe bronchi-
ectasis and scattered mucous plugging. Her FEV1 was 70%
predicted. Analysis of CFTR function demonstrated a mean
sweat chloride value of 33 mmol/L. CFTR genotype revealed
the presence of 1 copy c.1521_1523delCTT (legacy: F508del)
and 1 copy c.3737C>T (legacy: T1246I).
Shewas initiated on inhaled tobramycin and standard airway
clearance. Subsequent cultures have continued to grow
methicillin-sensitive Staphylococcus aureus, and intermit-
tentlyPaeruginosa, P fluorescens/putida, and Serratiamarcescens.
Shewas initiated on pancreatic enzyme replacement,with reso-
lution of steatorrhea. After 2 years of CF center care, her FEV1
has improved to 101%, with marked reduction in hemoptysis
and decreased cough. She has gained 3 kg.
Which of the following statements are correct?
A. A sweat chloride of 33 mmol/L is too low to consider a diagnosis of CF
B. T1246I has not been established as “disease-causing” and therefore this
patient is unlikely to have CF
C. The diagnosis of CF can be made on clinical judgment in patients with
rare CFTR mutations of unknown significance
D. The benefit to an individual patient from standard CF therapies confirms
the diagnosis of CF
C – correct
This case demonstrates a rare presentation of CF diagnosed early in adulthood.
Her clinical features are typical for CF, including bronchiectasis, infection with
usual CF pathogens, chronic sinusitis, and pancreatic insufficiency. Although
her sweat chloride is relatively low, the diagnostic criteria developed at the
2015 CF Foundation Consensus Conference acknowledges the potential to
develop CF with sweat chlorides ranging from 30 to 59 mmol/L. Even though 2
CFTR mutations were identified, the second is very rare and not well-
characterized. However, there is no other plausible explanation for her
combination of clinical findings combined with evidence of CFTR dysfunction.
The diagnosis of CF best fits her clinical presentation at this time, and offers
her access to therapies that are likely to extend her life. Her response to
therapies is certainly fortunate, but many patients with bronchiectasis without
CF may also respond to these treatments. Appropriate care takes priority over
establishing a label, but it would be inaccurate to diagnose everyone who
responds to CF therapies as having CF.
Which of the following statements is correct?
A. In patients with symptoms consistent with CF and low sweat chloride values
or unusual CFTR mutations, it is important to evaluate for causes of their
symptoms other than CF
B. It is unusual to see pancreatic insufficiency with a low sweat chloride value
C. If available, ancillary testing such as NPD could be helpful in this situation
D. All of the above
D – correct
In cases such as this, confidence in the CF diagnosis is increased if other typical
causes of bronchiectasis have been ruled out. However, the presence of
pancreatic insufficiency in early adulthood is not consistent with other diseases
that result in bronchiectasis. In general, patients with sweat chloride values in
this range develop bronchiectasis much later in life and are typically pancreatic
sufficient. This case demonstrates that in the individual patient, a wide range of
disease severity is possible. An NPD test may be of interest in this case but is
likely to reflect the findings of the sweat chloride test.
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